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Summary
The ryanodine receptor  (RyR) is  a  large (563 kDa) tetrameric  calcium channel  that
controls the efflux of calcium ions from the large internal stores within myofibrils called
the sarcoplasmic reticulum. The cytoplasmic domain is connected to the pore via an
"interacting-domain" (I domain) which plays  an important role in the mechanism of
channel regulation. Within the I domain is a calcium binding region which resembles a
lobe of calmodulin and is thus called the calmodulin-like-domain (CaMLD). CaMLD
has a binding partner region, the calmodulin-binding-domain (CaMBD) located in the
cytoplasmic domain. Mutations in the cardiac isoform of RyR have been shown to result
in  the  clinical  presentation  of  a  lethal  disease  condition  called  catecholaminergic
polymorphic ventricular tachycardia (CPVT). Thus, mutations proximal to the CaMLD
and CaMBD region are of particular interest, since if these mutations affect the binding
of calcium or result in any conformational change of the protein, then the role of the
mutation could be explained.
Computer simulation methods were employed to investigate the role of CaMLD and
CaMBD in the overall  biology of RyR. The individual  domains  and also the entire
section of RyR containing both domains were modelled. This latter model underwent a
simulated folding process to generate a tool to further investigate the role of CPVT
mutations within this region in the context of the structural changes brought about by
the changes in amino acid residues of the protein.
CaMLD and CaMBD were produced as  recombinant  proteins  and selected  CaMLD
CPVT mutants generated. The calcium dependent interaction of these two domains was
examined through a range of functional techniques, in particular circular dichroism. All
the studied mutants displayed a calcium induced conformational change associated with
the functional protein. However, one particular mutation was identified which appeared
to  significantly weaken the  structural  stability and have  reduced calcium sensitivity
when compared to the wild type recombinant protein. 
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Chapter 1:
Introduction
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The aim of this  thesis  is  to understand the importance of the ryanodine receptor in
excitation contraction coupling in normal and pathological disease states of skeletal and
cardiac muscle. In particular the role of calcium and calmodulin in regulation of RyR
activities.  The  ryanodine  receptor  is  situated  in  the  sarcoplasmic  reticulum  (SR)
membrane and acts as a calcium “release-channel” for the SR calcium store.  
1.1 Calcium and calcium channels
The calcium ion (Ca2+) is a vital signalling agent for a large number of events from a
cellular level upwards from the earliest  stages of life through to death.  These many
processes include the activation of oocytes at fertilisation to the death of cells, muscle
contraction,  synaptic  transmission,  energy  metabolism,  activation  of  transcription
factors,  and  apoptosis  and  necrosis  (Berridge  et  al.  1998),  (Bootman  et  al.  2001).
Although in lower concentrations than other ions, Ca2+ required careful treatment by the
earliest cells. Ca2+ interacts easily with biological molecules and, at high concentrations,
will precipitate with phosphates, weaken lipid membranes, and aggregate nucleic acids
and proteins.  As such, even the most basic of lifeforms maintain Ca2+ homoeostasis
retaining internal  concentration around 100nM, significantly lower than the external
micromolar concentration  (Case  et  al.  2007).  The  maintained  difference  in  internal
versus external concentrations generates a gradient which allows the cell to use Ca2+ in a
signalling role. 
To  permit  the  controlled  transfer  of  calcium  ions,  channels  were  required  in  the
membrane. It has been proposed that the first of these were not protein based, instead
relying on bacterially produced polymers to produce a channel which was sensitive to
ion  concentration  and  selective  for  divalent  cations.  Voltage-gated  protein  calcium
channels eventually evolved and various types are now found in bacteria and higher
organisms. Prokaryotic examples of these channels are simpler in structures involving
less domains than eukaryotic versions (Case et al. 2007). 
              
The development  of  the complexity of  the Ca2+ channels  produced several  types  of
influx channel;  these tend to  be  classified  by how they are activated.  Mechanically
triggered channels have been found in cells that need to respond to physical changes the
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cell experiences whereas store-operated Ca2+ channels (SOCCs) respond to a decrease in
internal Ca2+ concentration. The latter are thought to function through binding with a
cellular messenger produced with the decrease in Ca2+ levels or by direct interaction
with internal calcium release stores (Bootman et al. 2001). 
As  a  large  variation  of  cell  types  display  increased  calcium entry  on  depletion  of
internal stores, it is proposed that SOCCs may be the most common membrane calcium
channel.  Receptor  operated  calcium channels  (ROCCs)  are  activated  by binding  of
agonists  to their  extracellular domains.  These are located in large numbers at  nerve
endings  and  on  secretory  cells.  In  addition,  they  have  a  range  of  structural  and
functional differences (Bootman et al. 2001). 
Voltage  operated  calcium channels  (VOCCs)  are  activated  by  depolarisation  of  the
membrane. They are commonly located in muscle cells, neurons and other excitable
cells. VOCCs contain several protein subunits which function in the role of pore and its
gating.  Isoforms  of  these  subunits  have  been  identified  permitting  a  range  of
combinations  as  observed in  the tissue  specific  VOCCs that  are  found.  VOCCs are
commonly  characterised  by  their  response  to  pharmacological  agents  and  gating
behaviours  (Bootman et al. 2001). The L-type calcium channel (also referred to as a
dihydropyridine receptor) shown in figure 1.11 is a VOCC.
Another factor introduced by the development of eukaryotic cells was the inclusion of
organelles that amongst other functions would serve as calcium stores. Mitochondria,
with  their  bacterial  heritage  contain  a  calcium  channel  (calcium  uniporter)  and  a
Na+/Ca2+ exchanger  (NCX).  Hence,  they  were  able  to  adopt  to  this  role.  Increased
calcium concentration in the mitochondria promotes activity of enzymes in the citric
acid cycle leading to enhanced ATP synthesis (Case et al. 2007). 
Another example of an internal calcium store is within the endoplasmic reticulum (ER).
Here, they play a key role in protein synthesis, post-translational protein modification
and  transport  of  molecules  around  the  cell.  The  ER maintains  a  much  higher  Ca2+
concentration; in the range of several hundred micromolar, compared to the intracellular
space  (where  calcium concentration  is  normally around 1-2 mM).  This  intracellular
store serves as another source of calcium adding a further layer to calcium signalling.
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The release of Ca2+ from the ER stores is operated by three main sets of intracellular
channels;  NAADP controlled receptors,  inositol  1,4,5-triphosphate (InsP3)/Ca2+ gated
InsP3 receptors (IP3Rs), and calcium-gated ryanodine receptors (RyRs). Although RyRs
and IP3Rs share similar structure and function, the former is much more advanced down
the evolutionary process (Bootman et al. 2001), (Case et al. 2007).        
The increased concentration in Ca2+ can be used as a single signal per event such as in
muscle contraction. However, the rate and/or amount of increase can be controlled to
provide greater  finesse in signalling.  This mechanism of control  is  important as the
increase in the amplitude of the Ca2+ signal is thought to become less effective as cells
have reduced sensitivity to  increasing concentrations  of  Ca2+ (Berridge et  al.  1998).
Calmodulin dependent protein kinase II (CaMKII) is a commonly cited example of the
monitoring  of  the  frequency  of  Ca2+ signal.  The  subunits  of  the  kinase  respond
differently to the rate of signal. Therefore, allowing for a graduated response to the rate
of Ca2+ signal. 
Excitation-contraction coupling (ECC) in muscle cells is a prime example of the use of
Ca2+ for the regulation of a highly specified physiological function. The ECC process
involves compartmentalisation and many feedback loops to maintain Ca2+ homoeostasis.
Ca2+ itself directly regulates many of the key proteins and also acts indirectly through
the modulatory protein calmodulin (CaM). It should be noted that one of the pivotal
proteins involved in the regulation of ECC is RyR (Bers 2002).
1.2 Identification of ryanodine receptors 
Ryanodine receptors were first identified from images captured of striated muscle using
electron microscopy. The junctions between sarcoplasmic reticulum (SR) and transverse
(T) tubular system at the triad were examined. RyRs were seen as part of the “foot”
structures  at  these  junctions  (Franzini-Armstrong 1970),  (Campbell  et  al.  1980).  As
discussed above SR, smooth ER located in smooth and striated muscle, was known to
act as a calcium store and contain calcium channels. Electrophysiology experiments in
which  SR  membrane  extracts  were  incorporated  into  lipid  bilayers  displayed  the
presence of a channel behaving in the role of a Ca2+ release. 
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RyR was purified from the SR and demonstrated to be part of the previously observed
foot  structures.  This  extracted RyR was shown to be sensitive  to  the  plant  alkaloid
ryanodine when operating in  its  role  as a  conductivity channel.  Low concentrations
(submicromolar)  of  ryanodine  locked the  channel  in  an  open state  and reduced the
current passing through the “open” channel to about 40%. Ruthenium red was known to
close the channel but in this ryanodine open locked state this did not occur though there
was a further reduction in conductivity. Higher concentrations, 300μM, of ryanodine
closed the channel  (Nagasaki  & Fleischer  1988).  Work conducted in  rabbit  skeletal
muscle isolated RyR as an integral SR membrane protein and confirmed its role as a
Ca2+ release channel (Lai et al. 1988), (Lai et al. 1989), (Meissner et al. 1989). 
RyRs were subsequently identified across a range of tissue types and 3 clear types of
channel identified. RyR1 was found in rabbit skeletal muscle (Marks et al. 1989) and is
mainly found in skeletal muscle though does occur at lower levels in some brain tissues.
RyR2 was initially extracted from rabbit cardiac muscle (Otsu et al. 1990), where it is
the predominant isoform, and is also found in neurons. RyR3 was initially isolated from
rabbit brain (Hakamata et al. 1992) but has been found at low levels across a variety of
tissues.  Complementary  DNA was  cloned  for  the  3  isoforms  and  gene  sequences
determined for these 3 isoforms; RyR1  (Takeshima et al.  1989), RyR2  (Nakai et  al.
1990), (Otsu et al. 1990) and RyR3 (Hakamata et al. 1992). 
It  was  determined  that  there  was  approximately 65% amino  acid  sequence  identity
between the mammalian isoforms. Despite the range of tissues in which RyRs occur and
the variation between isoforms their major identified role is in ECC in muscle cells, the
process  of  converting  an  electrical  nerve  stimulus  into  the  mechanical  response  of
muscle contraction  (Endo 2011). This process is discussed in further detail in a later
section of this chapter. 
1.3 Structure of the ryanodine receptor
Continuing research has revealed more about the structure of the largest known ion
channel  (Capes  et  al.  2011).  Within  SR,  RyR  was  found  to  be  a  homotetramer
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containing a central pore, each subunit has a mass of ~560 kDa (Lai et al. 1988). The
size  of  the  channel  has  lent  itself  to  study  by  cryo-electron  microscopy.  With
advancements in microscopes and image processing algorithms the resolution of the
produced images have improved from ~30Å (Radermacher et al. 1994),  (Serysheva et
al. 1995), (Sharma et al. 1998) to ~10Å (Ludtke et al. 2005), (Samsó et al. 2005).  
Figure 1.1 3D reconstruction map of RyR1 (Radermacher et al. 1994).  
30Å  resolution  map  processed  from cryo-EM data  illustrating  the  “toadstool”  like
shape of RyR. Also shown is the numbering of putative domains as proposed by the
Wagenknecht group. TA relates to the transmembrane assembly and p to a feature of the
pore. 
Similar topological surface maps have been produced by the various techniques though
the increasing resolution has started to reveal more detail about the overall structure.
Analysis of these images has shown the 4-fold symmetry of the homotetramer and led
to the “toadstool” analogy model of the structure (see figure 1.1 above). The “stalk” of
this  structure equates to  the transmembrane portion of RyR, which acts  as the pore
section of the channel in the SR membrane. 
The “head” section, represents the region that sits facing the inner cytoplasmic space of
the SR. Discrete globular domains separated by solvent-accessible regions have been
observed in the cytoplasmic portion. The cytoplasmic head seems to be separated from
the transmembrane stalk by 4 columns (Samsó et al. 2005). 
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There appears to be differences in the transmembrane section if the channel is treated
with  ryanodine,  though  the  low-resolution  of  the  images  makes  this  difficult  to
determine. However, domain rearrangement is observed between the open and closed
states of RyR (Orlova et al. 1996a). This has lead to the suggestion of an iris lens-style
opening and closing mechanisms for the channel (Serysheva et al. 1999). The improving
image  resolution  combined  with  other  techniques  such  as  the  incorporation  and
subsequent monitoring of green-fluorescent-protein (GFP) has allowed for attempts to
map specific domains and binding areas onto the overall structure of RyR. 
Work conducted mainly on the N-terminal region of RyR has revealed the localisation
of domains containing known mutations within the quaternary structure of the protein
(Liu et al. 2002), (Liu et al. 2005), (Wang et al. 2007). This approach has illustrated the
potential  of  identifying  regulatory  regions  that  are  brought  together  through
conformational changes within RyR. However, the disruption caused by the insertion of
the GFP tag has to be considered. 
The increasing appearance of high resolution structures of regions of RyR has allowed
visualisation of mutations within the three-dimensional structure. The techniques of x-
ray crystallography and nuclear magnetic resonance (NMR) have been used to produce
these structures revealing the nature of the structural impact of the studied mutations.
Initially  a  short  stretch  of  the  RyR1  CaM binding  site  in  complex  with  CaM was
observed  (Maximciuc  et  al.  2006).  A more  detailed  discussion  of  this  structure  is
presented in chapter 3, also the CaM binding site is further explored later in this chapter.
Focus has been, primarily, on the N terminal domain region of RyR with a succession of
released structures containing more sequence and further studied mutations (Amador et
al. 2009), (Lobo et al. 2011), (Tung et al. 2010), (Kimlicka et al. 2013). Other regions of
RyR  are  being  investigated  by  these  techniques,  recently  structures  of  the  central
domain phosphorylation sites,  including likely CaM kinase II  interaction sites,  have
been published (Sharma et al. 2012), (Yuchi et al. 2012).     
Figure 1.2 shows the 10 Angstrom resolution electron microscopy topographical map of
the ryanodine receptor.  Van Petegem and colleagues have done an in silico docking of
the recently deduced N-terminal 3D crystallographic structure into this topographical
map, this data shows a strong possibility where the N-terminal “repeat-region” should
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be located  (see  figure  1.2).  Furthermore,  it  also  shows the  putative  location  of  the
central regions of phosphorylation. Maps such as these contain important information as
to  where  crucial  functional  domains  may be  located  and  provides  clues  as  to  how
mutations present on domain interfaces may cause disruption by disruption of domain-
domain interactions, thereby destabilising the channel.
Figure 1.2.  Docked crystal structure of N terminal of RyR1 in cryo-EM map of 
RyR1 (Tung et al. 2010).  
Looking down onto “head” of RyR from cytoplasmic side displaying 4 fold symmetry of
RyR  tetramer.  2.5Å  resolution  x-ray  crystallography  determined  structure  of  RyR1
amino  acid  residues  1-559 docked  in  9.6Å cryo-EM map of  RyR1.  The  N-terminal
structure  has  been  split  into  3  different  coloured  predicted  domains  that  interact.
Mutations have been observed in small clusters at the interfaces between the domain
boundaries.  
1.4 Muscle contraction
Each muscle fibre is  multinucleate and behaves as a single unit  (and therefore it  is
called a syncytium). It  contains  bundles of myofibrils,   surrounded by sarcoplasmic
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reticulum  (SR)  and  invaginated  by  transverse  tubules  (T  tubules).  Each  myofibril
contains interdigitating thick and thin filaments arranged longitudinally in sarcomeres.
Figure 1.3 Components of muscle tissue (Braunwald 2007). 
Schematic  diagram  showing  arrangement  of  muscle  fibres  in  bundles  (myofibrils)
surrounded by sarcoplasmic reticulum (SR) and T-tubules.
Skeletal and cardio-myocytes are made up of bundles of sarcomeres.  Sarcomeres are
bundles of myosin and actin that slide over each other.
Figure 1.4 The “sliding filament” mechanism of muscle contraction.  
The  sliding  filament  model  of  muscle  contraction  is  where  the  “thin-filaments”  of
muscle “slide-over” the “thick filaments”.
Briefly, the sliding-filament theory is where actin and myosin filaments slide over each
other, thus gradually shortening the length of the sarcomere. This is an active process
requiring ATP.
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The flood-like massive release of calcium ions from the SR via the RyR1 channels
allow calcium ions to flow into the cytoplasm. These large pools of calcium are now
capable  of  binding  to  Troponin  C.  This,  in  turn,  causes  the  troponin  complex  to
dissociate from tropomyosin. The role of tropomyosin is important to shield the myosin-
binding  site  preventing  the  binding  of  actin  and  the  formation  of  cross-bridges  in
absence of calcium. Myosin can then bind to the uncovered sites on actin, a crucial step
in  the  sliding  filament  theory",  see  figure  1.5.  Thus,  muscle  contraction  occurs  in
response to previous electrical events.
Figure 1.5 Regulation of contraction and relaxation in the muscle  (Davison et
al. 2000).
Schematic  view  showing  the  spatial  relationships  of  actin  (A),  troponin  T  (TnT),
tropomyosin (TPM), troponin C (TnC) and troponin I (TnI). In the relaxed state (on the
right),  tropomyosin  occupies  the  myosin  binding  site  on  the  actin  molecule.  This
therefore prevents actin from forming cross-bridges with myosin. The troponins; T, I
and  C  are  associated  with  each  other,  in  low  calcium  levels,  troponin  C  loosely
associates with troponin I via a single site. When there is a large release of calcium
ions, troponin I strongly associates with troponin C via two binding sites, so altering the
overall  conformation of the troponins and “pulling” tropomyosin out of the binding
cleft  on  actin.  This  then  allows  myosin  to  form  cross-bridges  with  actin  and  thus
commence muscle contraction. 
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1.5 Excitation-contraction coupling
Excitation-contraction  coupling (ECC)  is  the  process  by  which  an  electrical  signal
brings about a mechanical contractile event.  The events described for contraction in
skeletal muscle are different when it comes to cardiac muscle. Firstly, skeletal muscle is
under voluntary control. The intent to move a muscle begins first with a higher cortical
response  which  travels  down  the  cortico-spinal  tract  and  exits  at  the  appropriate
vertebral level via the ventral horn, finally ending as a motor end-plate (synaptic bulb)
on  a  muscle  where  calcium  channels  control  the  release  of  the  neurotransmitter
acetylcholine that trigger off the rest of the excitatory process (Braunwald 2007).
Cardiac  myocytes  near  the  sino-atrial  node  and  the  atrio-ventricular  nodes  have  a
property  called  automaticity.  This  is  an  important  property  of  these  cells  that  can
spontaneously generate periodic oscillations of electrical current and set off an action
potential. In the hearts of higher vertebrates, so-called “pacemaker” cells exist, these
cells  have  low  contractility  but  have  the  capacity  to  generate  periodic  electrical
oscillations. The generated action potential then spreads via the “Purkinje fibre” system
and the bundle of His, down the septum and upwards around the ventricles, spreading
the  excitatory  impulse  throughout  the  myocardium  to  the  individual  myocytes
(Braunwald 2007).
Figure 1.6 Flowchart summarising events leading to opening of RyR channels.  
The  various  events  from  the  propagation  of  the  action  potential  through  to  the
activation of the dihydropyridine receptors and finally the opening of the SR stores of
calcium via the RyR1 receptor.
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1.5.1 Action potential 
Figure 1.7 Neurotransmission of signals to muscles.  
(a) the mechanism by which ligand-gated Na+ channels work; when they bind to ACh,
the  channels  open  allowing  sodium  to  rush  into  the  muscle  cell,  depolarising  the
sarcolemma. 
(b) false colour scanning electron microscope of a presynaptic bulb of neuron (green),
ACh  molecules  are  coloured  in  blue  (SEM  image  from  www.brighthub.com,  with
permission).
A propagating action potential travels down towards the end of a motor neuron. There,
as  shown in  figure  1.7  (panel  A),  calcium ions  travel  down the  voltage-dependent
channels,  thus  gaining  entry  into  the  neuron.  The  calcium  ions  then  bind  to
synaptotagmin;  a  type  of  sensor  protein,  which  causes  the  release  of  the
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neurotransmitter acetylcholine (ACh) from the neuron into the synaptic cleft. ACh then
travels down the short space of the synapse (approximately 19 -20 nm), binding to the
receptors on the membrane of the muscle fibre (Braunwald 2007). 
The ACh receptors are in fact, ligand-gated nicotinic receptors. This means that, when
ACh (the "ligand") binds to these receptors (which also function as an ionic gate), the
gates "open", allowing entry of sodium ions into the muscle cells whilst allowing the
concomitant exit of potassium ions out of them.  The membrane of muscle cells at rest
are approximately between -90 mV to -70 mV. This relatively large negative polarity of
the muscle cell membrane is maintained by forcing three sodium ions out of the cell and
allowing two potassium ions in via an ATP driven pump leading to a net deficit of one
positive charge in the cell. The sudden large influx of sodium ions into the muscle cell
causes a shift towards positive values in membrane potential (towards +ve voltages). As
the sodium ions rush in, the sarcolemma depolarises rapidly and the membrane potential
gradually reach 30 mV (as shown in figure 1.8) (Braunwald 2007).
Figure 1.8 Action potential at the neuromuscular junction.  
The  rush  of  sodium  ions  into  the  myocytes  cause  a  rapid  depolarisation  of  the
sarcolemma. The initial sharp rise of depolarisation slows down towards the peak as
inward rectifying K+ channels open.  At stage 4,  the sodium potassium pumps begin
activating with the aid of ATP, restoring the resting membrane polarity. 
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At the resting membrane potential of –70 mV at the sinoatrial node, there is a steady
leak of potassium ions outward, and a slow trickle of sodium ions inward (the so-called
funny current of  If).  The gradual rise in potential  is also reached by the opening of
voltage-gated  calcium  channels  (L  type  calcium  channels)  and  this  allows  the
sarcolemma of the cardiac myofibrils to reach a threshold at –40 mV (Braunwald 2007).
The action potential curve of other myocytes has a slightly different shape than that of
the  pacemaker  cells  as  shown in  figure  1.9.  The  most  significant  difference  is  the
“plateau phase” in this action potential curve, where phase (1) is due to the deactivation
of the fast sodium channels. The notch observed in the plateau phase (figure 1.9 (b)) is
due to the efflux flow of potassium ions (I to1) and chloride ions  (I to 2) (going out of
the  cell).  The  notch  is  of  particular  significance,  without  these  transient  outward
currents, the repolarisation of the myocyte would not occur (Braunwald 2007). 
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Figure 1.9 Action potential in the heart.  
(a) the action potential  at  the sino-atrial node and (b) the action potential  and the
various phases at other cardiac myocytes (non-pacemaker cells).
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1.5.2 Activation of LTCC/DHPR 
The T-tubule system contains voltage-gated Ca2+ channels;  specifically,  these are the
dihydropyridine  receptors  which  are  also  referred  to  as  L  type  calcium  channels
(LTCC). The action potential described in figures 1.8 and 1.9, activates these receptors.
Dihydropyridines  are  compounds  that  contain  a  pyridine  (a  C5 heterocyclic)  group.
Clinically, drugs such as amlodipine, nifedipine and nimodipine are important calcium-
channel  blockers,  which  play  a  role  in  the  control  of  clinical  hypertension.  These
voltage  activated  dihydropyridine  receptors  then  trigger  and  activate  the  ryanodine
receptors that are present on the sarcoplasmic reticulum (SR). Once activated,  these
ryanodine receptors then open and release a flood of Ca2+ ions (Braunwald 2007).
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Figure 1.10 Arrangement of myofibrils showing T-tubules (Hayashi et al. 2009).  
(a) a schematic diagram showing the components of  the myofibril enveloped by the
plasma membrane (sarcolemma).  Tiny holes are apparent on the sarcolemma, these
“invaginations” lead to a tubular system down-beneath, called the T-tubules. 
(b) SEM photograph showing the triad (circled) amongst the SR (the sarcolemma has
been stripped off here). 
(c)  SEM  photograph  of  myofibrils  with  the  sarcolemma  intact,  showing  the
invaginations on the surface (arrowed in cyan).Scale bars 500 nm.
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1.5.3 EC coupling in RyR1 
A surge in the voltage causes a conformational change in DHPR which in turn causes an
allosteric  interaction  between  DHPR  and  RyR1  to  open  the  RyR1  calcium-release
channel, see fig 1.11 (a). It should be noted that the DHPR is only linked to every other
RyR1 and CICR may be responsible, in some way, for triggering these alternate RyR1
channels. RyR1, when isolated from the SR, can also be activated by Ca2+ but this is not
thought to be the direct physiological mechanism. When the stimulus for contraction
ceases, the cytosolic calcium is re-sequestered into the SR-Ca2+ store by the SERCA
pump (Blayney & Lai 2009). 
1.5.4 EC coupling in RyR2
The cardiac  DHPR itself,  when  it  is  activated  by voltage,  becomes  a  Ca2+ channel
allowing extra  cellular  Ca2+ to  flow into  the  cell  and activate  RyR2,  the  process  is
termed Ca2+ induced Ca2+ release (CICR). The influx of Ca2+ through the DHPR initially
flows into a confined space called the dyadic cleft.  Due to the small volume of this
space a small number of Ca2+ ions results in a rapid increase in concentration within the
dyadic  cleft  to  reach  the  threshold  of  RyR2  activation  (10-7umM)  (Bers  2002),
(Blayney & Lai 2009).  
As a result the RyR opens and the SR Ca2+ flows out to activate the myofilaments. In
order  for  relaxation  to  occur  the  systolic  Ca2+ is  re-sequestered  into  the  SR by the
SERCA pump and the proportion which corresponds to Ca2+ influx is returned to the
extra-cellular space via the Na/Ca exchanger. For this action to run to completion, the
RyR channel has to close. There a number of proposed mechanism for the closing of the
channel  including  reduced-luminal-calcium,  increased  calcium  in  the  dyadic-cleft
(which also contributes to the retrograde inhibition of the LTCC and the plateau phase
(2) of the action potential shown in figure 1.9), and mechanisms of inactivation within
the RyR itself. Thus, normally calcium homoeostasis is restored by returning calcium to
the store and extruding calcium (Bers 2002), (Blayney & Lai 2009).
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Figure 1.11 The difference between activation of RyR molecules in cardiac and
skeletal muscle.  
(A & B) In skeletal muscle, RyR1 molecules are coupled to the dihydropyridine receptor
(L  type  Ca2+ channel)  which  then  activates  the  opening  of  the  RyR1  molecule.  In
cardiac muscle, the influx of calcium ions via the L-type calcium channels drives the
opening of the ryanodine receptors via the process known as “calcium induced calcium
release” (CICR). The 10-12nm gap at the junction of the SR and T tubules in cardiac
muscle in referred to as the dyadic cleft. This is an important microdomain involved in
CICR with regards to increasing Ca2+ concentration.
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(C) The schematic arrangement of channels related to CICR mechanism. These include
voltage gated L-type calcium channels present in the T-tubule system, RyR2 in the SR
membrane,  and  also  the  SERCA and  NCX  (Na+/Ca2+ exchangers)  associated  with
repolarisation after CICR has occurred.  
1.6 Phosphorylation and the “stress” response
Phosphorylation has a number of roles related to the regulation of protein activity, often
a conformational change can be triggered in the target protein resulting in a change in
function or continuation of a signalling pathway. Serine is a commonly phosphorylated
amino acid with the addition of phosphate to the hydroxyl of the R group of the amino
acid. RyR2 has three clearly identified phosphorylation sites, all of which are serines.
These sites are acted upon by different combinations of kinase/phosphatase pairs; so
allowing for finer control of RyR through phosphorylation. 
The phosphorylation sites are usually referred to in conjunction with the kinase that is
thought to act upon that site, Ser 2809 (2843 in RyR1) and 2030 are associated with
protein  kinase  A (PKA)  and  Ser  2815  with  Ca2+/CaM-dependent  protein  kinase  II
(CaMKII)  (Niggli et al. 2013); amino acid numbers here are given for human RyR2.
There is still  some debate over the specificity of the kinases for these sites and the
precise effect that the phosphorylation of each site has on the function of the channel. It
is thought likely that there are additional phosphorylation sites throughout RyR which
may impact on the physiological activity that has been attributed to individual kinases in
some reports. 
A range of experiments, involving transgenic animals, indicates that CaMKII activity
leads  to  a  general  increase  in  activity  from  Ca2+ signalling  through  to  related
downstream events such as EC coupling. This increased response is more Ca2+ sensitive
and may occur through a response to increased Ca2+ levels (MacQuaide et al. 2007) but
operates in a less well regulated fashion than the non-phosphorylated state. It should be
noted that some of these effects are due to CaMKII having other targets in addition to
Ser 2815. These include the L type Ca2+ channel, linked to increased Ca2+ signalling, and
the  phospholamban  associated  with  SERCA,  found  to  increase  SERCA activity  in
34
preparation for the next excitation-contraction event (Niggli et al. 2013). 
PKA appears to have a similar range of targets to CaMKII but its overall effects seen at
the cellular and above level maybe more subtle and, as such, are difficult to pinpoint
with conflicting data appearing in the literature. Generally there is an increase in heart
function activity, as observed with CaMKII activity, as PKA is activated by increasing
cAMP levels  caused  as  part  of  adrenergic  stimulation  through  the  flight  or  fight
response.  Hyperphosphorylation  of  Ser  2809  has  been  linked  to  heart  failure  by
promoting increased Ca2+ leak but analysis of more recent studies are suggesting Ser
2815  as  a  stronger  candidate  for  this  mechanism  (Valdivia  2012).  Part  of  this
mechanism may be linked to the apparent dissociation of FKBP12.6 from RyR seen in
some hyperphosphorylation models (Marx et al. 2000a).  
Phosphorylation  is  linked  to  up-regulation  of  ECC  in  response  to  beta-adrenergic
stimulation also known as the flight or fight response.  Essentially,  raised circulating
adrenaline  levels  activates  the  beta  1  adrenegric  receptors  on  the  myocyte  surface.
These G protein linked receptors activate adenyl  cyclase which converts  ATP to the
second messenger cyclic AMP which freely diffuses throughout the myocyte to activate
protein PKA. PKA is associated with a number of key proteins involved in ECC, these
include PLB which activates SERCA, LTCC, RyR and troponin (as shown in figure
1.11). The net effect is to up regulate calcium fluxes throughout the cell increasing heart
rate. 
1.7 Arrhythmia
RyR are  associated with arrhythmic events  which are triggered  by phosphorylation.
However, arrhythmias can arise from many causes as illustrated in figure 1.12 below.  
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Figure 1.12 Relationship of the cardiac action potential to the ECG.  
(a) The effect of sodium channel inhibitors, shows that the slope of phase O is shifted to
the right (as shown in the red slope) when sodium channel inhibitors are used.
(b) The lengthening of the ST segment can be achieved by potassium channel inhibitors
or even calcium channel inhibitors.   
In heart  failure,  low cardiac  output  due  to  weakened pumping activity of  the  heart
results  in  low  blood  pressure  and  impaired  tissue  perfusion.  This  is  sensed  by
baroreceptors in the circulation which feedback to the brain, increasing the sympathetic
tone  by  enhanced  sympathetic  activity.   This  also  results  in  enhanced  release  of
adrenaline, and therefore greater release of calcium ions from stores. However, as the
contractile  apparatus  is  damaged in  heart  failure,  even this  increased  calcium wave
would not have much of an effect on increasing contractile efficiency, conversely, it
would cause depletion of calcium stores in the SR, leading to lower circulating calcium
levels (Braunwald 2007). The increased sympathetic tone in damaged muscle, increased
circulating  catecholamines  and  the  low calcium levels  all  lead  to  increased  risk  of
arrhythmias in the myocardium.
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Figure 1.13 The hypothalamic-pituitary axis feedback circuit (Braunwald 2007).
As shown here, increased stress levels will elicit greater release of adrenaline into the
systemic circulation which will increase the heart rate, forcing more blood around the
circulation.
During intense exercise or when greater cardiac output is needed, feedback circuits to
the brain increase adrenaline release, which then encourage enhanced cardiac muscle
contractility  by  enhancing  greater  release  of  calcium  ions  from  stores  by  opening
ryanodine receptors. 
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1.7.1 Mutations in ryanodine receptors 
1.7.1.1 RyR1
Mutations  in  the  skeletal  isoform of  the  gene  (RyR1 gene)  are  associated  with  the
clinical manifestation of malignant hyperthermia (MH), encountered when these gene
carriers are administered volatile anaesthetics such as the commonly used halothane.
Malignant hyperthermia is a potentially fatal condition which if noted during surgery,
only a short window of time exists before the administration of life-saving dantrolene (a
muscle relaxant) can have an effect and prevent death  (Braunwald 2007).  Some MH
mutations  result  in  central  core  disease  (CCD)  which  manifests  as  disordered
myofilaments and muscle weakness. 
1.7.1.2 RyR2
Similar  point  mutations  in  RyR2  cause  an  arrhythmic  condition  termed
catecholaminergic polymorphic ventricular tachycardia (CPVT) or arrhythmogenic right
ventricular dysplasia/cardiomyopathy (ARVD/C) type 2, the latter typified by fibro-fatty
streaks in the right atrium (Norman & McKenna 1999). In addition, it should be noted
that some CPVT mutations are also found in calsequestrin (Mohamed et al. 2007). 
The heart beat is normal at  rest  but exercise or emotional stress (e.g. flight or fight
response i.e.  phosphorylation) can result in tachycardia leading to a potentially fatal
cardiac  arrhythmia.  The majority  of  identified  disease  causing  mutations  have  been
located in  3 cluster  regions  within RyR as  shown in figure 1.14 (below).  Sequence
analysis conducted on carrier families revealed the first set of known mutations in RyR2
(Priori et al. 2001). 
Equivalent clusters of mutations in the N and C terminal, and central regions are seen
for RyR2 (CPVT and ARVD2) and RyR1 (MH and CCD). With specific mention to
CPVT mutations in RyR2, the C terminal domain region is usually further split into the
cytoplasmic I domain and transmembrane domain which also includes the C terminal
region itself (Thomas et al. 2006). Selected CPVT mutations studied in the interacting
(I)  domain  were  seen  to  trigger  increased  signal  variability  in  Ca2+ release  and
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destabilise interdomain interaction (George et al. 2006).    
Figure 1.14 Locations of CPVT mutations within RYR2
Each  CPVT mutation  represented  by  vertical  bar,  these  mutations  can  be  seen  to
grouped into clusters. Selected mutations are shown throughout the RyR2 amino acid
sequence. 1136 marks the end of the N terminal mutation cluster, 1724-2534 the central
region cluster, and 3946 and 4076 are indicated within the I domain section of the C
terminal cluster.   
1.7.2 Effect of catecholamines on the myocardium
To  further  explain  CPVT,  the  nature  and  effects  of  catecholamines  have  to  be
considered. Figure 1.15 illustrates the chemical structure of some of the catecholamines
present in the body.  In post-infarct patients, the incidence of sudden cardiac death is
greatly  reduced  by  regular  intake  of  beta-blocking  drugs.  This  fact  highlights  that
ischemic  events  induce  enhanced  sympathetic  activation  (hence  local  catecholamine
activity)  and  this  leads  to  increased  arrhythmogenic  properties  of  the  myocardium
(Anon 1981), (Yusuf et al. 1985).
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Figure 1.15 Structure of Catecholamines.  
Catechols are naturally occurring chemicals (name originating from the extracts of the
tree  –  Acacia  catechu)  which  have  an  aromatic  ring  with  two  hydroxyl  groups.
Catecholamines  are  therefore  catechols  with  an  amine  group.  Naturally  circulating
catecholamines  in  the  body  such  as  dopamine,  noradrenaline  (norepinephrine)  and
adrenaline (epinephrine) are synthesised from tyrosine and phenylalanine.
1.7.3 How a faulty RyR2 channel produces cardiac arrhythmias 
Inherited or de novo mutations in the RyR2 gene or ischemic events, hypertrophy of the
heart  wall,  increased  sympathetic  tone  or  cardiac  failure;  all  these  mechanisms  can
cause a diastolic Ca2+ leak through the RyR2 channel. This leak of calcium ions can
produce transient increases in calcium currents via the heart muscle cells. The wave of
calcium ions released at inappropriate timings will reverse NCX thus extruding 2 Ca2+
and bringing in 3 Na+. This triggers delayed-after-depolarisations (as shown in figure
1.16). If sufficient DADs are generated within a certain space of time, this can cause the
depolarisation of heart muscles above the threshold limits. Since the excitation event is
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linked to contraction (EC-coupling), these sudden groups of DADs can result in either a
single  or  multiple  premature  heartbeats,  thus  resulting  in  arrhythmia.  The  events
described above are summarised in figure 1.17 (Iwasaki et al. n.d.).
Figure. 1.16 Possible  way  in  which  ectopic  rhythms  contribute  to  cardiac
arrhythmias (Iwasaki et al. n.d.).  
The above trace shows how a deviation from the normal action potentials can give rise
to an arrhythmogenic pathway,  namely delayed-after-depolarisations  (DAD).   AP =
action potential. 
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Figure 1.17 How a leaky RyR2 channel leads to arrhythmia (Braunwald 2007).  
The untimely wave of calcium ions trigger the inward activating NCX, thus activating
multiple DADs.  These then trigger an action potential that is asynchronous with the
rest of the heartbeats, triggering a premature heartbeat, thus throwing the rest of the
heart-beat rhythms into dysryhthmia.
The common arrhythmia  caused by faulty  RyR2 molecules  that  gives  rise  to  leaky
channels,  is  a  “polymorphic  ventricular  tachycardia”.  There  are  a  number  of  ways
ventricular tachycardia can evolve in a heart muscle although a thorough discussion of
these are beyond the scope of this thesis.  Whenever the heart rate is above 100 beats
per minute, a patient is termed clinically to be in tachycardia. This is usually measured
on an ECG trace by calculating the distance between subsequent R waves. Ventricular
tachycardia usually has a common morphology, broad QRS complexes (wide distances
between the Q and S wave) (Braunwald 2007).
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Figure 1.18 ECG displaying polymorphic ventricular tachycardia.  
Ventricular tachycardia is any tachy-rhythm that has an R-R rate of more than 100
beats per minute.   Untreated VT can quickly progress to life-threatening ventricular
fibrillation  and  once  noticed  on  a  heart  trace  or  cardiac  monitor  is  a  medical
emergency.  
It is clear from the morphology of the trace, that the peaks of the QRS complexes are
appearing to “dance” around the ECG-paper, hence giving it the old name of “torsade
de pointes” or the polymorphic nature of the QRS complexes. The rhythm is not in
sinus, as there are no atrial contraction peaks (P waves) seen at all and there is a clear
beat-to-beat variation between each QRS complex. This type of ventricular arrhythmia
is commonly seen when patients inherit a faulty RyR2 gene.  (note: patient names and
details are blackened out to preserve patient confidentiality).
1.8 Overview of the regulation of RyR channel 
The previous sections of this chapter have discussed the origin of the electrical impulse,
the  conversion  of  that  form of  energy to  mechanical  contraction,  and  subsequently
explored  the  genesis  of  normal  and  abnormal  rhythms.  The  focus  of  the  following
sections is now shifted onto the regulation of the ryanodine receptor itself. 
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1.8.1 Domains and interaction sites within RyR 
Analysis of the amino acid sequence combined with a range of experimental techniques
have located a number of domains and functional sites throughout RyR. In RyR2,  Ca2+
is the most important physiological regulator. In the absence of Ca2+ the channel does
not open. 
The RyR displays a bi-phasic response to cytoplasmic Ca2+, the threshold for activation
is between 10-8 and 10-7 M. Maximal activation at between 10-6 and 10-5M, inhibition at
10-3M. RyR is also regulated by luminal Ca2+ concentration. The Ca2+ activation site(s)
have not been definitively identified, one potential candidate is E 3885  (Chen et al.
1998).
There are other small molecules that a play a physiological regulation role such as ATP
which  opens  the  channel  and  Mg2+; which  in  millimolar  concentrations,  closes  the
channel. There is some suggestion that Mg2+ can compete for the Ca2+ activation site(s)
(Gillespie et al. 2012).
There  are  a  number  of  small  protein  modulators  which  predominantly  inhibit  the
channel such as FKBP12/12.6 and CaM that act upon the cytoplasmic region of the
channel. In addition, calsequestrin, triadin and junctin are associated with the luminal
portion  of  RyR  (MacKrill  1999).  These  proteins  are  discussed  below  and  CaM  is
examined in greater detail later in this chapter (see section 1.8.2).  In addition to these
sites of interaction there are organisational domains throughout RyR. Some of these
many sites and domains are shown in figure 1.19 and are discussed in the following
subsections.
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Figure 1.19 Key sequences and ligand binding sites of RyR 
(Upper) Locations shown on linear map of RyR (D’Cruz, L.G., Yin, C.C., Williams,
A.J., Lai 2009). 
(Lower) Detailed section of RyR2 amino acid sequence displaying locations of CPVT
mutations within this region and domains of interest to this thesis. 
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1.8.1.1 Calsequestrin, triadin and junctin
The role of calsequestrin in Ca2+ concentration sensitivity in ECC is mentioned earlier in
this  chapter.  With  this  Ca2+ binding  function,  calsequestrin  has  been  suggested  as
playing a role as part of a luminal Ca2+ sensor for RyR. Calsequestrin, which undergoes
a conformational change with Ca2+ binding, forms a complex with triadin and junctin,
which both have luminal and transmembrane regions. This complex appears to reduce
the open probability of the RyR channel when Ca2+ concentration is low, however, this
inhibition is reduces as the Ca2+ concentration increases (Györke et al. 2004). 
1.8.1.2 Mutation clusters
The majority of identified disease causing mutations have been located in  3 cluster
regions within RyR as shown in figure 1.14. Sequence analysis conducted on carrier
families  revealed  the  first  set  of  known  mutations  in  RyR2  (Priori  et  al.  2001).
Equivalent clusters of mutations in the N and C terminal, and central regions are seen
for RyR2 (CPVT and ARVD2) and RyR1 (MH and CCD). With specific mention to
CPVT mutations in RyR2, the C terminal domain region is usually further split into the
cytoplasmic I domain and transmembrane domain which also includes the C terminal
region itself (Thomas et al. 2006). 
1.8.1.3 Divergent regions
Within the  RyR amino acid  sequence,  3  areas  of  conspicuous variation were  found
which were labelled divergence regions D1, D2 and D3. These regions are, for RyR1
and RyR2 (in brackets), amino acids, D1 4254-4631 (4210-4562), D2 1342-1403 (1353-
1397), and D3 1872-1923 (1852-1890) (Sorrentino & Volpe 1993). It is thought that D2
plays  an important  role in  excitation-contraction coupling (ECC). In mutated mouse
skeletal  myocytes,  in  which  the D2 region had been deleted,  RyR was still  able  to
function as a Ca2+ release channel but ECC activity was lost. Expression of wild type
RyR1 restored ECC activity in these cells however, if RyR2 was expressed instead there
was no return of ECC function (Yamazawa et al. 1997). 
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D3 has  also  been  suggested  to  play  some  role  in  ECC.  Through  yeast  two-hydrid
experiments, D3 of RyR1 has shown to interact with a region of the L type Ca2+ channel.
When  D3  of  RyR2  was  substituted  occasional,  weak  interactions  were  observed
(Proenza et al. 2002). D1 appears to play a role in the channel's sensitivity to Ca2+ and
caffeine  concentrations.  Deletion  mutants,  and  chimeras  of  RyR  1  and  2  displayed
altered  responses  to  those  of  wild  type  channels  in  ryanodine  binding  experiments.
Complete  deletion  of  D1 did  not  remove caffeine  or  Ca2+ responses  in  the  channel
indicating that D1 does not contain binding sites for these molecules (Du et al. 2000).
Tagging the divergent regions with green fluorescent protein, subsequent cryo-EM and
comparison to the wild type during 3D reconstruction has suggested locations of these
regions on the model of RyR.    
1.8.1.4 FKBP 12/12.6
FK506 binding proteins (FKBP) are members of the immunophilin family which are
binding targets of immunosuppressive drugs, in this case tacrolimus (initially designated
FK506).  They  have  peptidyl-prolyl  isomerase  activity  catalysing  the  cis-trans
isomerisation of peptide bonds. As regards to RyR, FKBPs were first identified when
they were co-purified with RyR1. These FKBPs were named for their molecular masses,
FKBP12 and FKBP12.6. One FKBP12 was shown to interact with one RyR1 subunit
(Jayaraman  et  al.  1992),  so  that  four  FKBP  molecules  are  associated  with  the
functioning channel  homotetramer.  RyR1 associates  with both FKBPs though RyR2
appears to preferentially bind FKBP12.6. However, a recent study indicates that there
may  be  variation  in  FKBP  type  binding  preference  for  RyR2  across  species
(Zissimopoulos et al. 2012a). A FKBP12 binding site is shown in figure 1.19, this site
has  not  been  consistently  reported  in  the  literature  and  other  sites  within  the  RyR
sequence, in particular for RyR2, have been suggested  (Zissimopoulos & Lai 2005a),
(Zissimopoulos & Lai 2005b).  
Both FKBPs have high affinity binding with RyR in either the open or closed state,
however there is greater affinity for the closed channel (Jones et al. 2005). FKBP12.6
binding to RyR2 stabilises the closed conformation of the channel so inhibiting RyR2
activity. While there is some disparity in reported results, it is suggested that these may
be due to other effects on the EC coupling machinery, a reduction in FKBP12.6 levels
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leads to greater Ca2+ transients and more muscle contractions  (Xiao et al.  1997). As
expected,  an increase in  FKBP12.6 leads to  reduction of channel  activity shown by
decreased calcium spark frequency, amplitude and frequency (Gómez et al. 2004).
1.8.1.5 Phosphorylation sites
A number of phosphorylation sites, their interactions with PKA and CaMKII and the
associated changes in physiological function in RyR have been previously discussed in
section 1.6 of this chapter.
1.8.1.6 Interacting (I) domain
This  region has  been studied  in  RyR2 and proposed to  be involved in  interdomain
interaction  and,  as  such,  has  been  named  the  interacting  (I)  domain  (George  et  al.
2004a).  The  I  domain  of  RyR2  comprises  of  two  distinct  domains,  the  interaction
domain located between residues 3722-4353 and the modulatory domain,  containing
two putative TM domains located at residues 4353-4610 (George et al. 2004a), (George
et  al.  2006).  It  should  be  noted  that  this  region  contains  a  high  number  of  CPVT
mutations. Selected CPVT mutations studied in the interacting (I) domain were seen to
trigger  increased  signal  variability  in  Ca2+ release  and  destabilise  inter-domain
interaction (George et al. 2006).    
The interaction of the I domain may been through this region being able to behave like a
hinge. It has been shown that the regulatory events at the cytoplasmic domain are not
appropriately conducted to the pore domain following RyR2 mutations in the I domain
(George et al. 2004a), (George et al. 2006). It is thought that a number of hydrophobic
regions in the I domain are involved in the regulatory interactions that this section of
RyR2 performs (George et al. 2006). 
Homologous regions have been identified in RyR1 and RyR3. In addition, within the I
domain, a series of amino acid repeat sequences that are present in IP3Rs and RyR have
been identified. This region of repeats has been termed the RyR and IP3R homology
(RIH) associated domain, and has been proposed to possibly have protein binding or
related function  (Ponting 2000). Within the I domain a region containing 2 EF hand
48
motifs has been identified. This region has been termed the CaM like domain (CaMLD)
and is discussed in later in this chapter. 
Figure 1.20 The RyR2 I  Domain  intrinsically  controls  RyR2 opening through
conformational rearrangement (Jundi 2010).  
Schematic diagram, showing that conformational re-ordering within the I domain is
associated  with  RyR2  channel  opening  and  closing,  based  on  data  obtained  from
fluorescence resonance energy transfer (FRET) studies of cytoplasmic (light grey) and
transmembrane  domain  (dark  grey)  interactions.  Functionally  distinct  sub-regions
within the I domain are predicted from experimental data and computational analysis.
1.8.1.7 CaM Binding Site 
A CaM binding site (CaMBD) has been identified in RyR1 between amino acids 3614-
3643. An equivalent,  highly conserved region was found in RyR2 between residues
3583-3603.  Further  details  of  this  site  and the  potential  significance  of  its  flanking
regions are discussed later in this chapter. 
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1.8.1.8 Transmembrane domains
The transmembrane domains are clearly the key region of the channel forming the pore
within  the  SR  membrane.  A  number  of  models  exist  predicting  the  number  of
transmembrane  segments  present  in  this  domain.  A site  directed  antibody approach
appeared  to  support  at  least  4  segments  of  proposed  models  and  considered  the
possibility of an even number up to a total of 10 segments. Additional data from this
experiment  indicated  that  the  transmembrane domain  was  supported  by a  relatively
short C terminal and longer N terminal cytoplasmic domains  (Grunwald & Meissner
1995). 
 
1.8.2 CaM and RyR regulation
CaM regulates the RyR channel both directly and indirectly. A CaM interaction of note
is  the  activation  of  CaMKII.  A range  of  experimental  techniques  reported  in  the
literature indicates that CaMKII activity leads to a general increase in activity from Ca2+
signalling through to related downstream events such as ECC. This increased response
is  more  Ca2+ sensitive  and  may occur  through  a  response  to  increased  Ca2+ levels
(MacQuaide et  al.  2007) but operates in a less well  regulated fashion than the non-
phosphorylated state. It should be noted that some of these effects are due to CaMKII
having other targets in addition to Ser 2815. These include the L type Ca2+ channel,
linked to increased Ca2+ signalling, and the phospholamban associated with SERCA,
found to  increase  SERCA activity  in  preparation  for  the  next  excitation-contraction
event (Niggli et al. 2013). 
The interaction of CaM with the CaMBD of RyR is of particular interest to this thesis.
CaM is known to inhibit the three RyR isoforms at Ca2+ concentrations greater than 1
μM. At submicromolar concentrations RyR1 and RyR3 are stimulated by Ca2+ (Tripathy
et al. 1995). However, at these lower concentrations RyR2 was either unaffected (Fruen
et al. 2000) or inhibited (Balshaw et al. 2001) by CaM. 
CaM is  known  to  bind  with  high  affinity  to  α  helical  sections  of  protein.  Several
variations of CaM interaction motifs have been proposed from this structure and lead to
the identification of CaM binding sites in a number of proteins that contain the “IQ
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motif”  (named  after  the  first  2  amino  acids  in  the  sequence  motif);  seen  in  many
proteins including RyR and myosin (Rhoads & Friedberg 1997). 
Tryptic  digests  on  RyR1  revealed  that  the  arginine  residues  3630  and  3637  were
protected by apo and Ca-CaM binding (Moore et al. 1999). Both forms of CaM were
shown to bind to a synthetic peptide matching amino acids 3614-3643. Deletion of the
last 9 residues removed the ability to bind apo-CaM but not Ca-CaM  (Rodney et al.
2001).  Fluorescence  resonance  energy  transfer  (FRET)  based  experiments  have
subsequently  agreed  with  the  3614-3643  location  of  a  CaM  binding  site  in  RyR1
(Cornea et al. 2009). A highly conserved site was identified in RyR2, amino acids 3583-
3603.  Deletion  of  this  region  resulted  in  the  prevention  of  CaM  binding  to  RyR2
(Naohiro Yamaguchi et al. 2003).
Mutational studies conducted on the CaM binding site of RyR1 and RyR2 indicated that
regulatory CaM binding is to the one highly conserved site (Naohiro Yamaguchi et al.
2003). Substitution of the non-conserved N and C terminal flanking regions to the CaM
binding site in RyR1 and RyR2 resulted in the Ca2+ concentration response to CaM as
expected for the opposite  isoform. This  result  suggested that  the Ca2+ concentration
response to CaM by the RyR isoforms is as a result of the difference in sequence in
these flanking regions. Further experimentation pointed to residues in the C terminal
flanking region being responsible for the CaM inhibition of RyR2  (Yamaguchi et al.
2004).    
S100A1, a member of the S100 protein family which contains two EF hand motifs, has
been shown to bind to the same site on RyR1 as Ca-CaM. This S100A1 binding site in
RyR  consists  of  12  residues  identified  in  the  highly  conserved  CaM  binding  site
discussed above. In RyR1 this site is amino acids 3616-3627. An NMR structure of Ca2+
bound S100A1 interacting with a peptide of this 12 amino acid RyR1 binding site (PDB
entry 2K2F) has been determined (Wright et al. 2008).
Comparison of this structure with Ca-CaM bound to a peptide of the RyR1 binding site
(PDB entry 2BCX, (Maximciuc et al. 2006)) indicates 6 residues within the 12 amino
acid peptide that have favourable interactions with S100A1 are involved with Ca-CaM
binding.  The  location  of  these  key  binding  residues  within  S100A1  binding  site
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contained within the CaM binding site of RyR supports the observation that Ca-CaM
can still bind if the last 9 residues of the CaM binding site are deleted  (Rodney et al.
2001). 
Cryo-EM studies have suggested 2 different neighbouring sites for apo-CaM and Ca-
CaM binding in RyR1. However, a 33 ± 5 Å distance between the centres of the 2 bound
forms of CaM was observed (Samsó & Wagenknecht 2002). A number of possibilities
were suggested by the authors to explain the distance between the 2 types of CaM that,
the previously discussed data suggests, share one conserved binding site in RyR. Most
of  these  suggestions  involved  the  movement  of  CaM  and/or  the  domains  involved
around the CaM binding site. Additional cryo-EM studies have been conducted which
suggests  that  there  are  2  overlapping  binding  sites  for  CaM,  in  RyR1,  within  the
reported 30 amino acid binding site. 
The  involvement  of  Ca2+ appears  to  play  a  key  role  in  the  binding  process.  The
conformational change triggered by Ca2+ binding to CaM appears to cause CaM to shift
in its binding position and orientation. It has also been suggested that the binding of
Ca2+ to RyR1 may well promote a conformational change in RyR that alters that the
CaM binding site. A mutant form of CaM unable to bind Ca2+ was found to consistently
bind to the apo-CaM position even in the presence of Ca2+. As regards to RyR2, only
one CaM binding location was observed by this set of cryo-EM experiments. Apo-CaM,
binding to RyR2, appears to bind in the equivalent location of Ca-CaM in RyR1 (Huang
et al. 2013). 
This data would appear to agree with the observation that CaM binding to RyR2 inhibits
the channel even at the lower Ca2+ concentrations that are non-inhibitory for the other
RyR isoforms. It was suggested that this may form the basis of a structural regulation
model in which there is an “inhibitory” and “activating” CaM binding location with the
conserved binding site. The inhibitory location only appears to be functional in RyR2; it
may well be that the flanking regions, particularly those downstream of the binding site,
reported  by  Yamaguchi  et  al  (Naohiro  Yamaguchi  et  al.  2003),  (Yamaguchi  et  al.
2004)are somehow involved in this process.    
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Figure 1.21 Proposed  CaM  binding  locations  within  CaMBD  for  RyR1  and
RyR2.
Schematic showing summary of literature for the proposed CaM lobe interaction sites
within conserved CaMBD of RyR1 and RyR2. Where known, sizes of locations given in
number of amino acids. 
1.8.3 CaMLD
A region of rabbit RyR1, amino acids 4064-4210, was found to have CaM like structure
containing  2  putative  EF  hands,  binding  Ca2+ and  displaying  a  Ca2+ induced
conformational change. Peptides of this region were found to interact with an identified
CaM binding site, 3614-3643, within RyR1. Owing to this behaviour the region was
termed the CaM-like domain (CaMLD) (Liangwen Xiong et al. 2006). Antibodies raised
against CaMLD and the CaM binding site both significantly inhibited ryanodine binding
to  RyR1  suggesting  interaction  between  the  two  domains  is  required  for  channel
activation.  Experiments  conducted in  which the CaM binding site  was fluorescently
labelled  displayed  a  Ca2+ dependent  interaction  with  CaMLD  (Gangopadhyay  &
Ikemoto  2008).  It  was  found  in  stimulated  neonatal  cardiomyocytes  that  CaM
dissociates  from  RyR  which  lead  to  an  increased  rate  of  Ca2+ release  events  and
eventually  hypertrophy  of  the  cells.  When  an  anti  CaM  binding  site  antibody,  so
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preventing the interaction of CaMLD with the binding site, was included these events
did not occur. It was suggested that the uncontrolled interaction between the 2 domains
could lead to the disease state of the cardiomyocytes (Gangopadhyay & Ikemoto 2011).
Due to the importance of this interaction, the focus of this thesis involves the study of
this calcium binding domain within the I domain of RyR2. Structural and functional
aspects of this domain are further examined in chapters 3 and 5 respectively.      
1.9 EF hand motifs
In  terms  of  RyR  function  the  importance  of  the  CaMLD/CaMBD  association  is
highlighted by the fact that the CaMLD portion of the molecule contains a number of
CPVT point mutations which are also prevalent in the sequence flanking this domain
(see figure 1.19, lower panel). As previously stated, within CaMLD two EF hand motifs
have been identified (Xiong, 2006). To further understand the potential mechanism of
interaction  between CaMBD and CaMLD, and the  potential  impact  of  CPVT point
mutations within the CaMLD region requires the EF hand motif to be examined. 
The  presence  of  Ca2+ binding  proteins  (CaBPs)  has  allowed  greater  control  in  the
propagation and site of effect of Ca2+ signalling (Case, 2007). It is probable that these
CaBPs act as Ca2+ sensors and they transduce their effect via the EF hand motif. This
motif enables the binding of Ca2+ to be converted into a functional output through the
binding protein (Grabarek 2005). 
The structure of a carp muscle CaBP protein, parvalbumin, was determined by x-ray
crystallography. Within this structure a helix-loop-helix motif with Ca2+ bound in the
loop was identified, a neighbouring repeat of this motif also containing Ca2+ was seen.
As this  motif  could be visualised by a  right  hand with the thumb and index finger
extended at a near right angle, the other fingers clenched (see Fig. 1.22), so the term EF
hand was coined (Kretsinger & Nockolds 1973).    
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Figure 1.22 EF hand motif (Haiech et al. 2011).
The second of the pair of EF hand motifs is formed by helices E and F, and the loop
between them. The index finger representing helix E points towards the N terminal of
the protein. The clenched fingers describe the loop to which Ca2+ is bound. The thumb
representing helix F points towards the protein C terminal. The first EF hand motif is
formed by the helices C and D containing a loop. The two motifs are separated by a
short linker.  
Since the discovery of parvalbumin, thousands of distinct EF hand sequences have been
reported. It is not clear how all these alterations between the sequences result in the
variations  in  properties  of  the  EF hands and the  function  of  their  associated CaBP.
However,  most  known functional  high affinity Ca2+ binding EF hands share a basic
overall sequence which relies on the attraction of Ca2+ to a number of side chain oxygen
molecules, commonly 6 or 7, present in the loop (Grabarek 2005), (Nelson et al. 2001).
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Figure 1.23 Canonical sequence of EF hand. 
Schematic image of helix-loop-helix motif displaying shared features of residues found
in  location  of  common  EF  hand.  Nomenclature  of  canonical  EF  hand  taken  from
parvalbumin where helix E is joined to helix F by a loop. Positions of hydrophobic
residues in the helices are shown by n. The * positions are non-conserved and can be
occupied by any amino acid. Commonly conserved amino acids, including variations,
are shown. In the loop there are six conserved residues as indicated by the numbered
residues.  These positions are sometimes labelled X, Y, Z, -Y, -X and -Z, this system is
based on the first three Ca2+ coordinating residues defining the axes of ligand geometry.
Positions 1 (X), 2 (Y), 3 (Z) and 6 (-Z) are side chain oxygen ligand amino acids. The -Y
position is indicated by a # symbol in the loop, this residue is a backbone carbonyl
ligand. There are two other shown residues in the loop. One of these is a glycine which
is not always conserved. The other is between positions 4 and 5, in earlier studied
examples this was often an isoleucine residue. 
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The canonical EF hand, as shown above (figure 1.23), consists of a twelve residue loop.
The first coordinating ligand, position 1 (X), is commonly an aspartate and the last,
position  6  (-Z),  is  predominantly a  glutamate  which  contributes  two  oxygen  atoms
serving as a bidentate ligand. In addition with positions 1 (X), 2 (Y), 3 (Z) and 6 (-Z),
the contributing two oxygen molecules from positions 4 (-Y)  and 5 (-X), mean that
bound Ca2+ is attached to 7 oxygen atoms in pentagonal bipyramid. 1 (X) and 5 (-X) act
as  the  cap  and  base  with  the  other  positions  forming  the  pentagon.  The  centrally
positioned 4 (-Y) residue binds with the main carbonyl chain oxygen atom as opposed
to a side chain oxygen. The immediate downstream residue is hydrophobic, prevailing
valine, leucine or isoleucine as shown in the figure. The 4 (-Y) residue and its neighbour
are part  of a short  β sheet.  In paired EF hands, as seen for parvalbumin, these two
residues form two hydrogen bonds with their  equivalent  residues in the matching β
sheet so connecting the two loops (Strynadka,  1989).  These two β sheets linked by
hydrogen bonding are referred to as the EF hand β scaffold (Grabarek 2005). 
There are examples of the 6 (-Z) position glutamate being substituted for another amino
acid however there is usually compensation by insertion of additional residues in the N
terminal  of  the  loop.  This  restores  the  coordination  geometry  of  the  Ca2+ binding
(Grabarek  2005).  Mutational  work  has  been  conducted  on  this  glutamate  residue
replacing it with an amino acid only able to provide 1 oxygen atom. The reduction of an
oxygen is thought to reduce the stability of the orientation of the binding Ca2+ which is
observed in a reduced affinity for Ca2+ (Maune et al. 1992). Mutations have been studied
in the other residues of the loop in calbindin D9K. Glutamate and aspartate residues
were replaced individually and in multiples by their amide equivalents glutamine and
asparagine. Individual mutations in both ligating and non ligating residues in the loop
caused  only  small  structural  differences  though  there  was  some  accumulation  for
multiple mutations. Non ligating mutations were found to reduce Ca2+ affinity as well as
those in coordinating positions (Linse et al. 1991).
Additional mutations in the hydrophobic residues, which have no direct contact with
bound Ca2+, in calbindin D9K have been studied. Mutations were selected to alter the
side chain volume of hydrophobic residues. Structural differences were only observed
when the mutated amino acid had grossly different structure to that of the wild type. The
mutations were found to significantly decrease Ca2+ affinity and increase the rate of
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release of bound Ca2+  (Kragelund et al. 1998).        
There are no known monomeric CaBPs, a large number of known CaBPs contain paired
EF hands, for example troponin C. Troponin T binding to troponin C provides a good
example of how a minimal  EF hand dimer connected by a helix  binds to a partner
protein, in this instance troponin I (see figure 1.24 below). 
Figure 1.24 Cardiac muscle troponin complex showing interaction of EF-hand
with partner proteins. 
The cardiac  muscle  troponin  structure  showing  the  acidic  residues  within  the  loop
region  of  the  EF hand in  Troponin  C (ochre  coloured)  holding  the  calcium ion  in
position. The TnI molecule is an extended helix, clamped between the helices of the EF
hand of troponin C. Troponin T is also an extended helix which swaps interactivity with
troponin I in the organisation of the thin-filament. (Figure generated in pymol using
coordinates from PDB: 1J1E).
In these structures there were two Ca2+  bound to the C terminal domain of the protein
while the two EF hand motifs of the N terminal were unbound. It was observed that the
two  domains  had  very  different  conformations.  The  C  terminal  was  in  an  open
conformation  which  presented  a  large,  solvent  exposed hydrophobic  pocket.  The N
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terminal had a closed conformation in which the domain helices were tightly packed
against  each  other  (Herzberg  &  James  1985).  It  was  proposed  that  Ca2+ binding
triggered the conformation from the closed to the open state. The exposed hydrophobic
pocket of the open conformation acting as the target binding site (Herzberg et al. 1986).
This transition model has been named the HMJ model, the name derived from the first
letter of the authors surnames, Herzberg, Moult and James. Subsequent biochemical and
structural data has supported this model. As structural data are required to fully confirm
this type of conformational change it is unknown how extensive this model is amongst
other EF hand CaBPs.
Other proteins, such as CaM, contain two pairs of EF hands. A few proteins contain odd
numbers of EF hands, for example parvalbumin contains three, one of which functions
in an ancillary role to the binding pair. As the EF hand motifs in the heterodimer have
variations in their amino acid content,  as shown in canonical EF hand motif  (figure
1.23),  this  confers  slightly  different  characteristics  upon  the  functioning  pair,  most
importantly  Ca2+ binding  affinity.  It  should  be  noted  that  under  conditions  of  high
concentration of magnesium ions (Mg2+) and low Ca2+, some EF hand motifs will bind
Mg2+. This binding impacts on the behaviour of the related CaBP though it is not known
what  component  of  the  sequence  of  the  binding  loop  confers  Mg2+ binding.  These
variances allowed for greater  control  of Ca2+ signalling through the development  of
domains with different Ca2+ conformation responses that had specific binding targets.
The N and C terminals of CaM are a well  researched example of this difference in
paired EF hand domains (Grabarek 2005), (Nelson et al. 2001). 
The EF hand motif heterodimers are linked by the hydrogen bonds in the short section
of β sheet and this linkage is further maintained by many hydrophobic contacts between
the helices from the residues in the n positions (as shown in figure 1.23). The Ca2+
bound form receives extra strengthening from Ca2+ ligand interactions and hydrogen
bonding between polar groups and closely surrounding water molecules  (Strynadka &
James 1989). The stability of the paired EF hand heterodimer has been compared to
synthetic  pairings  of  homodimers.  Chemical  denaturation  studies  combined  with
circular dichroism and NMR conducted on troponin C revealed that the heterodimer is
more easily formed and has greater stability (Shaw et al. 1994). The EF hand scaffold
structure  has  been found to occur  without  the  support  of  the  hydrophobic  contacts.
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However, the contacts between the helices greatly strengthen the overall structure of the
EF hand pair (Wójcik et al. 1997).
There are two general functional divisions within the EF hand CaBPs. Firstly, signal
modulators, including calbindin D9K and parvalbumin, which affect properties of the
Ca2+ signal.  These  CaBPs  do  not  undergo  Ca2+ binding  induced  structural
rearrangements  or  target  interaction.  This  class  is  usually  involved  in calcium
homoeostasis. The second type, of greater interest to this project, are calcium signal
sensors. This class, which includes CaM and troponin C, undergo a calcium induced
conformational changes that allows for binding to their target site (Nelson et al. 2001). 
As stated previously, CaM is a well studied example of an EF hand containing CaBP.
Crystal structures of CaM bound with calcium (Ca-CaM) and calcium free (apo-CaM)
have been obtained showing that CaM follows the HMJ transition model  (Finn et al.
1995), (Zhang et al. 1995). These structures combined with biochemical data display the
differences between the N and C terminal paired EF hand containing lobes of CaM. The
N lobe has been shown to dissociate Ca2+ more quickly than the C lobe. This has been
reflected in the binding affinity with the C terminal having a higher affinity than the N
terminal  (Black et  al.  2006).  The Ca2+ dissociation rate  and binding affinity can  be
affected by the target protein so further fine tuning the Ca2+ signal. Target proteins can
display preferential binding for Ca-CaM or apo-CaM. Those selecting Ca-CaM cause a
slower dissociation rate  of Ca2+ from the bound CaM. However,  proteins preferably
binding  apo-CaM  tend  to  release  CaM  as  the  Ca2+ concentration  increases.  It  is
proposed that in cardiac myocytes that the low intracellular Ca2+ concentrations may not
be sufficient to favour Ca-CaM over apo-CaM. As such apo-CaM may be bound near
local sources of calcium, as Ca2+ concentration increases so CaM is released and goes
onto bind Ca-CaM preferring sites (Saucerman & Bers 2012). Within cardiac myocytes
one of the major proteins that CaM interacts with is RyR as discussed earlier in this
chapter.
The use of mutational studies in examining the EF hand has been discussed. However,
functional mutations related to cardiac disease have been recently observed within CaM
including CPVT linked mutations (Nyegaard et al. 2012). Some of the studied mutations
are associated with a disruption of the CaM inhibition of RyR2 which results in more
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erratic Ca2+ release frequency and duration leading to impaired cardiac function. Cardiac
hypertrophy and earlier  than expected death has been observed in mouse models of
these  mutations  (Arnáiz-Cot  et  al.  2013),  (Yamaguchi  et  al.  2013).  Additional
mutations  associated  with  long  QT syndrome  and  cardiac  arrest  have  been  located
within the conserved residues of the EF hand loop of CaM (Crotti,  2013). As these
mutations are observed in CaM it is worth considering the locations of the known CPVT
mutations  with relation  to  the  EF hand motifs  of  RyR2.  The CPVT point  mutation
E4076K is contained in the loop of the 2nd EF hand motif of RyR2 (see figure 1.25
below)  when compared to  the  canonical  EF hand shown in  figure  1.22.  While  this
mutation is not in one the conserved positions of the loop it is not clear how it will
effect the function of the EF hand. During the time of this thesis this is the only known
CPVT mutation contained within the EF hand motifs of RyR2.    
Figure 1.25 Sequence alignment of RyR2 2nd EF hand motif against canonical EF
hand motif.
RyR2 amino acid sequence shown as top line with closest matching canonical sequence
underneath. Sequence within EF hand loop section is highlighted by box. CPVT point
mutation  E4076K location  is  shown in  red in  RyR2 sequence.  As  in  figure  1.23,  *
indicates non conserved position, n indicates predicted hydrophobic residue within α
helix either side of loop. Threonine residue present in RyR2 where ? symbol is used to
represent expected Ser (or Asp or Asn) residue in canonical amino acid sequence.   
As illustrated above, while there is increasing knowledge about RyR and the role of
mutations upon the channel's function there still much to be understood. Certain regions
within  RyR  have  undergone  more  scrutiny  than  others.  The  advancement  in
comprehending  the  role  of  these  regions  has  increased  as  shown by the  structures
obtained for the N terminal region of RyR. The I domain has been studied and shown to
be involved in domain interaction which is key for the function of the channel. Within
the I domain, a CaM like domain which interacts with a CaM binding site has been
identified. The interaction between these two domains is of particular interest to this
project.
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1.10 Aims of project
It is planned to focus upon the CaMLD which is proposed to interact with the CaM
binding site. Figure 1.26 (see below) summarises what is currently known and indicates
potential interactions between CaMLD and CaMBD, within the context of the proposed
model of I domain regulation of channel gating. To test the role of CaMLD and CaMBD
within  this  model  (working hypothesis),  it  is  intended to  adopt  a  structure/function
approach to  investigate  the  relationship  between the  two domains  and the  potential
effect of CPVT mutations within this region. Both regions will be made as recombinant
proteins and used in various interaction studies. The recombinant proteins will also be
characterised  and  used  for  crystallisation  studies.  Homology  modelling  of  the  two
individual domains, and also both domains and their linking region will be undertaken
to assess key residues essential to their interaction. 
Figure 1.26a Overview of proposed interactions between RyR2 central region and
pore domain. 
Magenta ovals and linker to pore represent I domain. Red pore section from KCSA pore
x-ray determined structure. CaMBD and CaMLD are labelled. 
(A) Basic overview of proposed interaction transitions of I domain, and CaMBD and
CaMLD as RyR2 channel goes from open to closed state.
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Figure 1.26b Overview of proposed interactions between RyR2 central region and
pore domain. 
Section of I domain (magenta) with indented region representing location of CaMLD.
Within CaMBD (blue), CaM lobe interaction location (yellow-green) and C terminus
flanking region (spotted orange) are shown. 
(B) Focus on interaction between CaMBD and CaMLD from panel a. Basic proposed
mechanism for disassociation of CaM from CaMBD with increasing Ca2+ concentration
and transfer to binding of CaMLD to CaMBD. In this figure the linking region between
the N and C terminal lobes of CaM is extended for graphical purposes to illustrate the
possibility of the two lobes of CaM interacting with different locations of RyR2.  
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Chapter 2:
Materials and Methods
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2.1 Materials
2.1.1 General Laboratory Reagents and Chemicals
All  reagents  and  chemicals  were  of  suitable  or  higher  grade  for  the  conducted
experiments  and were obtained from Sigma,  Fisher or Calbiochem unless  otherwise
stated. Equipment for polyacrylamide gel electrophoresis (PAGE) was obtained from
BioRad unless otherwise stated. All solutions were stored at room temperature, unless
otherwise stated. All filter sterilization was through 0.2 μm filters (Sartorius).
2.1.2 General Biological Reagents
• CaCl2, 1M stock: a 1 M solution was filter sterilised and stored at 4°C.
• DNA loading buffer, 5X stock: 50% v/v glycerol, 0.25% w/v orange G, 5x TAE. 
• EGTA 1 M stock: Dissolved in H2O at pH 8.0. Filter sterilised and stored at 4°C.
• IPTG, 1 M stock: prepared and filter sterilised as required.
• Molecular weight DNA markers: obtained from NEB and Sigma
• TAE, 50X stock: 2 M Tris, 2 M acetic acid, 50 mM EDTA
2.1.3 Protein Biochemistry Reagents
2.1.3.1 General reagents
• Ammonium persulfate: 10% w/v.
• Molecular  weight  protein  markers:  pre-stained  Kaleidoscope  (Broad  Range)
markers  obtained  from  BioRad  and  pre-stained  Colorplus  (Broad  Range)
markers obtained from NEB.
• EDTA free protease inhibitor cocktail: obtained from Roche.
• Protein loading buffer, 5X stock: 0.2 M Tris, 10% w/v SDS, 40% v/v glycerol,
0.05% v/v 2-mercaptoethanol, 0.25% w/v bromophenol blue, pH adjusted to 6.8.
• Running buffer, 5X stock: 15 g/L Tris, 72 g/L glycine, 5 g/L SDS.
• Semi-dry transfer buffer: 48 mM Tris, 39 mM glycine, 0.0375% w/v SDS, 20%
v/v methanol.
65
• TBS, 10X Stock: 0.2 M Tris, 1.37 M NaCl, pH adjusted to 7.5.
• TBS-T buffer: 1X TBS, 0.1% v/v Tween-20. 
• Tris, 0.5 M: a 0.5 M solution was pH adjusted to 6.8.
• Tris, 1.5 M: a 1.5 M solution was pH adjusted to 8.8.
• Coomassie stain: 48% v/v MeOH, 42% v/v H2O, 10% v/v glacial acetic acid,
0.2% w/v Coomassie brilliant blue R-250.
• Coomassie destain: 48% v/v MeOH, 42% v/v H2O, 10% v/v glacial acetic acid.
2.1.3.2 Protein purification reagents and specific buffers
• Ni tag standard buffer: 93.2 mM Na2HPO4, 6.8 mM NaH2PO4, 300 mM NaCl,
pH adjusted to 8. 
• Ni tag resuspension buffer:  93.2 mM Na2HPO4,  6.8 mM NaH2PO4,  300 mM
NaCl, 60 mM imidazole, 0.002% v/v 2-mercaptoethanol, pH adjusted to 8. 
• Ni tag bead wash buffer: 93.2 mM Na2HPO4, 6.8 mM NaH2PO4, 300 mM NaCl,
70 mM imidazole, 0.002% v/v 2-mercaptoethanol, pH adjusted to 8. 
• Ni tag bead elution buffer:  93.2 mM Na2HPO4,  6.8  mM NaH2PO4,  300 mM
NaCl, 250 mM imidazole, 0.002% v/v 2-mercaptoethanol, pH adjusted to 8. 
  
• GST tag resuspension buffer: 57.7 mM Na2HPO4, 42.3 mM NaH2PO4, 300 mM
NaCl, 2 mM DTT, pH adjusted to 7.
• GST tag bead wash buffer: 57.7 mM Na2HPO4, 42.3 mM NaH2PO4, 300 mM
NaCl, 2 mM DTT, 5 mM glutathione reduced, pH adjusted to 7.
• GST tag bead elution buffer: 100 mM Tris, 300 mM NaCl, 2 mM DTT, 20 mM
glutathione reduced, pH adjusted to 8.
• General assay buffer: 50 mM Tris, 300 mM NaCl, 2 mM DTT, pH adjusted to 8.
For all protein samples undergoing purification stages utilising a His tag, Ni sepharose
(6 fast flow, GE healthcare) beads were used.  
For all protein samples undergoing purification stages utilising a GST tag, glutathione
sepharose 4B (GE healthcare) beads were used. 
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2.1.4 Bacterial Cell Culture Reagents
Growth media was obtained from Fisher, for some culture work ready made powdered
LB media was purchased from Formedium. All glassware was washed in detergent-free
water prior to use and in some instances also autoclaved (121 C, 15 min). Growth
media  were  autoclaved  under  the  same  conditions  prior  to  antibiotic  addition.
Procedures were conducted in a sterile fume hood or with the use of a Bunsen burner
flame. All surfaces were cleaned with 70% v/v ethanol before and after use. 
• LB broth: 10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl. Autoclaved. Medium
cooled to <50°C before antibiotic addition. Stored at 4°C.
• LB-agar medium: LB broth, 15 g/L agar. Autoclaved. Medium cooled to <50°C
before antibiotic addition. Stored at 4°C once poured.
• TB broth: 12 g/L tryptone, 24 g/L yeast extract, 4 ml/L glycerol made up to 900
ml with H2O. Autoclaved. Medium cooled to <50°C before addition of 100 ml
0.17 M KH2PO4 and 0.72 M K2HPO4, and antibiotic. 
• SOC medium: 20 g/L tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 0.18 g/L KCl,
0.95 g/L MgCl2. Autoclaved. Medium was cooled to <50°C and 2% glucose w/v
was added. Stored at -20°C.
• Ampicillin,  1000X  stock:  100  mg/ml,  dissolved  in  deionised  H2O,  filter
sterilised, stored at -20°C.
• Kanamycin,  1000X  stock:  30  mg/ml,  dissolved  in  deionised  H2O,  filter
sterilised, stored at -20°C.
• Chloramphenicol,  1000X stock: 40 mg/ml, dissolved in deionised H2O, filter
sterilised, stored at -20°C.
2.1.5 Oligonucleotides
Custom oligonucleotide primers were ordered from Sigma-Genosys and were obtained
as  lyophilised  pellets.  Pellets  were  resuspended  in  an  appropriate  volume of  sterile
deionised  H2O  to  give  stock  solutions  of  100  μM,  according  to  manufacturer’s
instructions. Working solutions of 20 μM or 3.2 μM, as appropriate, were prepared by
dilution with H2O and all primers stored at -20°C. The primers used in this study are
shown in chapter 5 accompanying the relevant construct.
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2.1.6 Plasmid Vectors
2.1.6.1 pET15b expression vector
A modified version of the pET15b vector (Novagen) was provided by Dr. M. Bochtler.
This modified version of the commercial vector retains the lac promoter, the N-terminal
His tag and allows for ampicillin selection. However the thrombin cleavage site has
been  removed  meaning  the  His  tag  cannot  be  cleaved  from the  expressed  protein
sequence.  
Figure 2.1.1 Vector map of pET15b (Novagen (Merck)). 
Note that modified version of vector used had thrombin cleavage site removed. 
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2.1.6.2 pETMM Vectors
The pETMM series of expression vectors were generated at EMBL Heidelberg. The
specific pETMM vectors used in this project were provided by Dr. M. Bochtler. The
used  vectors  shared  the  features  of  allowing  for  kanamycin  selection  and  a  TEV
cleavage site which allows for the removal of the N-terminal dual tag. The N-terminal
tags consisted of a His tag and a highly soluble protein. Solubility tags used included
thioredoxin (Trx) (pETMM20), maltose-binding protein (MBP) (pETMM41) and NusA
(pETMM60), an E. coli protein associated with transcription termination. As the vectors
are derived from pET vectors they share a common multiple cloning site (MCS) and the
lac promoter. 
 
Figure 2.1.2 Vector map of pETMM 60 (NusA).
Only  difference  from  other  pETMM vectors  used  is  the  solubility  tag.   Map  from
supplied information received with vector. 
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2.1.6.3 pGEX-6P-1 Vector
pGEX-6P-1  vector  was  obtained  from GE Healthcare.  The  vector  codes  for  an  N-
terminal glutathione-S-transferase (GST) tag, contains the lac promoter and allows for
ampicillin selection.
Figure 2.1.3 Vector map of pGEX-6P-1 (GE Healthcare). 
Expansion shows multiple cloning site of vector, demonstrating the frame of the GST
coding sequence.
2.1.7 Antibodies
The following antibodies were used in this study:
• Ab-103T,  rabbit  polyclonal,  raised  against  glutathione-S-transferase.  Used  at
1:10000 dilution for western blotting.
• Anti-NusA, mouse monoclonal.  Obtained from Santa  Cruz.  Used at  1:20000
dilution for western blotting.
• anti-His (penta His), mouse polyclonal. Obtained from Qiagen. Used at 1:2000
dilution for western blotting.
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• CaM (G-3), mouse monoclonal, raised against amino acids 1-149 human CaM.
Obtained from Santa Cruz. Used at 1:2000 dilution for western blotting. 
• Donkey  anti-mouse  IgG-HRP.  Obtained  from  Santa  Cruz.  Used  at  1:10000
dilution for western blotting.
• Donkey  anti-rabbit  IgG-HRP.  Obtained  from  Santa  Cruz.  Used  at  1:10000
dilution for western blotting.
2.1.8 Computer Software and Data Analysis
Stained protein gels and western blots were scanned at 600 dpi, when possible, using
various image scanners and a densitometer (GS-700, BioRad), image processing was
performed using Paint Shop Pro X (Corel).  Standard spreadsheet packages present in
office  software  (Microsoft  and Libreoffice)  were  used to  analyse  data  and generate
graphs.
DNA and protein sequence analysis  were performed using software available  at  the
ExPASy (http://www.expasy.ch/tools/dna.html), and European Bioinformatics Institute
(http://www.ebi.ac.uk/services)  websites.  In  addition,  protein  secondary  structure
sequence prediction was conducted using the network protein sequence analysis web
server  based  at  the  Pôle  Bioinformatique  Lyonnais  (http://npsa-pbil.ibcp.fr/cgi-
bin/npsa_automat.pl?  page=/NPSA/npsa_server.html).  Open  reading frame analysis  of
DNA sequence was performed using the Chromas Lite 2.01  (Technelysium). 
In silico modelling and analyse software was used to generate the models shown in
chapter 3 and 4. Models were generated using MODELLER (academic licence, Salilab,
http://salilab.org/MODELLER/) was used with the Swift MODELLER GUI (Mathur,
http://www.bitmesra.ac.in/swift-MODELLER/swift.htm). Model simulation was run in
CHARMM  (Karplus,  http://www.charmm.org/),  models  were  prepared  in  Insight  II
(Accelrys)  prior  to  loading  into  CHARMM.  Model  analysis  was  conducted  using
Procheck  (EBI,  http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/)  and  VMD
(Humphrey,   http://www.ks.uiuc.edu/Research/vmd/).  Gnuplot
(http://www.gnuplot.info/) was used generate graphs from some of the data output from
CHARMM. Specific information to the operation of these programmes is detailed in the
relevant chapter. 
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2.1.9 Health and Safety
All reagents were handled and stored as recommended by manufacturer’s safety sheets.
All  experiments  were  carried out  in  accordance  with  COSHH regulations  and local
college regulations. 
All genetic manipulation was carried out following GMAG guidelines.
All bacterial cultures were disinfected with Haz-Tabs (Guest Medical) at manufacturer's
recommended concentrations (1 tablet/L of water) prior to disposal. 
2.2 Methods
Standard  molecular  and  biochemical  techniques  were  performed  according  to
procedures  described  in  Molecular  Cloning:  A Laboratory  Manual  (CSH) or  Short
Protocols  in  Molecular  Biology  (Wiley).  DNA purification  techniques  and  in  vitro
transcription/translation  protocols  were  carried  out  according  to  users’  manuals
provided by system manufacturers (Promega, Qiagen and Pierce), as detailed below.
2.2.1 Nucleic Acid Biochemistry Techniques
2.2.1.1 PCR amplification of DNA
PCR reactions were carried out according to reagent manufacturers’ instructions, using a
GeneAmp 9700 (Applied Biosystems) PCR machine. Taq DNA polymerase (Promega)
was used for diagnostic reactions only, whilst Phusion polymerase (NEB) was used for
generation  of  high  fidelity  PCR  products  for  cloning  purposes.  Standard  reaction
mixtures and thermal cycling conditions, including annealing temperature and extension
times, as recommended for the polymerase used were followed. 
Following analysis of PCR products by agarose gel electrophoresis, PCR products were
purified by excision from the agarose gel, using the QIAEX II Agarose Gel Extraction
Kit (Qiagen).
2.2.1.2 Agarose gel electrophoresis
DNA fragments were analysed by agarose gel electrophoresis and compared to DNA
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standard size markers. Agarose (Euorgentec), usually 1% w/v agarose, was added to
TAE buffer  (1X)  and heated  at  high  power in  a  microwave oven until  the  agarose
dissolved. The solution was allowed to cool to <50°C and ethidium bromide was added
to a final concentration of 0.2  μg/ml. The solution was cast in a gel tray, assembled
according to manufacturer’s instructions (BioRad), and a comb inserted to mould the
wells.  Once the gel had set,  DNA samples in 1X DNA-loading buffer were loaded,
along with standard DNA molecular weight markers (NEB). Electrophoresis was then
performed in a gel tank containing fresh 1x TAE at a constant voltage (70-120V). The
gel was visualised on a UV transluminator and the image acquired using Quantity One
software (BioRad). 
2.2.1.3 Cloning of DNA fragments
Plasmid DNA was digested with 100 U of predetermined endonuclease enzymes (NEB),
typically 100 μg DNA in 100 μl reactions for 2 hr at 37°C, in the appropriate buffer as
instructed  by the  enzyme manufacturer.  Primers  were  designed to  allow compatible
double digests within the same vector system. The digestion mixture was heat denatured
at 80°C for 20 minutes prior to treatment with alkaline phosphatase (~100 units CIP,
NEB) for 1 hr at 37°C. The digested product was purified using the QIAquick PCR
purification kit  (Qiagen) with the DNA eluted eluted in a minimal volume (<50 μl)
dH2O. Purified PCR products were digested following the same protocol except the heat
denaturing and phosphatase treatment steps were omitted.  
Ligations were carried out using a molar ratio of 3:1 or even 5:1 of insert to vector. The
ligation  was  performed  using  T4  DNA ligase  (NEB)  in  supplied  1X  buffer  and
incubated  at  4°C  overnight.  The  ligation  mixture  was  subsequently  used  for
transformation into chemically competent E. coli bacteria as described below.
2.2.1.4 Bacterial cell culture
Bacteria  were  cultured  under  aseptic  conditions  at  37°C  in  LB  medium,  either  in
suspension with rotation at 180 rpm (Innova 4300 shaker incubator, New Brunswick) or
on solid support medium on LB-agar plates (plate incubator, Heraeus). Where bacteria
were transformed with plasmid DNA, the growth medium was supplemented with the
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appropriate antibiotic.
For every positive clone, a glycerol stock of the host bacteria was prepared for long-
term storage; 1 ml of a saturated overnight culture wad pelleted by centrifugation at
10,000g  for  5  min  and  resuspended  in  1  ml  of  LB:glycerol  1:1,  containing  the
appropriate antibiotic. The glycerol stock was then snap frozen in liquid nitrogen and
stored at -80°C. Bacteria were revived from stock by streaking a sample of the frozen
stock on an LB-agar plate (containing the appropriate antibiotic) to produce individual
colonies.
The cell density of growing cultures, where required, was determined by measuring the
light absorbance of the suspension at a wavelength of 600 nm. 
2.2.1.5 Preparation of competent bacteria
Chemically competent TOP10, BL21 (DE3) and Rosetta (DE3) cells were made in the
laboratory using the CaCl2 method. Aliquots (120  μl) were flash frozen using liquid
nitrogen and stored at –80C for up to six months. 
Rosetta  2  (DE3)  (Novagen/Merck)  were  purchased  for  some  stages  of  the  project
involving mutant constructs.  
2.2.1.6 Transformation of competent bacteria
5 μl of ligation reaction mixture was added to chemically competent E. coli as soon as
they started to  thaw. The cells  were then incubated on ice for 30 minutes  and then
subjected to ‘heat-shock’ by being placed at 42°C in a water bath for 45 sec and then
returned to ice for a further 3-5 minutes. Cells were then suspended in 800  μl  SOC
medium and incubated at 37°C for one hour with shaking at 225 rpm. Unequal volumes
of the cell culture (commonly the equivalent of 100 μl and 800 μl) were plated on LB-
agar  containing  the  appropriate  antibiotic  and  incubated  overnight  at  37°C.  Culture
plates were then stored for a maximum of 4 weeks at 4°C.
2.2.1.7 Analysis of positive clones by PCR screening
From the  transformation  culture  plates  a  number  of  colonies  were  screened for  the
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presence of the recombinant plasmid. Colonies of interest were picked from the plate
and transferred to a PCR reaction containing primers specific to the subcloned insert.
Following  cycling,  the  PCR reactions  were  analysed  by  agarose  electrophoresis  as
above.  The  selected  colonies  were  also  used  to  innoculate  10  ml  of  LB  medium
containing any appropriate antibiotic which was grown overnight at 37°C with shaking
at 225 rpm. Plasmid DNA was purified from any culture that the parent colony that had
a given a positive result  from PCR screening. Purification was performed using the
Wizard SV Minipreps plasmid purification kit (Promega) following the manufacturer’s
recommended protocol except DNA was eluted with 30 μl dH2O per kit spin column.
Some of the colonies were further tested by restriction digest following the protocol
described above. 
The presence and correct orientation of the subcloned insert was confirmed by DNA
sequencing of the plasmid DNA. Sequencing samples were prepared using the BigDye
Terminator  v3.1  cycle  sequencing  kit  (Applied  Biosystems)  following  the
manufacturer’s instructions. The prepared sample was sent for sequence reading and the
returned  chromatograms  compared  against  predicted  sequence.  Samples  of  plasmid
DNA from sequencing confirmed colonies were stored at -20°C.
2.2.1.8 Quantification of DNA
DNA concentration was determined by spectrophotometric  quantification of  a  1:100
dilution sample (in duplicate) by measuring the absorbance at 260 nm (A260) in a quartz
cuvette  using  a  Perkin-Elmer  MBA2000  spectrophotometer.  The  concentration  was
calculated using the equation: 1unit A260 = 50 g/ml of double stranded DNA.
2.2.1.9 Point mutation of recombinant DNA constructs
Mutation of recombinant DNA constructs was performed using the QuikChange  II XL
Site-Directed  Mutagenesis  Kit  (Stratagene)  according to  manufacturer’s  instructions.
Complementary primers incorporating the desired mutation were designed for use with
the kit for which manufacturer’s instructions were followed.  
Post the thermal cycling step, 1 μl of DpnI was added to digest the methylated template
DNA and  the  reaction  incubated  for  1  hr  at  37°C.  5  μl  of  the  reaction  was  then
transformed into the supplied XL10-Gold competent cells. Recombinant colonies were
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screened by PCR and restriction digest, and the presence of the mutation confirmed by
DNA sequencing. 
2.2.2 Protein Biochemistry Techniques
2.2.2.1 SDS-polyacrylamide gel electrophoresis
Protein sample quality was assessed by comparison to standard molecular weight (MW)
markers by running SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Gels were
made,  assembled  and  run  according  the  instructions  in  the  Mini-Protean  tetra  cell
manual  (Bio-Rad).  The  acrylamide/Bis  percentage  of  the  separating  gels  were
determined by the MW of the proteins to be assessed. The separating gels were covered
with  water  until  set  which  was  removed  using  blotting  paper  prior  to  pouring  the
stacking gel.  Wells  were flushed with water  then filled with running buffer prior to
sample loading. Samples were heated treated at  80°C for 10 minutes in 1X loading
buffer. Electrophoresis was conducted at constant voltage (usually 150V) until the dye
front had travelled far enough to allow visualisation of the protein samples. Gels were
visualised by staining with Coomassie stain followed by several washes of destain. Gels
were stored in water prior to scanning. 
2.2.2.2 Transfer of proteins to membranes
Proteins from SDS-PAGE gels were transferred to a polyvinylidene difluoride (PVDF)
(Immobilon-P, Millipore) membrane using a semi-dry transfer apparatus (BioRad). The
SDS-PAGE gel and membrane were pre-equilibrated in semi-dry transfer buffer for 20
minutes at  room temperature (PVDF membranes were pre-soaked in methanol for 1
minute).  The  transfer  apparatus  was  assembled  according  to  the  manufacturer’s
instructions,  with  the  membrane between the  gel  and the  anode.  The proteins  were
transferred by electrophoresis at a constant voltage (15 V) for 45-60 minutes, dependent
on protein size, at room temperature. 
2.2.2.3 Western blot analysis
After protein transfer,  the membrane was incubated in TBS-T buffer  containing 5%
(w/v)  skimmed  milk  powder  (Marvel)  (TBS-T/milk)  overnight  at  4°C  with  gentle
mixing. Primary antibodies were added in the appropriate dilution in TBS-T/milk for 60
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minutes at room temperature with gentle mixing. The membrane was then washed three
times (10 minutes/wash) with TBS-T/milk. The secondary antibody was added in an
appropriate dilution in TBS-T/milk and incubated at room temperature for 60 minutes
with gentle mixing. The membrane was then washed three times (10 minutes/wash)
with  TBS-T.  The membrane was then  sprayed with  a  single  step  chemiluminescent
substrate, ECL reagent (Calbiochem/Merck). The reagent was allowed to work for 3-5
minutes prior to exposure to film (Kodak) for various periods of time as required for
visualisation of immunoreactive bands. The exposure and subsequent film development
(Compact X4 developer, Xograph) was conducted in a darkroom. 
2.2.2.4 Determination of protein concentration
Protein concentration was mainly determined by application of the Beer-Lambert law.
Absorbance  readings  were  taken  at  280  nm  using  a  MBA 2000  (Perkin  Elmer)
spectrophotometer with a 1 cm light path. The theoretical molar extinction coefficients
used  in  the  calculation  were  generated  by  amino  acid  sequence  analysis  by  the
ProtParam tool (ExPASy site tool). 
For some protein samples protein concentration was determined using the BCA assay
kit (Pierce) according to manufacturer’s instructions. The assay was performed in a 96-
well plate and the absorbance read at 560 nm in a Multiscan EX (Labsystems) plate
reader using the Genesis (Labsystems) software program. Sample measurements were
taken  in  duplicate  for  three  appropriate  dilutions.  These  were  then  compared  to  a
standard  curve  produced by measurement  of  various  known concentrations  of  BSA
(62.5 μg/ml – 2 mg/ml) using the same method.
2.2.2.5 General expression and affinity purification of recombinant proteins
E.  coli Rosetta (DE3)  bacteria  were  transformed  with  appropriate  recombinant  tag-
fusion vector as described above. A 25 ml culture of LB containing the appropriate
antibiotic for the selected vector and chloramphenicol, to select for the Rosetta, was
inoculated with one colony of transformed bacteria and grown at 37°C overnight in a
shaking incubator. A 500 ml culture of TB containing both the vector selection antibiotic
and chloramphenicol was inoculated with 5 ml of the overnight culture. This culture
was then grown at 37°C and 180 rpm in a shaking incubator until the optical density
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(OD), measured by absorbance at 600 nm reached 0.7-0.8 at which point the incubator
was set to cool to 16°C.  The OD and temperature were then closely monitored, the OD
commonly reached 1.0 by the time the temperature had fallen to below 20°C. At this
stage expression was induced by addition of 100 μg/ml (final concentration) IPTG, and
the culture medium incubated at 16°C for a further 12-14 hrs. 
The culture medium was then centrifuged at 7000g (JLA-8.1000, Beckman) for 15 min
at 4°C to pellet the bacteria. The pellet was transferred to universal tubes and stored at
-80°C until  usage.  Stored pellet  was commonly resuspended in 20 ml/L (relative to
original culture volume), occasionally larger volumes were required, of the respective
buffer  for  the  tag  system to  be  used  for  purification.  EDTA free  protease  inhibitor
cocktail  tablets (Roche), 1 per 50 ml, were added to the resuspended pellet mixture
which was then left to mix by rolling for 1-2 hrs at 4°C. A pressure cell homogeniser
(Stansted)  was  pre-chilled  to  4°C and  flushed  through  with  water  followed  by the
appropriate  resuspension  buffer.  The  pellet  mixture  was  processed  through  the
homogeniser a minimum of two times in 50 ml batches with processed sample being
collected on ice. Lysed pellet was centrifuged at 50,000g (JA-25.50, Beckman) for 30
min 4°C. The supernatant was mixed with the appropriate affinity beads, which had
been pre-washed in resuspension buffer,  for the tag system being used.  Beads were
allowed to mix by rolling at 4°C for a minimum of two hours though more usually for
14 hours. Post this incubation phase, the mixed slurry was poured into small (less than 2
cm diameter) columns (Bio-Rad) allowing the beads to pack under gravity. Once all the
liquid from the slurry had flowed through the column then the beads were washed with
2 column volumes of appropriate resuspension buffer. Beads were then further washed
with 10-20 column volumes of bead specific wash buffer as required. Protein elution
from the column was monitored using the basic protein assay, stated above, with no
further wash buffer being used once no further blue colour was observed in the assay. 1
ml fractions were eluted using the relevant elution buffer, once again these fractions
were monitored using the basic protein assay.  Fractions were analysed for purity by
SDS-PAGE. 
It should be noted that for the pETMM60 CaM protein that the Ni tag buffer systems
were modified so that the harvested pellet was lysed in 20 mM imidazole, the incubated
beads washed with 40 mM imidazole and the CaM fusion protein eluted with 100 mM
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imidazole. These modifications were also applied for the production of the NusA-6His
tag control protein. 
If no further purification steps were required for the protein sample prior to downstream
application use, predominantly functional assays, then affinity purified protein samples
underwent dialysis. Desired protein fractions were pooled and loaded into SnakeSkin
dialysis  tubing (Pierce/Thermo Scientific),  either  10K or  3K MWCO depending  on
protein size. Dialysis tubing was placed in an excess volume (min x500 volumes) of the
appropriate downstream assay starting buffer, usually the general assay buffer, which
was left at 4°C overnight with gentle stirring. If required then the dialysis tubing was
transferred to a similar excess of buffer and left for an additional 3-4 hr period under the
same conditions. Dialysed protein samples were concentrated using Vivaspin (Sartorius)
centrifugal  concentrators  (PES membrane,  relevant  MWCO to  protein  sample)  until
suitable concentration for the downstream application was achieved. 
2.2.2.6 Further stages of purification of recombinant proteins 
The  affinity  purified  protein  samples  underwent  further  purification  stages  prior  to
certain experiments described in chapters 5 and 6. 
2.2.2.6.1 Tag cleavage from fusion proteins
Fusion tags were cleaved from recombinant protein samples by incubation with the 
appropriate protease, TEV for pETMM and 3C for pGEX based constructs. Commonly
the cleavage was combined with the post  affinity purification dialysis  step with the
protease added to the respective dialysis tubing usually in the concentration range 1:20
to  the  fusion  protein.  The  protease  and  cleaved  fusion  tag  was  removed  by  an
incubation,  30  minutes  at  4°C with  rolling,  with  an  equivalent  amount  of  relevant
affinity bead as used in the purification step for that batch of protein. The slurry was
passed through a gravity drip column and the follow through, containing the cleaved 
protein, was retained. Recombinant 3C and TEV were produced in the laboratory using
the procedures described above except that the Ni tag standard buffer was used to lyse
the TEV harvested pellet and the affinity purification wash step was omitted for both
proteases. 
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2.2.2.6.2 Gel filtration
A sephacryl HR-300 column (GE healthcare) was pre-washed with the general assay
buffer  using  an  ÄKTA FPLC  system  running  Unicorn  software  (GE  healthcare).
Affinity purified protein was concentrated, usually 1-5 mg/ml, and a sample of less than
10 ml was injected onto the column. A constant flow rate of <0.5 ml was maintained,
elution was monitored by UV absorbance and fractions were collected during the course
of the run. Elution peaks of interest were analysed by SDS-PAGE.     
2.2.3 Functional Assay Techniques
2.2.3.1 Pull down assays
Protein  and  antibody  concentrations  were  tested  to  allow  sufficient  detection  of
potential interactions by western blot analysis. A slight excess of protein, commonly 20-
30 μg per protein per assay, was subsequently used in the pull down assays. To allow
detection by western blot the tagged fusion proteins were used except for CaM which
had its tag removed. Some experiments were conducted with commercially obtained
CaM-agarose beads (Stratagene). An excess of affinity beads, min vol 30 μl, were used
to immobilise the bait protein. The beads had been previously washed in general assay
buffer containing the desired Ca2+ for the experiment. The pull down assay Ca2+ and
EGTA buffers were made by addition of the relevant stock solution to general assay
buffer, the Ca2+ buffers were not chelated. The potential binding partner protein was
added with pull down assay buffer, to give a total volume of x10 the bead volume used,
and allowed to incubate with mixing for a minimum of 20 minutes. Post incubation the
beads were centrifuged <100 g to remove liquid from the beads. This was followed by 3
further washes of x3-4 volume of beads using the specific pull down assay buffer. Post
the final centrifuge step the beads were resuspended in x2 volume protein loading buffer
prior to SDS-PAGE and western blot analysis.    
   
For a limited number of the interaction experiments glutaraldehyde cross linking was
used. The protocol as above was followed except 0.25% v/v glutaraldehyde solution
(Sigma) was added during the incubation phase.  Post  the incubation stage 20% v/v
hydrazine solution (Sigma) was added to prevent further cross linking.   
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2.2.3.2 Circular Dichroism
Purified  protein  samples  were  dialysed  into  a  buffer  system  suitable  for  circular
dichroism (CD), commonly 20 mM Tris, 300 mM NaF, pH adjusted to 8 using H2SO4
rather than HCl. Post dialysis the samples were concentrated, if possible into the range
1-2 mg/ml, and then checked for UV absorbance in the wavelength range 190-250 nm if
the sample was to be tested for secondary structure features. CD data was collected in
the  far  (190-250  nm)  and  near  (250-350  nm)  UV  regions  using  a  DSM20
Monochromator (Olis) using a range of sample cell lengths, dependent on the protein
sample quality, on the B23 beamline at the Diamond Light Source synchrotron. Data
were analysed using Globalworks software (OLIS). Additional data was collected using
a Chirascan CD spectrometer (Applied Photophysics), these data were directly entered
into a spreadsheet package for analysis. On both systems data collection rates (scan
speed,  nm/sec)  were optimised to  provide best  signal  quality against  noise within a
practical time frame. Multiple data sets were collected per experiment and experiments
were conducted across several batches of purified protein.      
Ca2+ sensitivity and potential interaction experiments were mainly conducted in the 250-
350 nm range monitoring changes in the 3ry structure of aromatic residues of the tested
protein  samples.  Although  the  protein  samples  being  tested  had  different  relative
contributing signal strengths; data was recorded using 1:1 concentrations for interaction
studies. Experimental Ca2+ concentrations were achieved by addition of stock CaCl2 and
EGTA solutions. Volumes were pre-calculated to minimize dilution effects on protein
signal strength with H2O used as an equivalent volume when no stock solutions were
added. Variations in protein concentrations between purification batches were also taken
into account to allow comparison across the data collected.    
2.2.3.3 Mass Spectrometry
Gel plugs (1.5 mm diameter) were manually excised, placed in a 96-well plate and 
peptides recovered following trypsin digestion using a slightly modified version of the 
(Shevchenko et al. 1996) method. Sequencing grade modified trypsin (Promega UK 
Ltd) was used at 6.25 ng/μl in 25mM NH4HCO3 and incubated at 37ºC for 3 hours. 
Finally the dried peptides were resuspended in 50% (v/v) acetonitrile in 0.1% (v/v) 
trifluoroacetic acid (TFA; 5 μl) for mass spectrometry (MS) analysis and an aliquot 
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corresponding to 10% of the material (0.5 μl) was spotted onto a 384 well MS plate. 
The samples were allowed to dry and the overlaid with α-cyano-4-hydroxycinnamic 
acid (CHCA, Sigma, Dorset, UK; 0.5 μl prepared by mixing 5mg matrix with 1ml of 
50% (v/v) acetonitrile in 0.1% (v/v) TFA). 
Mass spectrometry was performed using a MALDI TOF/TOF mass spectrometer 
(Applied Biosystems 4800 MALDI TOF/TOF Analyzer; Foster City, CA, USA) with a 
200 Hz solid state laser operating at a wavelength of 355nm (Medzihradszky et al. 
2000), (Bienvenut et al. 2002), (Brennan et al. 2009). MALDI mass spectra and 
subsequent MS/MS spectra of the 8 most abundant MALDI peaks were obtained 
following routine calibration. Common trypsin autolysis peaks and matrix ion signals 
and precursors within 300 resolution of each other were excluded from the selection and
the peaks were analysed with the strongest peak first. For positive-ion reflector mode 
spectra 800 laser shots were averaged (mass range 700-4000 Da; focus mass 2000). In 
MS/MS positive ion mode 4000 spectra were averaged with 1 kV collision energy 
(collision gas was air at a pressure of 1.6 x 10-6 Torr) and default calibration. 
Combined PMF and MS/MS queries were performed using the MASCOT Database 
search engine v2.1 (Matrix Science Ltd, London, UK) (Perkins et al. 1999) embedded 
into Global Proteome Server (GPS) Explorer software v3.6 (Applied Biosystems) on the
Swiss-Prot database. Searches were restricted to proteins of human  and E.coli origin, 
with digestion-profiles limited to tryptic fragmentation.  The tolerances were set for 
peptide identification searches at 50 ppm for MS and 0.3 Da for MS/MS.  Cysteine 
modification by iodoacetamide was employed as a fixed modification with methionine 
oxidation as a variable modification. Search results were evaluated by manual 
inspection and conclusive identification confirmed if there was high quality tandem MS 
(good y-ion) data for ≥2 peptides (E value p < 0.05 for each peptide; overall p < 0.0025)
or one peptide (only if E value was p < 0.0001).
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Chapter 3:
Computational modelling of human
RyR2
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3.1 Introduction 
3.1.1 The role of the C terminus of RyR 
As discussed in chapter 1 there are a number of key regions within RyR related to
function. The carboxy-terminal, ~ 1000 amino acids of RyR, is a very important region
for the functioning of the protein as a channel. It contains the pore that is responsible for
the exit of calcium ions from the sarcoplasmic reticulum (SR) (Bhat et al. 1997), (Xu et
al.  2000),  a  number  of  calcium interaction  sites  (Du  et  al.  2001) and  the  site  for
ryanodine binding  (Callaway et  al.  1994),  (Witcher et  al.  1994). This region is  also
critical for the tetrameric organisation and assembly of the intact RyR channel (Gao et
al. 1997), (Stewart et al. 2003). As described in Chapter 1, the disruption of the amino-
acid  sequence  in  key regions  of  the  RyR  contributes  to  the  pathology observed  in
malignant hyperthermia (or malignant hyperpyrexia) and in stress induced polymorphic
ventricular  tachycardia  (George  et  al.  2003),  (Marx et  al.  2000b),  (McCarthy et  al.
2000),  (Thomas  et  al.  2007).  It  is  believed  that  the  activation  of  the  RyR channel
depends on the rotation of the C-terminal transmembrane assembly and the important
changes to the conformation at the  N-terminal cytoplasmic domains  (el-Hayek et al.
1995),  (Orlova  et  al.  1996b),  (Sharma et  al.  2000).  The organisation  of  this  region
according to the current literature is shown below.
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Figure 3.1.1 Proposed organisation of functional domains at the C-terminus of
human RyR2. 
Regions of interest in this section of RyR2 are highlighted in the amino acid sequence. 
Conflicting results from colleagues have demonstrated that residues 3900-4450 in RyR2
is a span of hydrophobic residues that facilitate the transduction of modulatory events
from the cytoplasmic domain to the pore region at the carboxy-terminus (George et al.
2004b). Experiments using GFP-tagged RyR2 fragments corresponding to the 4TM and
10TM assemblies of RyR (aa 4485-4967 and aa 3722-4967, respectively) have indicated
intra-RyR  interaction  between  these  regions  and  a  dsRed-tagged  cytoplasmic  (N-
terminal) RyR2 fragment, detected by FRET technology (George et al. 2004b). This is
in contrast to the reported transmembrane regions that lie in this region as reported by
other  laboratories  (Bhat  et  al.  1997),  (Brandt  et  al.  1992),  (Wagenknecht  &
Radermacher 1995). 
Nevertheless, this region constitutes important domains that denote the functionality of
the protein as a calcium channel. Thus, knowledge of the 3D structure of the various
domains  and  its  interaction  is  important  to  understand  how  these  various  regions
communicate  with each other  to  function  as  a  channel.  The experimental  structural
determination of this region is under way in the laboratory and chapter 5 details the role
of this project in that operation. However this process is fraught with experimental and
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technical difficulties. Since there are multiple domains within this region as shown in
figure 3.1.1,  it  is  possible  to  construct  a  theoretical  model  of this  region,  partly by
homology  modelling.  Comparative  modelling  relies  on  the  assumption  that  protein
domains of sufficiently matching sequence homology will share equivalent structural
similarity. If suitable amino acid sequence alignment can be made between a potential
3D template and a protein of interest then a homology model can be generated. The cut
off point for the shared similarity between two protein sequences is generally accepted
to be a 30% match. Ideally 40% or greater homology yields a more accurate modelled
structure in which 90% of main chain atoms are modelled with an RMSD (root mean
square distance) error of about 1 Angstrom. 30% homology corresponds to a RMSD
error of 3.5 Angstrom for about 80% of main chain backbone atoms. Loops and side-
chains mainly contribute to the structural difference which is amplified by insertions
and  deletion  regions  as  the  sequence similarity  diminishes.  Under  30%  homology
usually severely limits  the detection  of  homologue structures  as  alignment  becomes
further  reduced  so  drastically  increasing  insertion  and deletion  regions  between  the
compared sequences (Sánchez & Sali 1997), (Xiang 2006). 
As  such  it  is  important  to  achieve  at  least  30%  sequence  homology  between  the
experimentally  determined  3D  template  sequence  and  the  protein  sequence  of  yet
undetermined structure (Hill et al. 2002), (Park et al. 1998). In the case of modelling a
multi-domain protein thus, it is possible to use multiple templates structures (Carpenter
et al. 2007),  (Fraternali & Pastore 1999). When there are intervening regions between
identified  domains  which  cannot  be  modelled  directly  using  a  3D-template,  the
secondary structure of these regions can be predicted using well-known computational
methods (eg. Chou-Fassman algorithms, SOPMA) (Chou & Fasman 1974),  (Geourjon
& Deléage 1995). These can be folded as helices or sheets using modelling-software
methods (Insight Software, Accelrys) or within MODELLER itself (Reddy & Kaznessis
2007). Subsequent molecular dynamics runs coupled with energy minimisation methods
can be carried out to obtain a theoretical 3D fold of the domain. The secondary structure
prediction of the amino acid residues 3579-4085 in RyR2 using SOPMA (Geourjon &
Deléage 1995) is shown below.
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Figure 3.1.2 Secondary structure  prediction of  the amino acid  residues 3579 –
4085 of human RyR2 using SOPMA 
The boxed residues are the calmodulin binding domain and calmodulin like domain,
respectively.  The regions outside (between) these two boxed domains will be modelled
using the above secondary-structure predicted results.
3.1.2 CaM Binding Domain and CaM Like Domain
Studying elements of the role of calmodulin (CaM) in relation to RyR aids with the
understanding of the CaM binding domain (CaMBD) and CaM like domain (CaMLD)
in  the  process  of  modelling  these  domains.  As  discussed  in  chapter  1,  CaM  is
universally recognised as  a  major  calcium sensor  and regulator  of  cell-cycle  events
through its role in a diverse group of cellular proteins. Due to this important role, there
is a need to define the region of interaction between CaM and its cellular targets, and
the action of CaM on target protein function.
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CaM binds with high affinity to a short α helical region found in many proteins. The
interaction of CaM to its target protein sequence mainly consists of a single amino acid
that acts as a hydrophobic anchor point and this residue characteristically reaches into
the N-lobe core, thus the CaM binding protein or peptide (CaMBP) typically is encased
between both lobes of CaM (Ikura, Barbato, et al. 1992), (Ikura, Clore, et al. 1992). In
many CaM-CaMBP complexes, the CaM molecule almost engulfs the entire binding
region, reducing the solvent accessible area of the binding motif to less than 20%. This
typical interaction is illustrated schematically below. 
Figure 3.1.3 Typical  interaction  between  calmodulin  (CaM)  and  a  calmodulin
binding peptide or protein (CaMBP).  
A key hydrophobic residue in the CaMBP acts as anchor, reaching into the core of CaM.
A few hydrophobic residues (in this example from PDB entry 1G4Y) also serve to clamp
onto the binding motif.
The CaMBP consensus sequence is conserved through evolution (see figure 3.1.4) and
the presence of such a sequence in a previously uncharacterised protein would serve to
identify it as one that would interact with CaM to varying degrees.
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Figure 3.1.4 Schematic representation of CaM with a calmodulin binding peptide
(CaMBP) from PDB entry 2BCX.
(a) A side-on view of CaM with the binding region shown as a helix in magenta.  
(b) View showing the C-terminal end of the CaMBP proximal to the reader. 
(c) View showing the N-terminus of CaMBP proximal to the reader, both these views
demonstrate  the  interaction  of  side  chains  of  CaMBP with  the  “clamp-like” cavity
generated by CaM.  
(d) the conservation of residues of the CaMBP of the ryanodine receptor across the
animal  kingdom,  minor  residue  changes  in  organisms  imply  that  those  residues  if
mutated within the human isoform may be tolerated with little implication to function.
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The CaMBP region in RyR1 and equivalent CaMBD in RyR2, residues 3583-3603, (N.
Yamaguchi et al. 2003) have been identified. It is the CaMBP from RyR1 that is shown
in  figure  3.1.4.  Previous  studies  on  skeletal  muscle  RyR  (RyR1)  have  shown  an
important segment resembling the structure of CaM within aa 4064-4210 of the rabbit
sequence, resembling the structure of CaM containing possible Ca2+ binding sites. This
region has also been shown to interact with CaMBP in RyR1 and has been termed the
CaM like domain (CaMLD) (L. Xiong et al. 2006).  
Figure 3.1.5 Residues in the  ryanodine receptor having a calmodulin like domain
(CaMLD) and a corresponding calmodulin binding domain (CaMBD).  
(a)  Sequence  homology  between  a  known  EF  hand  domain  of  the  experimentally
determined structure – 2BCX. 
(b) shows sequence alignment between rabbit RyR1 and RyR2 and comparisons with
corresponding  sequences  from  human  RyR1  and  RyR2  further  illustrating  the
conservation of residues in this region. The region boxed in red shows the sequence that
is implicated in binding to CaM. The conserved residues boxed in blue when mutated in
previous studies have shown dramatic reduction of Ca2+ binding properties. 
It should be noted that the EF hand domain shown in (a) figure 3.1.5 is from CaM as
shown  in  figure  3.1.4  reflecting  the  CaM  “like”  structure  of  CaMLD.  A  major
component of this similarity is a result of the 2 EF hand motifs associated with Ca2+
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binding contained with CaMLD. The two lobes of CaM contain 2 EF hands each which
lead to comparison of CaMLD to a lobe of CaM both in structure and proposed function
(Liangwen Xiong et al. 2006). Although there are amino acid variations within different
types of EF hand, there is a high conservation of residues critical to the Ca2+ binding
function of the domain within EF hand families (Grabarek 2005). 
Figure 3.1.6 Amino acid sequence alignment of CaM with CaMLD.
The region of match between the two sequences relates to the area of the 2 EF hand
motifs within CaMLD. The 2nd matching region is located a few residues downstream of
the 2nd EF hand motif. 
The immediate surrounding regions, including portions of α helix, to the EF hands have
been identified in the “clamp like” binding of CaM to CaMBP (Kawasaki & Kretsinger
2012).   
Figure 3.1.7 Predicted secondary structure of CaM.
Boxed section is the 2nd matching region of CaM in figure 3.1.6. This boxed section
overlaps 2 predicted sections of α helix which are predicted to play a role in binding to
CaMBP.      
There are a range of disease mutation sites located throughout RyR including the CPVT
mutations with CaMLD as discussed in chapter 1. Studying the nature of the interaction
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between CaMLD and CaMBD will aid with the understanding of the pathophysiology
of CPVT and, in the case of RyR1,  malignant hyperthermia. Intuitively, it is envisaged
that such minute changes in interaction between two domains may be brought about by
small changes to the overall structure. 
3.2 Results
To aid the further study of the interaction between the CaMBD and CaMLD domains, a
primary aim of the earlier stages of the  in-silico work was to produce a model of the
overall region of RyR2 containing the two domains. As this process would consist of
several  stages  so  initially  models  of  the  two separate  domains  were  made  prior  to
commencing the construction of the larger planned model.
The  following  sections  detail  the  process  of  homology  modelling  of  human  RyR2
CaMBD and CaMLD, and the subsequent computations that were performed to refine
the models.   
3.2.1 In silico modelling of CaMLD and CaMBD regions of RyR2
To generate the models of the domains the homology modelling software MODELLER
(A Sali  & Blundell  1993) was  used,  all  models  were  generated  with  MODELLER
v9.10. A front end GUI (graphical user interface), swift MODELLER v2.0 (Mathur et
al. 2011), was used to run MODELLER in automated mode so that sequence alignment
and  model  generation  were  controlled  by  the  software.  Discrete  Optimised  Protein
Energy (DOPE) scores are used in MODELLER to evaluate how the model compares
with the template structure used in homology modelling. Briefly, this method estimates
the positions of non-interacting atoms in an artificial sphere. The radius of the sphere is
calculated based on the extents of the native structure of the entire template molecule.
Thus, the difference between the calculated artificial sphere encasing the new model
and the volume of the sphere containing the entire template molecule is the basis of the
DOPE score (Shen & Sali 2006). The lowest DOPE scores in a collection of models is
desirable. Another method of assessment is the GA341 scores, these always range from
0.0 (worst) to 1.0 (native like).  Molecular PDF energy (molpdf) scores are also used for
assessment of models, these report the restraint energies in the model structure. Lower
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energies indicate less strain on the structure so lower molpdf scores are desirable. 
CaMLD shares  the high sequence homology with other  members  of  other  EF hand
families  as  described  in  chapter  1.  In  terms  of  the  identification  of  a  template  for
CaMLD, none of the more closely matched EF hand structures  were present  in  the
Protein Data Bank (PDB). Structures of other members of other less closely sequence
related  EF  hand  families  have  been  solved.  Initially  trials  of  modelling  CaMLD
focussed on using the highest percentage sequence homology match template possible.
However  it  was  not  possible  to  gain  matches  to  the  secondary  structure  predicted
regions of α helix, associated with CaMBD binding, with these templates. Small regions
of structures were identified that could be used as donors for these few α helical regions.
While multiple template modelling can be performed the use of these very small donor
sections was impractical. While CaM does not have such a close match to CaMLD it
still  falls  above  the  required  30%  homology  threshold  and  contains  the  predicted
required  secondary structure  elements  as  discussed  in  the  introduction.  There  are  a
variety of of available CaM structures, including the CaM component of 2BCX which
was selected as the template for modelling CaMLD.
Twenty models of CaMLD were generated by the process stated above using the CaM
component of 2BCX. Models were evaluated by DOPE scores. 
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CaMLD model no. molpdf DOPE GA341
1 436.78894 -6067.64014 0.56606
2 482.53687 -6239.92725 0.44066
3 474.44733 -5858.98779 0.63272
4 473.14145 -6116.59668 0.26535
5 447.55273 -5871.44971 0.40209
6 360.47827 -5984.33252 0.53040
7 445.15585 -6048.05908 0.51714
8 394.35928 -5980.94629 0.49276
9 532.34747 -5981.55469 0.22836
10 446.59985 -5960.28857 0.48357
11 413.00021 -6165.89990 0.66968
12 398.90665 -5993.46191 0.36087
13 450.62045 -5849.70117 0.65303
14 370.50214 -6035.63623 0.51170
15 484.21292 -5692.58838 0.57380
16 372.79172 -6271.97900 0.39410
17 471.26294 -5904.84521 0.65400
18 438.81503 -6157.76025 0.53179
19 449.60641 -5992.08203 0.55847
20 373.29279 -5954.35742 0.29167
Table 3.2.1 Assessment scores of generated CaMBD models.
Model  13  is  highlighted  as  having the  lowest  DOPE score  and one  of  the  highest
GA341 scores. 
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Figure 3.2.1 DOPE scores per residue of CaMLD model 13.
The CaM template is shown by the green trace and the CaMLD model shown in red.
Usually  better  models  are  produced  when  there  is  template  structure  covering  the
entirety of the model sequence as in this case. As expected the DOPE score per residue
of the template is lower than the model, the closer the model scores are to the template
indicates lesser deviation from the template structure in the model. 
95
Figure 3.2.2 Ramachandran plot of CaMLD model 13.
Most favourable areas are shown in green, next most favourable in orange. The better
the model the more residues (black spots) that are expected within the most favourable
areas. Poor models or those requiring further improvement would have a number of
residues outside of the favourable regions.  For this  model  only one such residue is
observed.  
The Ramachandran plot provides a visual measure of the limits of the movement of the
bond angles that are present in the backbone of the protein molecule. The Phi (Φ) and
Psi (Ψ) angles describe these torsion angles between the atoms. 
Figure 3.2.3 Phi and psi torsion angles within protein backbone. 
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Analysis of known structures provides a reference of tolerances of the torsion angles.
The favourable areas include phi and psi angles that are observed within this reference
set. Residues with bonds falling outside of these areas can indicate an “unlikely” angle
for a valid protein structure. The Ramachandran plot provides a tool for the location of
these residues so that the model structure can be analysed. Issues such as kinks in the
structure and overlapping bonds can be seen though in some cases an outlying residue is
not considered a problem if the structure appears viable.      
Figure 3.2.4 Structure of CaMLD model 13.
While not having as much α helix content as CaM (see figure 3.1.4) there are clear
areas of conserved secondary structure within this model. The overall structure seems
viable with no obvious structural deviations. 
As already shown the PDB entry 2BCX contains a section of RyR1 CaMBP which has
very  close  homology  to  the  equivalent  region  of  interest  in  RyR2,  so  was  used  a
template for modelling CaMBD. The process as described above for the CaMLD model
was followed. As the CaMBP structure is a simpler, tube of magenta α helix (figure
3.1.4),  so  an  even  closer  model  to  the  template  with  no  associated  problems  was
produced. 
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Figure 3.2.5 Computer-generated model of RyR2 CaMBD.
The CaMBD region folds naturally as a helical segment as shown here.
3.2.2 In silico modelling of RyR2 between residues 3578-4085
The  CaMLD  and  CaMBD  regions  were  folded  by  homology  modelling   in
MODELLER. However,  the regions between these two were subsequently modelled
using  information  that  had  been  rationally  deduced  from  the  secondary  structure
bioinformatic analysis.    
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Figure 3.2.6 Sequence alignment between human RyR2 (labelled here as CMBD)
and the experimentally determined template sequence of 2BCX.  
The sequence alignment is presented in the “PIR” format. For simplicity of coding in
the scripts, the actual amino acid residue numbers of RyR2 are not used (ie: proline
3578 is represented as proline 1; lysine 4085 is represented as lysine 507). The asterisks
at the end of each line denote the “end” of the sequence.
To ensure  that  the  CaMBD segment  is  positioned  “beneath”  the  CaMLD segment,
several force restraints; rsr (real space residuals: where in xray crystallography, rsr is a
measure of the agreement between an electron-density map calculated directly from a
structural model and one calculated from experimental data) were applied as follows. 
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Figure 3.2.7 Distances between CaMLD and CaMBD.  
To position  the  CaMLD of  RyR  above  CaMBD during  the  modelling  process,  rsr-
distance restraints were applied. 
(a) Firstly, the distances (in Angstroms) between 2 residues in CaMLD and 3 residues in
CaMBD were measured using the measuring tool in Pymol.  
(b) These distances were compared to the equivalent residues in the RyR2 segment, and
the script file for MODELLER is shown here incorporating these distance restraints.
As evident from the alignment in figure 3.2.6, the middle portion of the sequence bears
no  resemblance  to  2BCX,  there  was  less  than  30%  homology  to  other  structures
deposited in the PDB. Thus this region was analysed using SOPMA, as shown earlier in
figure 3.1.2.  Helices were modelled ab initio within MODELLER using the following
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script segment.
Figure 3.2.8 Scripting of helices.  
Segment from the script that ensures specific residues predicted by SOPMA (secondary
structure  algorithm)  as  shown  in  figure  3.1.2  were  modelled  as  helices  within
MODELLER.  Without  this  segment  of  scripting,  the  regions  between  CaMBD  and
CaMLD (that bear < 30% sequence homology to any PBD data) would be modelled as
one long extended piece of amino acid residues. 
From the SOPMA analysis in figure 3.1.2, the region between the CaMBD and CaMLD
of human RyR2 contains 6 beta-turns. A beta-turn is a type of non-regular secondary
structure in proteins causing a change in direction of the polypeptide chain. These beta-
turns are important in nature since it renders most proteins a globular shape instead of
being linear molecules.
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Figure 3.2.9 Beta turns.  
In a beta turn, a hydrogen bond is formed between the backbone carbonyl oxygen of
one residue (i) and the backbone amide NH of the residue three positions further along
the chain (i + 3).
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There is another type of structural turn, called a “g-turn”, which has a (i) to (i + 2)
hydrogen bond.  Two thirds of all beta turns that occur in nature are either type I or type
II beta-turns.  The difference between these turns are, as such, shown below.
Figure 3.2.10 Beta-turn residue preference and predicted beta-turns in RyR2.  
(a)  The  various  residue  preferences  in  beta-turns  that  occur  in  nature  are  shown.
However,  these  are  not  definitive  and  exceptions  to  these  residues  do  occur.  The
SOPMA algorithm incorporates various parameters to identify uncommon residues that
are involved.  
(b) The predicted beta-turns in the RyR2 segment between CaMBD and CaMLD with
the residue numbers given (note the residue numbers refer to the simplified residue
numbers corresponding to those in figure 3.2.6).  
(c) As beta-hairpin turns are ubiquitous in nature, an example of this was taken from
PDB entry 1HPV {Kim, 1995 #25}. The sequence between residue 49-52 (Gly-Ile-Gly-
Gly) was chosen as the template for modelling beta-hairpins in the RyR2 sequence.   
Following  the  above  analysis  of  the  sequence  between  the  CaMBD  and  CaMLD
domains, models were generated using the MODELLER software. For this process a
script was written to run directly in MODELLER as opposed to using an automated
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front end GUI. This script was initially run without  optimisation which generated a
number of clashes and erroneous structures as shown below. 
Figure 3.2.11 Preliminary optimisation of structures.  
(a) When structures were generated within MODELLER without energy minimisation,
erroneous  structures  were  obtained.  Examples  of  these  show  where  loops  traverse
within helices and loops occur within loops, both instances are not possible in nature.
Such examples also highlight the need for visualisation and examination of structures
by eye. 
(b) To circumvent and prevent erroneous structures occurring, optimisation using the
Variable  Target  Function  Method (VTFM) that  incorporates  the  conjugate  gradient
(CG) method was used. The script for this is shown here. The molecular dynamics (MD)
optimisation step incorporates a simulated annealing (SA) protocol for optimisation.
As with the modelling of the CaMBD and CaMLD regions, DOPE scores are used to
evaluate  the  model  quality.  DOPE  score  analysis  requires  comparison  to  known
structures, since a large proportion of this model does not have any sequence identity to
any  known  experimental  structure  so  DOPE  score  is  not  entirely  relevant  as  an
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assessment tool for the models generated. Despite this issue the DOPE scores can be
used as guide towards indication of better quality models. As previously, lower DOPE
and low molpdf scores, and GA341 scores closer to 1 are desirable. The evaluation of a
selection of the better models generated is shown below. 
Table 3.2.2 Assessment scores for selected models.  
The various computer-generated models are shown here with the MOLPDF and DOPE
scores.   Models that have a combination of the lowest molpdf values and the lowest
(more negative) DOPE scores were desirable
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Figure 3.2.12 Evaluation of models by molpdf and DOPE scores.  
Models that were successfully generated and had molpdf values less than 1x106 are
shown above.  Models that have a combination of the lowest molpdf values and the
lowest (more negative) DOPE scores were desirable. 
However, following optimisation by conjugate gradients (CG) minimisation and MD-
SA, the models were evaluated by Ramachandran analysis for any deviations of the phi-
psi torsion angles. 
Ramachnadran plots were generated for the 4 models, selected from the table below,
which  had  no  residues  in  the  disallowed  regions,  so  considered  potentially  better
models.   
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Table 3.2.3 List of residues by Ramachandran analysis region.
Models with no residues in disallowed regions are highlighted in the table.
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Figure 3.2.13 Ramachandran plots of selected models.
Models with no residues in disallowed regions are shown. 
Although no residues were present in the disallowed regions for these model indicating
reasonable models, further energy minimisation steps were run on the selected models
to  see  if  it  was  possible  to  increase  the  quality  of  the  model.  Steepest  descent
minimisation was used to try to improve models 2, 10, 25 and 41. Each model was run
through 1000 steps of steepest descent and then evaluated by Ramachandran analysis. 
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Figure 3.2.14 Ramachandran plots of model 2 after 1000 steps of steepest descent
minimisation. 
Residues in disallowed regions are shown in red.
Prior to the 1000 steps of steepest descent energy minimisation model 2 had no residues
in the disallowed region, post this step there were 8. A similar increase in residues in
disallowed regions was observed for the other selected models after the steepest descent
minimisation.  This  indicates  that  the  quality  of  the  models  has  decreased.  As  the
steepest  descent  minimisation  is  a  relatively  rapid  means  of  decreasing  the  overall
energy state of the model this may be a too rapidly drastic technique for these models.
The loop region of these models contains a number of residues which may be prone to
unfavourable conformations when exposed to steepest descent minimisation. While the
109
overall energy state of the model may appear to be decreasing bonds within these amino
acids have been forced into unrealistic positions so actually worsening the model. 
Conjugate  gradient  minimisation  unlike  steepest  descent  allows  for  an  a  potential
increase in energy within the model per step while trying to reach an overall  lower
energy state, usually after many steps. This approach potentially allows more freedom
of movement of the residues which may have the possibility of reducing the number of
unfavourable residue positions.  To reduce computing time model  2 underwent  5000
steps  of  conjugated  gradient  minimisation  and  the  resulting  model  was  tested  by
Ramachandran analysis.
Figure 3.2.15 Ramachandran  plot  of  model  2  after  5000  steps  of  conjugate
gradient minimisation. 
Residues in disallowed regions are shown in red.
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As with the steepest  descent  approach a  clear  increase  in  the  number  of  resides  in
disallowed regions can be observed. 24 residues were in disallowed regions post the
conjugate gradient minimisation. 
3.3 Discussion
The aim of this  chapter  was to  simulate  regions of the C terminal  of human RyR2
following two main stages. Firstly, the production of suitable quality models of CaMLD
and CaMBD regions. If this stage was successful, secondly,  model the entire region
between and including the two domains and then attempt to improve the quality of this
model. 
The first step of stage one was the selection of existing known structures to serve as
templates to the models. As discussed the percentage matching homology between the
amino acid sequence to be modelled and those of published structures has to be >30% to
be able to produce a model of acceptable accuracy. In the case of CaMBD there are
structures of CaM binding proteins in the PDB. For this project the CaM binding protein
region of RyR1,  equivalent  to  CaMBD in RyR2, in PDB entry 2BCX served as an
excellent donor template. The CaMLD region of RyR2 proved to be more of a challenge
to find a suitable matching structure. As CaMLD is meant to be, to some extent,  a CaM
mimic in  terms of  binding function  to  CaMBD, so it  was  decided to  use the  CaM
structure in the PDB entry 2BCX. CaM meets the 30% homology requirement and also
includes  all  the  secondary  structure  elements  assumed  to  be  required  for  CaMLD
binding to CaMBD. The use of these templates allowed models to be generated that met
the requirements of stage one.
Stage 2, the modelling of the region 3578-4085 proved to contain a significant number
of technical challenges. Primary of these was the strategy required to model the region
between the two known domains as there was no available template for this region. If
this region has been modelled completely ab initio without defining sections within the
area then it  is  likely that  a  long string of  undefined structure with the two defined
domains at either terminal would have been produced. The first step to correct this was
to set distance restriction limits on how far away CaMBD and CaMLD could be from
111
each other. As 2BCX, the donor template for the domains, consists of CaM interacting
with a CaMBP so the distances between selected residues were measured and these
distances applied to the equivalent residues in the RyR2 sequence. The second step was
to analyse the predicted secondary structure of the region between the domains. Areas of
α helix and beta turns were identified and the amino acid coordinates of these areas
logged. Scripts were written to tell the MODELLER software of these logged areas so
they would be produced in the models of the region.
It was initially thought that the two steps described above would be sufficient for the
generation of reasonable quality models  of the region.  However  examination of  the
produced models revealed a number of problems, as seen in panel A in figure 3.2.11,
including  physically  impossible  structural  elements.  To  address  these  issues  short
energy minimisation and molecular dynamics steps were added to the modelling script.
The  use  of  these  steps  was  aimed  to  generate  models  in  which  were  in  a  more
favourable energy state. While a wide range of possibilities were expected with this
approach including models with potentially even more flawed structures it was hoped to
produce some models which had reduced overall energy states while also having viable
structures. Initially 50 models were generated using the revised script. As expected a
number of these models had worse structures which was reflected in high molpdf scores
indicating  that  they  were  less  energetically  probable  as  viable  models.  The  models
which appeared to be potential solutions were analysed by Ramachandran plot, of these
4 had no residues in disallowed regions.  
It was decided to attempt to increase the quality of these models by using further energy
minimisation  steps.  Energy  minimisation  steps  can  be  conducted  using  a  solvated
molecule.  Water  shells  or a  water  box is  placed around the molecule simulating an
environment closer physiological conditions than a vacuum. Boundaries can be placed
to  limit  the  size  of  the  solvent  area  that  is  simulated  around  the  molecule  though
solvent-solvent interactions are modelled within these boundaries. Even with increasing
available  computing  power  these  calculations  can  be  very taxing on the  simulating
system and severely slow down the minimisation stages of refinement. As the models
produced by this project it  would have meant that a relatively very large volume of
water would have had to been simulated to solvate the model. As such it was decided to
conduct the minimisation stages in a vacuum to reduce processing time. 
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At first steepest descent was trialled by use of 1000 steps. Steepest descent applies a
simpler  algorithm  than  other  minimisation  techniques.  This  algorithm  moves  the
coordinates of the model towards energetically lower states and allows for the most
rapid  convergence  to  an  achievable  minimum  energy  state.  This  technique  tends
converge  to  an  overall  minimum  for  the  whole  molecule  with  little  tolerance  for
localised structure. This can force the model into unrealistic localised structures which
although  appearing  to  reduce  the  overall  energy state  of  the  molecule  in  that  step
actually adversely limit the progress towards the potential minimum. It is likely that this
is the outcome that was observed with the 4 models trialled with this method as their
overall structures were shown to worsen. Steepest descent is commonly used in limited
steps to improve new models. While a rapid step, on reflection this may not have been a
good choice as an approach as the models had already undergone limited minimisation
steps during the modelling process. 
        
Conjugate gradient minimisation was subsequently used on model 2. This method is
iterative taking into account the previous steps as well as progression towards an energy
minimum in determination of the next step. As a result this technique tends to have
better  convergence  characteristics  towards  an  energy  minimum  state  than  steepest
descent. However this method can become limited in attempts to move coordinates with
no real overall  improvement of the energy state  over  several  steps and still  enforce
worse structures upon the model. Some protein conformations are more prone to suffer
these problems and it is likely that the modelled region is one of those structures. As a
result  it  was  decided  to  not  trial  any  of  the  other  models  with  this  technique.
Improvements to the basic conjugate gradient method are included in the CHARMM
software. Mostly these rely on closer step based monitoring of the structure and can
place boundaries of acceptable movement for regions within the molecule which can be
updated  in  a  series  of  blocks  of  steps  rather  than  step  by  step  potential  variation.
However owing to the overall loop shape of the modelled region of RyR2 it is unlikely
that these alterations to the method would result in an improved structure.  
     
Although  there  are  other  minimisation  algorithms  available  within  the  CHARMM
software  as  the  two methods  trialled  have  both  led  to  an overall  decreasing  of  the
quality  of  the  model  it  was  not  viewed  as  being  worthwhile  to  pursue  further
minimisation  techniques.  The  improved  modelling  process  already  contains  some
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limited minimisation, and also molecular dynamics, steps so further minimisation does
not appear to yield any further benefits. Selected models generated from this modelling
process  already have  no  residues  present  in  disallowed  regions  when  examined  by
Ramachandran analysis. This meets the basic criteria of the second stage of the chapter
and  the  overall  aim which  was  to  produce  a  model  suitable  to  undergo  molecular
dynamics to enable further analysis of the function of CaMBD and CaMLD regions of
RyR2.    
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Chapter 4:
Refinement of the computational model
of human RyR2
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4.1 Introduction
The region of human RyR2 between amino acid residues 3579 – 4085 is an important
region that has a putative regulatory role influencing the function of the overall protein
as a calcium channel. Thus, studying how the structure of this region contributes in this
regulatory role would aid in the understanding of the function of the channel and the
impact of disease related mutations within this area.  
The tertiary folding of  secondary structure elements  into domains  is  a  key stage in
attaining the functional conformation of a protein. The tertiary structure of a domain
often facilitates the function of that domain. The loop model generated in chapter 3 was
processed to a state in which it contained relevant secondary elements and the overall
structure could not be further energy minimised. However to understand the regulatory
role of this region the structure needs to be folded into a three dimensional state. This
chapter explores the in silico theoretical folding of the protein. 
4.1.1 The problem of protein folding 
There are numerous ways that a polypeptide chain can possibly fold but there are certain
steric limitations where if two atoms were too close together, they would face large
opposing forces preventing that conformation from being stable in nature.  Normally
three conformations within polypeptide chains persist in nature that connects one amino
acid to two others (one at the N-terminus and the other at the C-terminus). These are the
extended conformation, cis-configuration and the trans-configuration as shown in the
figure below.
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Figure 4.1.1 A triple Glycine repeat (Gly-Gly-Gly) in three conformations that
are sterically stable.
a) extended conformation
b) cis configuration
c) trans configuration
Assuming these 3 states are the only ones allowed in nature, and bearing in mind that
the  first  and the  last  amino  acid  only connect  with  one  other  amino  acid,  so  in  a
polypeptide chain of “n”, where “n” is the number of amino acids in the chain, n-2
amino acids are able to exist in any of the 3 conformations as shown in figure 4.1.1.
Thus, for the length of the section of RyR2 protein that has been modelled, between
amino acids 3579-4085, giving a polypeptide length of 506 residues, there are (506-2)
or 504 residues that can exist in 3504 or 2.945 x 10240 different conformations. 
If protein folding were a completely random process in nature, then each protein being
synthesised  in  the  cell  would  undergo  random  perturbations  in  conformation.  For
example a 506 amino acid residue would undergo 2.945 x 10240 conformational changes
until it arrived at the final “desired one”, this would logically take a very long time.
Hypothetically, if a million conformations could be tried in a second, a polypeptide of
this length would take:
2.945 x 10240 /106 = 3.4 x 10229 days
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However, it is know that in nature, from experiments on the folding of large proteins
such as  cytochrome C that  proteins  fold in  millisecond time-scales  (Yang & Smith
1997).  The rationalisation  of  the protein folding  problem is  not  a  new concept,  the
apparent incredulity at the speed at which proteins fold in nature unlike the predicted
theoretical time it would take if it were a random process was first discussed by Cyrus
Levinthal in 1969 (Levinthal 1969). This apparent disagreement of the theoretical rate
of folding with that observed in nature is known as “Levinthal’s paradox” (Zwanzig et
al. 1992), (Ben-Naim n.d.).
It could be logically predicted that the end conformation after so many attempts would
differ each time if the folding process were truly random. Of course, each polypeptide
chain would not have to undergo every change and the criteria to stop trying different
conformations would include a random stop command. This does not happen in nature.
Each polypeptide chain folds to a destined shape, thus there has to be a set of predefined
rules that guides the folding process.
Early research into folding proposed that the code for tertiary folding must be somehow
included in  the  amino acid  sequence  of  the  protein  itself.  Nobel  laureate,  Christian
Anfisen had conducted a historic experiment to test this theory (Anfinsen 1973).
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Figure 4.1.2 The Anfisen experiment.  
Ribonuclease (124 aa) contains four disulphide bridges. When ribonuclease was treated
with 8M urea + β-mercaptoethanol, the protein linearised and lost enzymatic activity.
When this linearised, denatured protein was allowed to oxidise in the presence of urea
(as shown in the control experiment above), the sulphydryl (SH) groups randomly pair,
forming four disulphide bridges.  Despite the formation of the S-S bonds, enzymatic
activity was still extremely weak or lost.  However, when the 8M urea was completely
dialysed out, and the S-S bridges were then allowed to form, enzymatic activity was
restored. 
The  Anfinsen  experiment  proposed  support  for  what  became  known  as  the
“thermodynamic hypothesis”. This hypothesis  states that the native folded state of a
protein in nature is the one where the Gibb’s energy of the whole system is the lowest.
The Anfinsen experiment supported the concept that the information which determines
the way a protein folds is contained within the amino acid sequence.  The unknown
nature of this information which influences the tertiary folding of a polypeptide chain is
the essence of the “protein folding problem”. 
Further  research  has  been  conducted  on  this  problem.  Martin  Karplus  and  workers
proposed  the  “diffusion-collision-adhesion  model”  to  address  the  protein  folding
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problem  (Karplus  &  Weaver  1994).  In  this  model  a  polypeptide  chain  was
computationally simulated in which micro-domains of the polypeptide were encouraged
to  move  diffusively  and  repeatedly  collide.  Another  model  is  the  “hydrophobic
collapse” model (Dill 1985). In this model, the various hydrophobic stretches of amino
acids  gradually eliminate  water  from their  vicinity bringing about  a  collapse  of  the
structure, thereby two previously distant hydrophobic regions gradually migrate towards
each other. Many other proposed models of protein folding exist but it is likely that
many of these models are in fact working together in nature to enable the complex
folding process.
4.1.2 Simulating protein folding
In terms of structure, very little data was available pertaining to the protein sequence
between amino acid residues 3579 – 4085 of human RyR2. As discussed in Chapter 3,
this  region is  known to  contain  a  domain  (CaMBD) that  interacts  with  calmodulin
(CaM),  subsequent  mutation  studies  of  these  regions  have  demonstrated  loss  of
interaction with calcium (N. Yamaguchi et al. 2003). Additional studies have implicated
another domain (CaMLD) with similar structure and function to CaM (L. Xiong et al.
2006),  (Gangopadhyay & Ikemoto 2006),  (Zhu et  al.  2004).  As little information is
known  about  the  intervening  region  between  the  two  domains,  so  this  region  was
subjected to a secondary structure prediction using the SOPMA algorithm (Geourjon &
Deleage 1995).  Afterwards the region was folded in MODELLER (A. Sali & Blundell
1993) using the secondary structure prediction as demonstrated in figure 3.2.8.
In this chapter, the tertiary fold of all  the section in this region were encouraged to
evolve using molecular dynamics software within CHARMM (Brooks et al. 2009). The
PDB model files generated in MODELLER (A. Sali & Blundell 1993) were imported
into INSIGHT 2000 (Accelrys) in order to convert the coordinates to the CHARMM
format and to generate the protein structure files (PSF). Based on the findings of chapter
3,  the  models  were  then  subjected  to  closely  monitored  energy minimisation  using
improved algorithms. The minimised structures were then subjected to 1000 steps of
“heating” from 240 K to 800 K.  The final structure from this heating step was then fed
into an “equilibration” cycle where the temperature was gradually reduced from 800 K
120
down to 310 K.  The temperature values quoted are not to be literally interpreted as a
protein  heated  to  800 K (527°C)  would  obviously have  denatured  well  before  this
temperature  was  reached.  Temperature  in  molecular  dynamics  is  a  reference  to  a
statistical quantity. 
To fully appreciate the contribution of temperature in molecular dynamics (MD), the
following discussion is necessary.   
Newton’s first law of motion is stated as “objects at rest remain at rest and a moving
object remains in motion with the same speed and direction unless an unbalanced force
acts  upon  the  object  either  changing  its  direction  or  altering  the  speed”.  This  is
represented as follows:
F = ma
Where F = force, m = mass of the object and a = acceleration.  
Acceleration can also be represented as dv/dt where v = velocity and t = time.
An adiabatic system is one where thermodynamic energy or heat cannot enter or escape
the  system.  Observing  energy  changes  in  such  a  system  is  fortuitous,  since  one
confounding variable (namely heat) is eliminated, therefore any change in energy would
have to be due to either changes in intra-molecular forces or changes in kinetic energy.
Within an adiabatic system, it is possible to observe changes in potential and kinetic
energies with no change in the total energy. Within such an adiabatic system, Boyle’s
law for perfect gasses applies, this is summarised as below:
PV = nRT or PV = nkT         
            
Where  P  =  pressure,  V  =  volume  of  the  system,  n  =  number  of  moles  of
molecules/atoms in the system, R = gas constant, k = Boltzmann’s constant and T =
temperature.
From the equipartition theorem, for a system in thermal equilibrium (such as in a closed
adiabatic  system) all  matter  in  such a  system has  the  following average degrees  of
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freedom (degrees of freedom meaning independent ways in which matter can move):
 kT / 2  
Where k = Boltzmann constant and T = temperature.
Since there are 3 coordinate axes specifying three directions of possible motion (hence 3
directions for the degrees of freedom), the total kinetic energy of the system can be thus
represented as:
E kinetic = 3 x kT/2
But kinetic energy can also be represented as follows:
E kinetic  = ½ mv2
Thus the previous two equations can be represented as follows:
3kT/2  = ½ mv2 
and therefore the relationship of “temperature” and “velocity” in the previous equation
can be thus represented as follows:
T ≈ v2
So “increasing the temperature” in a molecular dynamics simulation is a computational
way of increasing the velocity of atoms/molecules in a computer model. Obviously, the
amount  of  kinetic  energy  provided  to  the  system  should  not  result  in  abnormal
fluctuations in the bond-lengths or bond-angles. 
Figure 4.1.3 Example of section MD script referring CHARMM software to use
set of parameters.   
In an MD system the bond-lengths, angles etc. are kept to within empirically determined
parameters  (shown  in  italics  and  underlined)  by  the  code  above  in  the  molecular
dynamics script.
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Otherwise, the molecules can also be restrained within empirical parameters using the
SHAKE algorithm (16). Thus in summary, “movement” of molecules in a computer
system can be simulated  at  different  kinetic  energy levels  using  the  relationship  of
kinetic  energy  to  heat  energy.   This  way,  there  can  be  an  audit  trail  of  various
fluctuations of energy within the system.
4.2 Results
4.2.1 Computer simulated folding of RyR2 aa 3579-4085
The final configuration of the models following  in silico folding by MODELLER, as
described in Chapter 3, is shown below.
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Figure 4.2.1a The  initial  models  produced  from  homology  modelling  using
MODELLER as described in chapter 3.  
The CAMLD and the CAMBD domains are both highlighted in red.
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Figure 4.2.1b The  initial  models  produced  from  homology  modelling  using
MODELLER as described in chapter 3.  
The CAMLD and the CAMBD domains are both highlighted in red.
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Various  conformations  are  present  between  the  2  domains  since  the  loop  regions
(regions of high entropy and disorder) may adopt any conformation and thus influence
the overall shape of the molecule. As discussed in chapter 3, large portions of the RyR2
region amino acids 3579-4085 had to folded using  de novo methods. Minimal energy
minimisation was carried out within MODELLER itself (using the conjugate gradient
method). These models were used as a starting point for subsequent simulation.  
Each of the models shown in figure 4.2.1 were subjected to  1000 steps of steepest
descent and 1000 steps of conjugate gradient energy minimisation using CHARMM.
Each energy minimisation run was scripted to produce a detailed log file. Figure 4.2.2
shows the gradual minimisation of overall energies using both methodologies on the
various models that were generated.
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Figure 4.2.2 Energy  minimisation  of  the  various  models  generated  using
MODELLER.  
The first  concave curve portion signifies the energy minimisation using the steepest
descent protocol. The second concave curve shows the minimisation carried out using
the conjugate gradients protocol. The data was extracted from the log files using the
following  script:  awk  '/MINI>/  {print  $2,  $3;}'  name_of_logfile.log  >
energy_output.txt., the graphs were plotted using gnuplot.  
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The composite figures in figure 4.2.2 show that both methodologies of minimisation
were necessary to achieve a final structure that had all the bond angles, bond lengths
and erroneous distances between atoms corrected according to empirically determined
values contained in the CHARMM parameter files. The first hyperbolic curve portion
signified the minimisation carried out using the steepest descent protocol, this method
quickly corrects any gross problems with the structure but does not approach minima
easily.  Subsequent  minimisation,  indicated  by  the  second  hyperbolic  curve  portion,
using the conjugate gradients method, further corrected any problems and reduced the
overall energy to that one of a more stable structure.
Between each minimisation step, there would be changes to the overall structure and
this can be monitored by evaluating the root-mean square deviation (RMSD) of the
positions of the C-alpha carbon atom chain between the starting model and that of the
final refined structure. If there were no difference between the two compared structures,
the RMSD value would be zero. Lower values of RMSD indicate a lesser degree of
deviation of the geometry of the compared structure against the starting model. Figures
4.2.3-5 show the RMSD deviations of the various models following ab initio folding by
MODELLER,  then  refinement  using  steepest  descent  minimisation  followed  by
conjugate gradients minimisation. Also shown in these figures are the structures of the
domains CAMLD and CAMBD. 
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Figure 4.2.3 RMSD values following energy minimisation.   
The difference between the original model and the refined model after steepest descents
(SD) and conjugate gradient (CG) minimisation are given above. A value of 0 indicates
that there is no difference between the compared structure and the original model. The
larger the value, the greater the difference between the two compared structures. 
Cyan = original model, Green = SD refined, Magenta = CG refined.
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Figure 4.2.4 RMSD values following energy minimisation. 
The difference between the original model and the refined model after steepest descents
(SD) and conjugate gradient (CG) minimisation are given above. A value of 0 indicates
that there is no difference between the compared structure and the original model. The
larger the value, the greater the difference between the two compared structures. 
Cyan = original model, Green = SD refined, Magenta = CG refined.
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Figure 4.2.5 RMSD values following energy minimisation.   
The difference between the original model and the refined model after steepest descents
(SD) and conjugate gradient (CG) minimisation are given above. A value of 0 indicates
that there is no difference between the compared structure and the original model. The
larger the value, the greater the difference between the two compared structures. 
Cyan = original model, Green = SD refined, Magenta = CG refined.  
Ramachandran analysis of the models post these stages of minimisation was conducted.
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Figure 4.2.6a Composite  of  Ramachandran plots of  models post-refinement (SD
and CG).
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Figure 4.2.6b Composite  of  Ramachandran plots of  models post-refinement (SD
and CG).
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Figure 4.2.7a Ramachandran statistics for models post-refinement.  
The various values following the Ramachandran analysis of the structures following
energy minimisation of  SD followed by CG methods.  The ramachandran plots were
calculated using PROCHECK. 
134
Figure 4.2.7b Ramachandran statistics for models post-refinement.  
The various values following the Ramachandran analysis of the structures following
energy minimisation of  SD followed by CG methods.  The ramachandran plots were
calculated using PROCHECK. 
From evaluation of the results in figure 4.2.7, model 49 showed the highest percentage
of residues in most favoured regions compared to the others. Model 2 did not have any
residues  in  the  disallowed  regions  post-refinement.  Thus,  it  was  decided  to  pursue
molecular dynamics analysis on these two models. 
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4.2.2 Molecular Dynamics
4.2.2.1 Analysis of Molecular Dynamics files
Each  molecular  dynamics  run  using  CHARMM  generates  an  “*.ene”  file,  which
contains all the energy output data.  
An example content from an "*.ene" file is as follows.
Figure 4.2.8 Example of the contents of an “*.ene” file following a CHARMM
simulation.
The  objective  was  to  plot  the  time-steps  or  the  time  (in  picoseconds)  against  the
energies.  To preserve  the  original  file,  in  case  of  any error  in  data  processing,  the
original file is copied and renamed. Subsequently, the new file is edited and the lines
coloured in red (as shown above) are deleted. In their place, the following three lines (in
green) are substituted in the file as shown below. 
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Figure 4.2.9 Example  of  the  “*.ene”  file  after editing  in  preparation  for data
extraction. 
The starting few header lines are deleted in the original file and replaced with three
“dummy” lines, which will serve as null-strings in subsequent data extraction steps. 
The  newly  edited  file  is  then  saved  under  a  different  filename,  such  as
“new_ene_file.ene”.
In order to extract the kinetic energy values from this huge data file, without having to
manually scan through the entire file, the following command was typed at the Linux
prompt.
 awk '{print $1, $4;}' new_ene_file.ene > 2column_energyfile_steps_vs_kineticE.txt
 
This command grabs the 1st and the 4th column from the file, and then places it in a new
file (2column_energyfile_steps_vs_kineticE.txt) containing two columns of data.
However, as the data needed is contained in every 4th line of these columns, the other
lines contain data that pertains to other parameters. Thus, in order to grab every 4 th line
and output  this  into  a  new file,  the  following command was  invoked at  the  Linux
prompt.
awk '0 == NR % 4'  2column_energyfile_steps_vs_kineticE.txt > every4th_line.txt
This newly generated file (“every4th_line.txt)  contains  data  that can be plotted in  a
standard  x,y coordinate  system,  using  any graphical  program.  Gnuplot  was  used  to
generate the graphs for this section of the project.
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4.2.2.2 Molecular Dynamics – Heating Step
The heating step of the molecular dynamics run served to “mobilise” the molecule, so
relieving any residues that are tethered to one another by virtue of van der walls forces,
protein-protein interaction or ionic charges. The heating step in a molecular dynamics
script is typically written as follows:
Figure 4.2.10 Example script of a CHARMM MD heating step.
In the above script, it can be seen that the time-step-size is fairly small, (0.001). Larger
step  sizes  would  allow  the  simulation  to  run  much  faster  as  there  would  be  less
sampling steps. However, larger step sizes also mean that for the “in-between” steps,
there would be a certain amount of data that is not recorded and therefore lost. There is
also a danger that simulations would crash with larger step sizes, this is primarily when
there is a loss of recording of data. If there is a need to reference a particular point
during the simulation which points to a time step not present in the data file, then the
simulation would crash.
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In addition, the heating step is taken from 240 K to 800 K. As discussed previously in
section 4.1.2, these values are related to kinetic energy and allows a means to provide
the appropriate amount of translational movement to a molecule in computation.
Figure 4.2.11 The heating step during CHARMM MD analysis of model 2.  
The linear line shows a gradual rise in kinetic energy with the number of steps. 
Since there is no sudden dip in the line, the overall starting structure must have been
adequately refined (minimised) to relieve any erroneous strain that may have prevented
parts of the molecule from mobilising appropriately.
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Figure 4.2.12 The heating step during CHARMM MD analysis of model 49.  
The linear line shows a gradual rise in kinetic energy with the number of steps. 
Both models, 2 and 49, show a stable and gradual heating step. It is difficult to assess
what the maximal heating step should be for molecules. This is usually performed on a
trial by error method, gradually increasing the maximal heating step in a simulation
empirically  until  a  point  is  reached  where  the  molecule  then  totally  unfolds  or
disintegrates, or the system crashes. Thus, a slightly lower temperature from that point
would be normally used. In this instance, however, a consensus temperature commonly
used was applied whilst carrying out the heating step. 
4.2.2.3 Molecular Dynamics – Equilibration Step
The subsequent process in the molecular dynamics simulation is the equilibration step.
In this process, the molecule is gradually cooled down to a stable temperature, at which
it is know that the molecule would be stable in a liquid state. This is usually selected at
normal physiological body temperature 310 K (37°C) although any temperature above O
K (-273°C) would suffice. 
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Figure 4.2.13 Example of the CHARMM molecular dynamics equilibration step.  
In this script, the molecule is slowly cooled from the final temperature of the previous
heating step (800 K) down to 310 K. The idea is to continue the equilibration until the
kinetic energy fluctuations of the molecule are minimal, whereby the molecule is at its
most stable conformation.
The kinetic energy at each step of this stage of the equilibration is recorded allowing for
this data to be plotted as seen in figures 4.2.14 (model 2) and 4.2.15 (model 49). A
protein  structure  file  (.psf)  and  a  trajectory  file  (.dcd)  of  the  changes  of  spatial
positioning of each amino acid are also generated. When these two files are both loaded
into suitable software, VMD  (Humphrey et al. 1996) was used, the movement of the
model as it undergoes conformational changes during equilibration can be viewed as a
film. This allows for clear observation of movement within the structure including the
reduction in movement,  as the kinetic energy decreases,  as a stable conformation is
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adopted. Figures 4.2.16-17 (model 2) and 4.2.18-20 (model 49) show images captured
at points selected based on the kinetic energy from the graphs below.  
Figure 4.2.14 The CHARMM equilibration step of model 2. 
Wide fluctuations in kinetic energy are seen below 4500 steps, above which, the system
starts to equilibrate, albeit minor fluctuations. These fluctuations continue to diminish
approximately at 15000 steps.  
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Figure 4.2.15 The CHARMM equilibration step of model 49. 
Two large groups of  wide fluctuations in kinetic  energy are seen below 7000 steps,
above which, the system starts to equilibrate, albeit minor fluctuations.
The following images are aligned, for both models, so that CaMLD in close proximity
to CaMBD is shown in the lower centre of the images. Also images at the different step
stages are taken from the same viewpoint allowing for easier observation of the change
in conformation. 
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Figure 4.2.16 Structure  of  model  2  during  equilibration  at  high  kinetic  energy
fluctuation point (step 2500).
Figure 4.2.17 Structure of model 2 at end of equilibration steps.
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Figure 4.2.18 Structure  of  model  49  during  equilibration  at  first  high  kinetic
energy fluctuation point (step 2000).
Figure 4.2.19 Structure of model 49 during equilibration at second high kinetic
energy fluctuation point (step 6500).
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Figure 4.2.20 Structure of model 49 at end of equilibration steps.
In  the  above  structure  images  the  movement  of  the  regions  towards  the  stable
conformation adopted at  the end of the equilibration stage can be observed.  This is
clearer  for  model  49 were two snapshots  have been taken during the  two zones  of
kinetic energy fluctuation allowing for clearer comparison with the stable conformation.
For both models CaMLD stays in close proximity with CaMBD, so not greatly differing
from the input structure for these parts of the models. The majority of movement is
observed in the loop between the two RyR2 domains. 
4.3 Discussion
The aim of this chapter was to improve the models generated at the end of chapter 3 so
they could offer greater potential as a tool for the study of human RyR2 between amino
acid residues 3579-4085. Within this area of RyR2, two domains with known structures
had been identified, CaMBD and CaMLD. The PDB entry 2BCX served as a template
for both domains as it contained the structure of two equivalent proteins interacting. At
the end of chapter 3 models had been generated containing CaMBD and CaMLD which
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had been positioned relative to each other based on distances obtained from 2BCX.
However, the remainder of the loop region between these two domains only had a basic
overall structure including predicted secondary structure elements. As discussed in the
introduction of this chapter, the tertiary structure of a domain has significant influence
on its  function.  Therefore,  to  improve  the  quality  of  the  models  it  was  decided  to
simulate the folding of the model structure into a three dimensional state. 
   
To enable the in silico theoretical folding of the protein a number of processes had to be
performed. An additional round of energy minimisation was conducted on the models 
from chapter 3. This was to confirm that these models were in the lowest achievable
energy  state  prior  to  the  simulated  folding.  Ramachandran  analysis  post  energy
minimisation revealed that model 2 had no residues present in disallowed regions and
that model 49 had the highest percentage of residues within the most favoured regions.
Thus, these two models were selected for further improvement. 
As discussed in the introduction there are various theories postulated about how the
amino acid translates into a tertiary folded protein structure. Within current computing
limitations the best simulation of a folding process is through a molecular dynamics
approach.  This  is  achieved  by  a  theoretical  heating  and  then  cooling  phase.  The
relationship  between  temperature  and  velocity  (kinetic  energy)  within  molecular
dynamics  has  been  discussed.  Basically  the  process  involves  increasing  the  energy
available (heating) to the molecule which allows movement within the structure. The
energy level  is  gradually  reduced  (cooling)  from this  high  energy state  so  that  the
structure adopts an energetically stable conformation. As mentioned, this process does
not contain the complexity or finesse of nature and, as a result, the final conformation
obtained represents a probable likelihood of the structure of the modelled region. 
Analysing the equilibration phase revealed that the majority of movement within the
structures to achieve the stable conformation occurred in the loop region between the
two identified domains. The CaMLD and CaMBD domains remained closely together
as in the input model structure. These two domains were already folded as based on
their respective template structures. The two domains were placed at distances observed
in the structure of PDB entry 2BCX. Thus, as the folding and positioning of these two
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domains was based on known structure, i.e. the result of protein that had undergone
folding in nature, these parts of the model structure were expected to be least affected
by the simulated folding. However, the region between the two domains was modelled
ab  intio as,  unlike  the  two  domains,  no  template  was  available.  Thus,  this  region
contained  less  structural  information  so  was  likely  to  be  most  influenced  by  the
simulated folding process. 
The difference in final structures obtained for the two models reflects the limitations of
the process. The conformation at the end of the equilibration phase is a product of the
molecular dynamics process upon the input model structure. As stated previously, this
process is a best possible simulation, and as the input models varied, it is to be expected
that variation in the final conformations would be observed. However, the process of
emulating some of the aspects of tertiary structure through simulated folding of the
models has increased their structural quality. As a result, the products of this process are
better tools with which to study this region of RyR2. 
It is assumed that some of the disease mutations within the human RyR2 region 3579-
4082 would disrupt the structure so impacting on the predicted regulatory role of this
region within the calcium channel. It is proposed that the disruption to structure would
be reflected in the energy states observed in relevant simulated models. As shown by the
generation of the two models of wild type RyR2, the tools exist to simulate this region
and monitor the energy state of the structure during this process. Further information
about  the  structural  impact  of  mutations  in  this  region  can  be  gained  by  the
computational simulation and manipulation of models containing studied mutations.  
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Chapter 5:
Cloning and expression of the
recombinant RyR-fragments and
Calmodulin.
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5.1 Introduction
As discussed in chapter 1 the interaction between various domains within the ryanodine
receptor (RyR) are known to play a crucial role in the regulation of the channel acting as
a calcium release store. As further elaborated in chapter 3 the calmodulin like domain
(CaMLD) and CaM binding domain (CaMBD) within RyR are indicated to be involved
in one of  these key interactions.  The binding of  these two domains  along with the
association of CaM is believed to play a role in the response of the channel to increasing
calcium concentration leading to channel opening. The presence of some of the known
catecholaminergic  polymorphic  ventricular  tachycardia  (CPVT) mutations  within
CaMLD is  postulated  to  disrupt  the  mechanism of  the  interaction  of  the  two  RyR
domains and hence affect channel opening leading to arrhythmia.
As the binding of these two domains and the involvement of CaM with this interaction
was targeted for this study so constructs of these regions were required. Chapters 3 and
4 discuss the computer based modelling of these regions.  While chapter 4 describes
simulating a much larger region of RyR linking the two domains of interest  for the
purposes of generating recombinant protein a similar approach to the smaller modelling
of the domains as followed in chapter 3 was adopted. A number of the initial studies of
these  regions,  as  described  in  the  literature,  were  conducted  in  RyR1.  This  study
identified  equivalent  regions  in  RyR2 for  the  basis  of  construct  design,  subsequent
additions to the literature regarding the CaMLD region in RyR2 have followed a similar
approach. The specifics of the construct domain boundaries are discussed further in the
relevant sections below.
The RIH associated domain was identified as a series of amino acid repeat sequences
present in IP3Rs and RyR that it was proposed may have possible protein binding or
related function (Ponting 2000). Studies conducted by colleagues indicate that residues
3722-4353 of the I domain of RyR2 are sufficient for interdomain interaction (George et
al.  2004a). It is possible that the RIH associated domain may be involved with this
process. While this may separate to CaMLD function, the RIH associated domain may
play a role in supporting the binding of CaMLD with CaMBD. It is because of this
possibility that the RIH associated domain has been identified as a region for potential
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further study.
The aim of this section of the project was to produce the required recombinant proteins,
including CaMLD constructs containing known CPVT mutations, required for further
experimentation to study the domain interactions. To enable this to occur so structurally
stable soluble recombinant protein has to be produced; the construct design phase is a
key stage in this  process.  A variety of factors as discussed in  chapter 1 have to  be
considered. With consideration to the regions of RyR being studied in this project the
identification  of  stable  “pieces”  that  can  be  independently  lifted  from  the  whole
molecule is required. Commonly complete domains and active regions are targeted, in
this case potential sections have already been identified in the literature. However to
enable the production of recombinant protein to the quantities and quality required for
structural  biology studies  then  further  work is  usually  needed to  determine  suitable
domain boundaries, and a number constructs and expression variables need to be tested.
    
5.1.1 Design of CaMLD constructs
As stated above RyR2 based CaMLD constructs have been reported in the literature.
This study used the RyR1 based Xiong, 2006 (Liangwen Xiong et al. 2006) paper as a
basis for identifying domain boundaries for RyR2 CaMLD constructs. The basis of most
CaMLD  constructs  are  designed  around  the  two  predicted  EF  hand  motif  regions
contained within the earlier section of the interacting (I) domain. 
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Figure 5.1.1 Map of  predicted regions in earlier section of  I  domain including
CaMLD.
Amino acid  coordinates  are  given  for  the  relevant  regions.  RIH associated  domain
determined from Ponting, 2000 (Ponting 2000). CaMLD coordinates in RyR2 derived
from Xiong, 2006 (Liangwen Xiong et al. 2006). Two EF hand motifs contained within
CaMLD from Pfam predictive software. Location of CaMBD relative to CaMLD within
RyR2 also shown.
As stated the initial coordinates for the domain boundaries for CaMLD constructs were
derived from the Xiong, 2006 paper (Liangwen Xiong et al. 2006). This paper reported
interaction  between  a  CaM  binding  motif  and  Ca2+-binding  domain,  4064-4210,  in
RyR1. The sequence homology of the relevant amino acid sequences between RyR1 and
2 were compared.  
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Figure 5.1.2 Amino acid homology sequence comparison between reported Ca2+-
binding domain in RyR1 and equivalent region in RyR2.
Sequence 1 is 4064-4210 section of RyR1. Sequence 2 is 3950-4150 region of RyR2 
As can be seen in figure 5.1.2 the potential matching region of RyR2 to the reported
RyR1 sequence is  slightly longer than the given coordinates in figure 5.1.1.  This is
because these residue numbers were determined by further analysis of the sequence in
the  surrounding  region  of  RyR2.  Initially  the  exon  boundaries  of  the  nucleotide
sequence were mapped to the amino acid sequence to try to identify complete coding
sequences within RyR2. 
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Figure 5.1.3 Exon  boundaries  mapped  onto  amino  acid  sequence  of  earlier
section of I domain of RyR2
Amino  acid  sequence  number  of  RyR2  is  shown  to  right  of  sequence.   The  exon
boundaries are illustrated by  a vertical separator ( |). The  Regions mapped in figure
5.1.1 including coordinates: 3826-3959 (RIH associated domain – boxed in red); 4019-
4126 (CaMLD -boxed in blue) and the EF hand motifs  lie between 4027-4055 and
4062-4090 (highlighted in ochre). Selected CPVT mutations shown in bold. 
Based on the analysis of the exon boundaries 4 potential construct start locations were
identified,  3 prior to  the start  of  the RIH associated domain and 1 before CaMLD.
However  using  the  end  point  of  the  exon  encoding  CaMLD  would  result  in  an
impractically  long  recombinant  protein  with  increased  technical  difficulties  for
expression and downstream experiments. To determine potential C termini of potential
constructs the predicted secondary structure of the I domain was examined.   
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Figure 5.1.4 Predicted  secondary  structure  of  I  domain region  downstream of
CaMLD.
Top line is  amino acid sequence of RyR2 including and immediately downstream of
CaMLD,  end  section  of  CaMLD  sequence  highlighted  in  turquoise.  Lowest  line  is
consensus  sequence  of  predicted  secondary  structure  generated  from  3  algorithms.
Location of potential C termini residue selections highlighted in green.  
A number  of  secondary  structure  prediction  algorithms  were  used  to  generate  a
consensus sequence so increasing the likelihood that the selected amino acid had the
predicted  secondary  structure  feature.  As  discussed  above  candidate  residues  were
searched for in regions of random coil that were clearly downstream of helix regions
that may be associated with the Ca2+ interaction region. The role of supporting helical
regions around EF hands to aid binding to target sites is discussed further in chapter 1.
The first identified C terminus site, amino acid 4163, also met the additional criterion of
being a proline residue. A second site, 4228, was also selected to test if better quality
recombinant protein required a longer sequence. 
Based  on  the  coordinates  derived  from  the  analysis  of  the  exon  boundaries  and
predicted secondary structure so 8 potential constructs were identified. Within these; 2
were identified as potentially preferred constructs. Firstly, the region encompassing the
matching Ca2+-binding domain of  RyR1,  construct  7  below,  this  construct  was later
referred to as the Ca2+ interacting region (CIR). Secondly, the construct containing the
155
RIH associated domain in addition to the Ca2+-binding domain, construct 5 below, later
referred to as CaMLD. 
Figure 5.1.5 Coordinates of 8 potentially identified constructs within the earlier
section of the I domain.
The  locations  of  known  CPVT mutations  within  these  8  potential  constructs  was
identified with a view to generating mutant forms of the constructs.  
Figure 5.1.6 Known  CPVT  mutations  contained  within  region  of  8  potential
constructs.
Location of mutation when present within identified domain of early I domain is given. 
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Within these mutations, 4 were selected of particular interest for further investigation.
G3496S owing to its position within the RIH associated domain. E4076K because of its
presence within the predicted EF hand motifs  and also because it  is  a  charge swap
mutation with the loss of the glutamic acid in this location. The potential importance of
the change of a negative to positive charge within an EF hand is discussed in further
length in chapter 1. N4104K is located in a surrounding α helix adjacent to the EF hand
motif believed to be important in supporting binding to CaMBD. Also this mutation
results in the gain of a positive charge from neutral with the change to a lysine residue.
Although H4108Q is not included in the predicted α helical regions downstream of the
EF hand motifs it may have some overlap as seen in the modelling conducted in chapter
3. Also this mutation results in the removal of a positive charge introducing a neutral
glutamine.
5.1.2 Design of CaMBD constructs
There are PDB entries containing CaMBD structures, 2bcx is cited in chapter 3 of this
thesis,  these  involve  a  short  peptide  with  an  α  helical  tube  like  structure.  For  the
purposes of this project it was decided to make a longer recombinant protein based on
human RyR2. Constructs were designed around the N and C terminal flanking regions
of RyR1, linked with CaM concentration response in RyR, and CBD2 as identified by
Yamaguchi et al (Yamaguchi, 2004). The CBD2 is a CaM binding site of RyR, this
region has high homology between the RyR isoforms and is located within the region
marked  CaMBD  in  figure  5.1.1.  Initially  4  constructs  were  designed  all  of  which
contained the CaM binding site of RyR2 in addition to the following specified regions.
The construct labelled “full” included both flanking regions, “N1” the N terminal and
“C1” the C terminal. The construct initially designated “short” and later referred to as
CaMBD was designed to include the CaM binding site and short sections of the N and
C terminal flanking regions. The domain boundaries of the construct, which determined
the amount of content of the flanking regions, were selected with reference to predicted
2rt structure using the same criteria as used in the design of the CaMLD constructs. 
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Figure 5.1.7 Predicted  secondary  structure  of  CaM  binding  site  and  flanking
regions of RyR2.
Top line is amino acid sequence of region of RyR2 containing CaM binding site. Section
highlighted  in  turquoise  is  equivalent  region  to  CBD2  and  both  flanking  regions
identified in RyR1.  Lowest line is consensus sequence of predicted secondary structure
generated from 3 algorithms. 
Based on location of proline residues relative to areas of conserved predicted helical
sections the following amino acids were identified as domain boundaries for construct
design: E3545 and K3646.
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This  design  process  resulted  in  4  potential  constructs  with  the  following  domain
boundaries in RyR2:
1) Full (includes both flanking regions) 3536-3691
2) Short (based on predicted secondary structure) 3545-3646
3) N1 (CBD2 + N term flanking region) 3536-3646
4) C1 (CBD2 + C term flanking region) 3545-3691
As  discussed  in  chapter  1  there  have  a  number  of  studies  examining  the  role  of
mutations in the regions flanking CaMBD particularly in reference to the difference in
calcium  sensitivity  between  the  RyR  isoforms  (Yamaguchi,  2004,  2005,  2009).
However, at the time of this project there are no published CPVT mutations within the
region of CaMBD being examined. 
5.2 Results
5.2.1 Production of CaMLD constructs
5.2.1.1 Cloning and expression in pET15bmod vector
Initially all 8 potential constructs were selected for cloning and expression trials prior to
further selection.  pET15b was chosen as a cloning vehicle because it contained a very
short  linker  sequence  downstream  of  the  hexa-histidine  (6His)  encoding  sequence
within the plasmid. This would mean that there would be that fewer non-specific amino
acids  are  incorporated  into  the  final  expressed  recombinant  protein. The  pET15b
plasmid is shown in figure 2.1.1.
Using the complimentary DNA (cDNA) of the human Ryanodine receptor isoform 2
(RyR2) as a  template,  the polymerase chain reaction (PCR) was used to  generate  a
number  of  different  synthetic  amplimers  that  were  then  ligated  into  pET15bmod (a
modified  derivative of pET15b (+)). These were transformed into TOP10 cells.  The
primers used to generate the amplimers are shown below.
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Construct ID Primer sequence Amplimer
size
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1 EcoRI
5'- CCGAATTCGGTGAAACTGGACC -3' (1F)
XhoI
5'- CCTCTCGAGCTACTCTTCCGGCC -3' (1R)
1.25 kb
2 EcoRI
5'- CCGAATTCGGTGAAACTGGACC -3' (1F)
XhoI
5'- CTCCTCGAGCTAGGGCTTCTCCC -3' (2R)
1.44 kb
3 EcoRI
5'- CGGAATTCAGTGTCCTTGACCTAAATGC -3' (2F)
XhoI
5'- CCTCTCGAGCTACTCTTCCGGCC -3' (1R)
1.09 kb
4 EcoRI
5'- CGGAATTCAGTGTCCTTGACCTAAATGC -3' (2F)
XhoI
5'- CTCCTCGAGCTAGGGCTTCTCCC -3' (2R)
1.28 kb
5 EcoRI
5'- CGGAATTCGGAGAAAAGGTTCTGC -3' (3F)
XhoI
5'- CCTCTCGAGCTACTCTTCCGGCC -3' (1R)
1.01 kb
6 EcoRI
5'- CGGAATTCGGAGAAAAGGTTCTGC -3' (3F)
XhoI
5'- CTCCTCGAGCTAGGGCTTCTCCC -3' (2R)
1.21 kb
7 EcoRI
5'- CGGAATTCGATTCCAGTCAAATTGAGC -3' (4F)
XhoI
5'- CCTCTCGAGCTACTCTTCCGGCC -3' (1R)
0.61 kb
8 EcoRI
5'- CGGAATTCGATTCCAGTCAAATTGAGC -3' 4F)
XhoI
5'- CTCCTCGAGCTAGGGCTTCTCCC -3' (2R)
0.80 kb
Table 5.2.1.1 Primer sequence and amplimer sizes of CaMLD pET15b constructs. 
All forward primers contained the EcoRI restriction site whereas the reverse primers
contained the XhoI restriction site. The restriction sites are underlined in the primers.
The  amplimers  were  double  digested  using  these  enzymes  prior  to  ligation  into
pET15bmod plasmid that had been digested similarly earlier. 
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Figure 5.2.1.1 Agarose gel of PCR products of 8 initial potential constructs.
Size of expected products by construct number.
1) 1.25 kb
2) 1.44 kb
3) 1.09 kb
4) 1.28 kb
5) 1.01 kb
6) 1.21 kb
7) 0.61 kb
8) 0.80 kb
PCR products of the expected size were generated for all  8 potential  constructs. As
detailed in chapter 2 the digested PCR products were ligated into pET15bmod vector.
Colony PCR (cPCR) was conducted on a range colonies from antibiotic selection agar
plates.
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Figure 5.2.1.2 Agarose gel of cPCR of selected pET15bmod constructs.
Bands of expected size observed for colonies of constructs 2 (1.44kb), 4 (1.28kb), 6
(1.21kb) and 7 (0.61kb).
Initially only positive cPCR results were observed for colonies of constructs 2, 4, 6 and
7.  While  not  all  potential  constructs  had  given  positive  results  the  majority  of  the
designed domain boundaries could be tested. Construct 7 was the only positive one to
feature the residue 4163 C terminus, however as identified by the analysis conducted
during the construct design phase construct 7 was targeted as a key construct to test. It
was decided to run protein expression trials with these constructs.   
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Figure 5.2.1.3 Expression of constructs in pET15bmod vector in Rosetta (DE3). 
The 6His constructs 2, 4 and 6 were lysed, and the entire protein lysate was subjected to
SDS-PAGE  alongside  protein  expressed  from  native  pET15bmod  (without  cloned
inserts). This figure shows that the constructs labelled 2, 4 and 6 gave strong protein
bands  in  the  expected  sizes.  Lanes  labelled  (a)  were  the  lysates  from  the  cells
transformed with native pet15b, in comparison, these control lanes do not show strong
protein bands as in the lanes labelled 2,4 and 6.
Expected size of constructs including tag from pET15bmod vector:
2) 56.0 kDa
4) 50.5 kDa
6) 47.9 kDa
Expression bands of the expected size were observed for constructs 2,4 and 6. Although
not shown similar expression levels were observed for construct 7 in later trials. To
observe the soluble protein content the lysate was centrifuged then applied to Ni-chelate
chromatography.  The  amount  of  recombinant  protein  that  remained  in  the  pellet
following  lysis  was  compared  to  the  amount  of  recombinant  protein  that  was
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successfully eluted from Ni-chelate chromatography. The eluate fraction represented the
soluble portion of  the protein preparation whereas  those that  remained in the pellet
following lysis  represented the insoluble fraction of the protein preparation.  By this
quick  screening  method,  it  was  possible  to  determine  which  constructs  had  higher
probability  to  deliver  good  soluble  protein  that  would  be  useful  and  amenable  to
downstream purification processes.
Upon  analysis  of  the  above  samples  it  was  noted  that  no  soluble  expression  was
obtained with the protein occurring in inclusion bodies. A number of variables within
the growth and induction phase were trialled. These included alterations to the timings,
temperatures  and  IPTG  concentration  stated  in  chapter  2.  A  range  of  additives
associated with reported increase in soluble expression including alcohol and glycerol
were included with the growth media. Additional Ca2+ in the growth media was also
trialled in case the presence of the EF hand motifs in the expressed constructs were
disrupting the Ca2+ homeostasis of the expressing cells. The addition of glycerol and
Ca2+, and also variations within the stated lysis buffers were tested. None of these tested
variables made an observable difference in the quantity of soluble protein.  
The only tested variable that made any observable difference to the amount of soluble
protein was the addition of detergent to the lysis buffer. As an initial trial NP40 lysis
buffer (Pierce) was added into the existing lysis buffer. The growth, induction and Ni
affinity purification protocols as detailed in chapter 2 were followed with the exception
that the basic Ni affinity protocol was used which omits the 60mM imidazole lysis and
70mM imidazole wash steps. As a result few of the contaminant bands, as observed in
the crude lysate preparation in figure 5.2.1.3, were removed from the sample. To try to
improve the purity of  the  sample,  ion  exchange chromatography (Q sepharose with
NaCl gradient) followed by gel filtration, as per chapter 2 protocol, was used. Samples
of the selected pooled fractions from the NP40 containing preparation of construct 4 are
shown in the figures below. 
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Figure 5.2.1.4   NP40 treated purification of construct 4/pET15bmod/Rosetta (DE3)
(Upper):  Coomassie  stain  of  equivalent  SDS-PAGE  to  Western  blot  of  NP40
purification of construct 4/pET15bmod/Rosetta (DE3).
(Lower): Western blot of NP40 preparation of construct 4/pET15bmod/Rosetta (DE3). 
Construct 4 expected size 50.5 kDa.
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Whilst  the  majority  of  protein  remained  in  the  insoluble  fraction  during  the  NP40
preparation sufficient material  was obtained to track a band of the expected size by
SDS-PAGE through the purification  stages  (upper  panel).  The Western  blot  showed
several bands for the imidazole fractions though the strongest signal is observed for the
band above the 32 kDa marker (lower panel). This was the only band seen after ion
exchange chromatography but is not clearly observable after gel filtration. It should be
noted  that  unlike  the  other  eluted  peaks  the  gel  filtration  fractions  were  not
concentrated.
Although only shown for construct 4, the above experiments were repeated for the other
constructs  including  7.  As  observed,  the  other  constructs  displayed  no  significant
increase in soluble protein content.   
5.2.1.2 Cloning and expression in pETMM vectors
In order to address the solubility issues observed with the expression of the recombinant
protein when using a hexa-histidine tag a range of other tags were selected to address
the solubility issue. The pETMM series of vectors contains the same multiple cloning
site (MCS) but with different tags that will be expressed at the N terminus of the cloned
insert. This allows the same set of primers to be used to generate insert suitable for the
chosen vectors in the range. The dual tag vectors pETMM 60 (NusA-6His), see figure
2.1.2, and pETMM 20 (Trx-6His) were initially selected owing to the reported increased
solubility of their associated tags. 
To further increase the speed of testing for the expression of soluble protein; 2 of the
initial 8 constructs were selected to be inserted into the pETMM vector series. These
were  constructs  5  (CaMLD)  and  7  (CIR).  Despite  failing  to  show  clear  soluble
expression  with  the  6His  tag  these  constructs  were  selected,  as  of  all  the  designed
constructs,  their  domain  boundaries  most  closely  matched  the  predicted  internal
domains within the region of the I domain being studied. 
Using the complimentary DNA (cDNA) of the human Ryanodine receptor isoform 2
(RyR2) as a  template,  the polymerase chain reaction (PCR) was used to  generate  a
number of different synthetic amplimers that were then ligated into either pETMM20 or
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pETMM60. These were transformed into TOP10 cells. The primers used to generate the
amplimers are shown in the table below.
Construct
ID
Primer sequence Amplimer
size
CaMLD EcoRI
5'-GAGCGAATTCGGGAGAAAAGGTTCTGCAGG-3'
(CaMLD_F)
SalI
5'- CGTCGTCGACTCAGGGCTTCTCCCACTGGGTTCG
-3' (PET_R1)
1.01 kb
CIR EcoRI
5'- GAGCGAATTCGGATTCCAGTCAAATTGAGCT-3'
(CIR_F)
SalI 
5'- CGTCGTCGACTCAGGGCTTCTCCCACTGGGTTCG-3'
(PET_R1)
0.61 kb
Table 5.2.1.2 Primer sequence and amplimer sizes of CaMLD pETMM constructs.
All forward primers contained the EcoRI restriction site whereas the reverse primers
contained the SalI restriction site. The restriction sites are underlined in the primers. 
The amplimers were then double digested with these enzymes and ligated into either
pETMM20 or pETMM60 plasmid vectors that had been digested similarity earlier. The
regions that were being amplified did not host these restriction sites prior to them being
engineered in. 
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Figure 5.2.1.5 Amplimers of CaMLD and CIR.
Bands of the expected size (CaMLD 1.01 kb and CIR 0.61 kb) were observed on an
agarose gel from samples run from the PCR used to generate the amplimers.
PCR products of the expected size were generated for all  8 potential  constructs. As
detailed in chapter 2 the digested PCR products were ligated into pET15bmod vector.
Colony PCR (cPCR) was conducted on a range colonies from antibiotic selection agar
plates.  These PCR products  were  digested  and ligated  into  the  pETMM 20 and 60
vectors. Restriction digests were conducted on plasmid DNA prepared from 2 selected
colonies per vector post ligation transformation. 
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Figure 5.2.1.6 Restriction digests of  CaMLD and CIR constructs in pETMM 20
and 60.
Bands of the expected size were observed for the tested colonies (CIR 0.61kb, CaMLD
(1.01kb) except for one of the CIR pETMM 20 colonies. No colonies were obtained for
CaMLD in pETMM20 so this construct was not tested at this time. 
 
The positive colonies from the restriction digest were transformed into TOP10 cells and
from these plasmid DNA prepared. This DNA was sequenced and the presence of the
desired inserts confirmed. The successful plasmid constructs were then transformed into
BL21(DE3) and Rosetta(DE3) E.coli cells for protein expression trials. The growth and
induction conditions as described in chapter 2 were followed. Cells were lysed and the
expression levels examined by SDS-PAGE.
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Figure 5.2.1.7a SDS-PAGE  analysis  of  expression  of  CIR  and  CaMLD
constructs in pETMM 20 and 60 vectors.
IPTG concentrations were varied in testing for the construct and vector combinations
in both BL21 (DE3) and Rosetta (DE3) cells. Cell pellets were lysed and analysed by
SDS-PAGE alongside protein expressed from the native non-recombinant vector (shown
on left of gels). This figure shows that the CIR construct in both vectors gave strong
protein bands in the expected sizes. However weak expression was observed for the 60-
CaMLD construct. No apparent differences were observed between the expression cell
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line used.  (Expected band sizes : 60-CIR -80 kDa; 20-CIR -42 kDa)
Figure 5.2.1.7b SDS-PAGE  analysis  of  expression  of  CIR  and  CaMLD
constructs in pETMM 20 and 60 vectors.
IPTG concentrations were varied in testing for the construct and vector combinations
in both BL21 (DE3) and Rosetta (DE3) cells. Cell pellets were lysed and analysed by
SDS-PAGE alongside protein expressed from the native non-recombinant vector (shown
on left of gels). This figure shows that the CIR construct in both vectors gave strong
protein bands in the expected sizes. However weak expression was observed for the 60-
CaMLD construct. No apparent differences were observed between the expression cell
line used.  (Expected band sizes : 60-CIR -80 kDa; 20-CIR -42 kDa; 60-CaMLD 99
kDa)
Despite the low level of expression seen for the 60-CaMLD construct it was decided to
include samples from this  construct  when testing for  soluble expression.  As for the
pET15bmod constructs the Ni-chelate chromatography approach was adopted.
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Figure 5.2.1.8 Ni-chelate  chromatography  purification  of  CIR  and  CaMLD
constructs in pETMM20 and 60 vectors.
Protein bands of the expected size were observed for the all the constructs tested. The
lysed band lane shows the lysed cell pellet material that was loaded onto Ni-chelate
affinity beads. The unbound lane is a sample of the material that was washed off the
beads. The eluted lane is the material eluted from the beads representing the soluble
partially purified content obtained from the cell pellet. Expected size of construct bands
including tag from pETMM vectors: 60-CIR -80 kDa; 20-CIR -42 kDa; 
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60-CaMLD -99 kDa
As discussed in the construct design section of this chapter the CaMLD construct had
been identified as the construct offering most possibility for further research. Despite
the  lower  yield  relative  to  the  other  constructs,  the  apparent  lesser  number  of
contaminants offered more potential for higher purity samples downstream. It has to be
acknowledged that usually higher yielding proteins are selected owing to the expected
loss at each stage of handling. Also the contaminants for 60-CaMLD appear to be at a
similar  concentration  to  the  desired  protein  which  can  often  mean  separating  a
meaningful amount of wanted material can be more difficult.  
Later  further  colonies  of  60-CaMLD were  tested  for  expression  levels,  from these,
colonies in Rosetta (DE3) cells that had similar expression levels to those seen for the
CIR constructs were identified. Subsequently these colonies gave matching yields from
Ni-chelate  chromatography.  Despite  concerns  that  an increase in total  protein might
result in an increase in the number of contaminants, only the 2 major contaminant bands
observed in figure 5.2.1.8 still remained though were present at obviously higher levels.
Once the initial apparent issue of low protein yields had been solved so 60-CaMLD
expressed in Rosetta (DE3) was selected for further work in this project.   
 
To aid the identification of the bands observed post Ni-chelate chromatography for 60-
CaMLD so mass spectrometry was conducted. Enzymatically digested samples from the
bands were run on an ABI 4800 MALDI TOF/TOF Analyzer and the generated peptide
fingerprint maps analysed.
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Figure 5.2.1.9 Mass  spectrometry  analysed  SDS-PAGE  samples  from  Ni-chelate
chromatography purified 60-CaMLD.
This figure illustrates the increased protein yield from 60-CaMLD as described above.
Samples from the numbered bands were analysed by mass spectrometry. Band 2 was the
only sample identified to a high probability confidence level. 
Band 1: fragments of NusA and RyR2 
Band 2: bi-functional polymyxin resistance protein ArnA (75 kDa E.coli protein)
Band 3: insufficient ions produced to give clear result
 
The mass-spectrometry data of band-1 correlated best with the known fingerprint tryptic
digest of the 60-CaMLD protein, hence confirming that the correct protein was being
purified.  Band  2,  the  ArnA protein,  is  an  E.coli protein  associated  with  antibiotic
resistance and lipid metabolism. It does not have any obvious connection to RyR2 and is
expected to be present to some extent in all the expressed construct protein samples.
Band 3 appears to be selected during purification with the 60-CaMLD protein. Although
not identified by mass spectrometry it is proposed that it may be part of the fusion tag
from the vector, the band appears close to the expected size of the NusA-6His tag.  
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Purification optimisation trials were conducted to remove bands 2 and 3, seen in figure
5.2.1.9, from 60-CaMLD samples. Following manufacturer recommendations initially
increasing concentrations of imidazole used as a series of wash steps was tested. 
  
Figure  5.2.1.10 SDS-PAGE  of  increasing  imidazole  concentration  wash  steps
during Ni-chelate chromatography on 60-CaMLD protein sample.
The numbered  lanes  indicate  the  concentration  (mM) of  imidazole  wash  used.  The
elution lanes represent 2 samples taken during the standard 250mM imidazole elution
step. The strong band at the top of the elution lanes is the 60-CaMLD protein. While
there is a small amount of the contaminant bands 1 and 2 present, the amount is much
reduced  compared  to  the  previous  Ni-chelate  purification  trials  shown.  The  20mM
imidazole wash step does remove some of the contaminant material but the 60mM step
is much more effective. The increase to 80mM does not bring any obvious increase in
sample purity while removing 60-CaMLD protein from the beads.
Prior to to these increasing imidazole concentration wash steps being conducted, cell
pellet had been lysed in 20mM imidazole and washed in 40mM imidazole. As a result of
this trial pellet was lysed in 60mM and washed with 70mM imidazole prior to elution
with 250mM imidazole as previously.  
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 Figure  5.2.1.11 SDS-PAGE  of  Ni-chelate  chromatography  purified  60-CaMLD
protein samples using 60mM imidazole lysis and 70mM wash. 
Samples  of  differing  concentrations  of  two purification  preparations  of  60-CaMLD.
While a few minor lower weight contaminants remain, the 2 major contaminant bands
have been removed using the increased imidazole concentration modification to the Ni
affinity purification protocol. For all further experiments requiring tagged 60-CaMLD,
protein of this purification quality was used.
As part of the purification process N terminal dual tag was cleaved from the fusion
protein. The pETMM vectors contain a TEV cleavage site downstream of the tag before
the expressed insert enabling the removal of the tag. 
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Figure  5.2.1.12 Trial  of  TEV protease  cleavage  of  fusion  tag  from 60-CaMLD
protein.
SDS-PAGE in  figure  shows  purified  in  house  produced  TEV that  was  used  for  tag
cleavage digests. A low concentration sample of 60-CaMLD protein, uncut lane, was
incubated with TEV for 2 hours and a concentrated sample from the digest mixture
loaded onto the gel, digest lane. A band, at the size of cleaved CaMLD (39 kDa), was
present in the digest lane indicating cleavage of the tag from the fusion protein.    
A 2nd pass through Ni affinity beads  was used to  remove the cleaved tag and TEV
protease,  TEV  used  was  expressed  with  6His  tag  allowing  for  purification  and
subsequent removal from sample post digest. 
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Figure 5.2.1.13 CaMLD protein samples after 2nd pass through Ni affinity beads
post TEV protease tag cleavage.
The beads lane is a sample of the Ni beads after the flow through was collected. This
lane contains CaMLD (middle band), also present are cleaved NusA tag (top band) and
TEV protease  (lowest  band).  The lane  marked flow indicates  material  that  was the
collected flow through from Ni beads, this sample only contains the cleaved CaMLD
protein.
Initial  tag  cleavage  trials  were  conducted  on  material  that  had  yet  to  undergo  the
increased imidazole wash steps hence the presence of the contaminant  bands in  the
samples shown. A higher yield of CaMLD protein was obtained from later samples that
had  been  purified  using  the  increased  imidazole  concentration  steps.  Also  in  these
preparations the dialysis step, to reduce the imidazole concentration, was combined with
the TEV cleavage step. Although TEV had lower activity in the dialysis buffer than
TEV specific buffers, sufficient activity was obtained when TEV was used at higher
amounts, 1:10 - 1:20 ratio range to CaMLD, that >90% tag cleavage was observed. This
level of TEV activity was observed when the protease was added to the dialysis samples
and left  overnight  at  4°C,  as  the  standard  protocol  involved  overnight  dialysis  this
allowed two purification steps to be conducted in the same time frame. The excess TEV
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was removed during the 2nd pass with Ni beads. The initial incubation time with the
beads  had  been  1  hour  however  this  was  reduced  to  30  minutes  which  improved
recovery of the CaMLD protein from the beads while the TEV and cleaved NusA tag
remained behind. 
Cleaved protein was combined and stored at 4°C. Examination of the pooled sample
after  overnight  storage revealed a  large amount of aggregation.  SDS-PAGE analysis
showed that the aggregate was composed of the cleaved protein, losses of ~80% of the
soluble material were observed. Increased NaCl concentration in the dialysis/cleavage
buffer was found to increase the storage time. As a result all buffers from lysis onwards
contained 300mM NaCl, as listed in the purification protocol in chapter 2. Storage of
smaller  aliquots,  rather  than  one  pooled  sample,  and  keeping  concentrations  below
2mg/ml also helped to reduce losses due to aggregation. All these measures combined
provided a window of less than 48hrs with which to work with the cleaved protein.
Uncleaved protein could be stored for 5 days at 4°C prior to usage. 
Once soluble purified CaMLD protein could be produced then work to produce the
mutant forms of CaMLD was conducted.  As discussed in the chapter introduction 4
CPVT mutations had been identified for further study, G3496S, E4076K,  N4104K
and H4108Q. Mutation of recombinant wild type (wt) CaMLD DNA was performed
using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) to generate 4
clones each containing one of the single mutations listed. The mutated plasmids were
used to transform TOP10 cells and fresh mutated plasmid DNA produced. Restriction
digests  were conducted to check for the presence of inserts of the correct size after
mutagenesis.
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Figure 5.2.1.14 Restriction digests of CaMLD DNA post mutagenesis.
Lanes 1 and 2 contain wt  CaMLD that  was checked prior  to  mutagenesis.  Lane 2
contains a band of the incorrect size so was rejected for further use. The other lanes
contain DNA post mutagenesis which is of the expected size.
Lane 3: G3496S
Lane 4: E4076K
Lane 5: N4104K
Lane 6: H4108Q
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Figure 5.2.1.15 Sequencing chromatograms of mutated forms of CaMLD.
Figure is split into 4 sections, one per mutation. In each section there are 2 panels
showing  the  region  of  DNA in  which  the  mutation  listed  occurs.  The  upper  panel
contains the chromatogram from the wt CaMLD and the lower displays the mutant
sequence. In the DNA sequence shown above each chromatogram the location of the
single nucleotide mutation required to generate the mutant form is highlighted. For all
4 mutant forms created the correct mutation is found.
Once the correct mutations has been confirmed by sequencing then the mutant plasmid
DNA was  used  to  transform Rosetta  (DE3)  cells.  Expression  and  purification  was
conducted as for the wt CaMLD following the protocols listed in chapter 2. A batch of
the wt and mutants forms of CaMLD was prepared. Post tag cleavage these samples
underwent gel filtration to give very pure samples. A western blot probing with an anti-
NusA antibody was conducted to check the detection of the wt and mutant forms of
CaMLD.
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Figure 5.2.1.16 SDS-PAGE and western blot of wt and mutant forms of CaMLD.
Forms of CaMLD are referred to by amino acid single letter code of mutation. Left
hand side of SDS-PAGE shows Ni affinity purified material which was used for the
western blot. As no antibody was available to the RyR2 CaMLD region the western blot
was probed using an anti-NusA antibody.  Only a single  band is  observed for  each
sample in  the western blot  which indicated the use of the anti-NusA antibody as a
detection tool. The right hand side of the SDS-PAGE displays CaMLD samples that had
gone through gel filtration after the fusion tag removal process. As can be seen very
pure samples were produced by these final steps however only a very small of protein
could be practically produced this way.    
5.2.2 Production of CaMBD constructs
5.2.2.1 Cloning and expression in pGEX-6P-1 vector
Initially all 4 potential constructs were selected for cloning and expression trials prior to
further selection. pGEX-6P-1 was chosen as a cloning vehicle because it contained an N
terminal GST tag, mainly this system was selected as this tag was not present in any of
the pETMM vectors used so avoiding potential downstream problems when working
with tagged CaMLD proteins. The presence of the tag would also allow for affinity
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purification of the expressed protein. The pGEX-6P-1 plasmid is shown in figure 2.1.3. 
Using the complimentary DNA (cDNA) of the human Ryanodine receptor isoform 2
(RyR2) as a  template,  the polymerase chain reaction (PCR) was used to  generate  a
number of different synthetic amplimers that were then ligated into pGEX-6p-1. These
were transformed into TOP10 cells. The primers used to generate the amplimers are
shown below.
Construct
ID
Primer sequence Amplimer
size
Full EcoRI
5'- GGACGAATTCAACAGGACTGATGATACCTCAG -3'
(1F)
XhoI
5'-  GCCACTCGAGTCAATAGGCCATATATAAAAAATC  -3'
(1R)
0.46 kb
Short
(CaMBD)
EcoRI
5'- CCTCGAATTCGAGAAGACGGTAGAAAGAG -3' (2F)
XhoI
5'- GGTCCTCGAGTCATTTTGCTAAATCTTCTATCAG -3'
(2R)
0.3 kb
N1 EcoRI
5'- GGACGAATTCAACAGGACTGATGATACCTCAG -3'
(1F)
XhoI
5'- GGTCCTCGAGTCATTTTGCTAAATCTTCTATCAG -3'
(2R)
0.33 kb
C1 EcoRI
5'- CCTCGAATTCGAGAAGACGGTAGAAAGAG -3' (2F)
XhoI
5'- GCCACTCGAGTCAATAGGCCATATATAAAAAATC -3'
(1R)
0.44 kb
Table 5.2.2.1 Primer sequence and amplimer sizes of CaM binding site pGEX-6p-
1 constructs. 
All forward primers contained the EcoRI restriction site whereas the reverse primers
contained the XhoI restriction site. The restriction sites are underlined in the primers.
The amplimers were double digested using these enzymes prior to ligation into pGEX-
6P-1 plasmid that had been digested similarly earlier. 
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Restriction  digests  were  conducted  on  plasmid  DNA  prepared  from  selected
transformed colonies grown after ligation.
Figure 5.2.2.1 Restriction digests of CaM binding site constructs in pGEX-6P-1.
2 colonies were selected from each potential construct and double digested.
Lane 1: pGEX 6P-1 (vector reference)
Lanes 2 + 3: Full, 460 bp
Lanes 4 + 5: Short, 300 bp
Lanes 6 + 7: N1, 330 bp
Lanes 8 + 9: C1, 440 bp 
Lane 10: negative control colony not containing insert
Bands of the expected size were observed for the tested colonies of the short, N1 and C1
constructs. No insert was observed for the full construct colonies. 
The presence of the short (CaMBD) and N1 inserts were later confirmed by sequencing.
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Expression trials  were conducted for the  short,  N1 and C1 constructs using Rosetta
(DE3) cells.   
Figure 5.2.2.2 Expression trial of CaM binding constructs in pGEX-6P-1 vector in
Rosetta (DE3). 
Lanes  are  headed with  appropriate  construct,  U indicates  uninduced sample  and I
induced sample.
There is a clear increase in an induced band of the expected size for the short and N1
constructs.  A much weaker  equivalent  band is  seen  for  C1 suggesting  much lower
expression of this construct. The GST tag is 26kDa, it is thought that the presence of the
large band at this size in all the induced lanes is GST.   
Expected size of constructs including tag from pGEX-6P-1 vector:
GST-short 38 kDa
GST-N1 39 kDa
GST-C1 47.9 kDa
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A western blot was conducted to analyse the expression from these samples. The blot
was  probed  using  an  anti-GST antibody as  this  would  confirm the  presence  of  the
tagged protein and possibly also the identity of the lower size band.
Figure 5.2.2.3 Western  blot  of  expression  trial  of  CaM  binding  site  constructs
probed with anti-GST antibody.
Bands of expected size are observed for all the constructs but as seen in the SDS-PAGE
there is very small amount of the C1 construct. Very heavy bands are observed at the
size expected of the GST tag for the N1 and C1 constructs, there is a much weaker band
at this size for the short construct. 
Based on the  comparison of  the SDS-PAGE and western  blot  there appeared  to  be
slightly more short (CaMBD) protein with much less GST present. As such the CaMBD
construct  appeared  to  be  a  better  selection  for  continuation  into  purification  and
downstream applications.  
 
5.2.2.2 Purification of CaMBD recombinant protein
Post  cell  lysis,  GST-CaMBD was first  affinity purified following the manufacturer's
recommended  protocol  buffer  system  for  the  glutathione  sepharose  4B  beads  (GE
healthcare). 
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Figure  5.2.2.4 Initial  affinity  purification  of  GST-CaMBD  following  bead
manufacturer protocol buffer system.
Expected size of GST-CaMBD, 38kDa.
Lane 1: Unbound material from beads
Lane 2: Binding buffer wash
Lanes 3a-e: 0.5 column volume elution fractions
Lane 4: Bead sample post elution step
Although some GST-CaMBD is eluted from the beads the vast majority remains on the
beads. However some of the GST tag contaminant material is removed by the elution
step. 
The manufacturer recommended protocol uses a 10mM reduced glutathione in TRIS at
pH 8 elution step, this glutathione concentration was found to be insufficient to elute the
GST-CaMBD. Through a series of trials, modifications were made to the recommended
protocol. This lead to the buffer system described in chapter 2. It was found that a 5mM
reduced glutathione wash step in phosphate buffer at pH 7 was sufficient to remove a
large quantity of the contaminant GST tag material without eluting the GST-CaMBD
protein.  A higher concentration of reduced glutathione could have been used in this
buffer without eluting the GST-CaMBD but this was found not to be necessary. The
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transfer to TRIS buffer at pH 8 was required to elute the GST-CaMBD, 20mM reduced
glutathione was found to be sufficient for this purpose.   
Figure 5.2.2.5 Affinity  purified  GST-CaMBD  following  buffer  system  listed  in
chapter 2.
Samples  from 2 preparations  of  GST-CaMBD using buffer  system described above.
Using this protocol high purity GST tagged CaMBD protein could be prepared. This
material could be stored at 4°C for 1 week prior to further usage. 
The pGEX-6P-1 vector contains a 3C protease site allowing for the cleavage of the GST
tag. 3C protease was found to have sufficient activity when used in combination with
the dialysis allowing a similar protocol to that used for the CaMLD constructs to be
adopted. The 2nd pass through glutathione sepharose beads was not as successful for
CaMBD as the equivalent step for the CaMLD constructs. It proved to be not possible
to practically remove a large amount of the cleaved GST tag which remained in the
CaMBD sample.  Similar  aggregation  problems  to  cleaved  CaMLD constructs  were
observed for cleaved CaMBD. As with CaMLD, cleaved CaMBD had a storage life of
<48 hrs.  
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5.2.3 Cloning and expression of CaM construct
A human CaM clone was obtained in the plasmid pAED4 (gift from Z. Grabarek). This
plasmid was transformed into Rosetta (DE3) cells and expression trials conducted. The
growth and early stages of purification were followed as described by Tan (Tan, 1996).
Although CaM protein was produced the reported levels could not be matched. Owing
to the successful use of the pETMM vectors with the CaMLD constructs, CaM was sub-
cloned into the pETMM60 vector. The 60-CaM plasmid was transformed into Rosetta
(DE3) and expression trials performed. 
Figure 5.2.3.1 Expression trial of 60-CaM.
60-CaM expected size 76kDa
Lane labelled U is uninduced pellet sample. Lanes P1-P8 are samples from induced cell
pellets, induced expression can be observed for all these lanes except P2. Pellets P1,
P3-P8 were stored for in preparation for purification. 
60-CaM was purified following the CaM specific protocols listed in chapter 2. 
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Figure 5.2.3.2 CaM protein  sample  post  TEV cleavage  and  2nd pass  through  Ni
beads.
The SDS-PAGE illustrates the purity to which CaM protein samples could be prepared.
This material could be stored at 4°C for 1 week prior to further usage. 
5.3 Crystallography Trials
Crystallisation trials of were conducted for CaMBD. The protein used in this trial was
concentrated  to  8mg/ml  after  a  gel  filtration  purification  step  following  affinity
purification.  Owing  to  the  small  amount  of  protein  that  could  be  produced  in  this
concentration range only 4 crystallisation screens could be trialled. 
200 nl protein with 200 nl screen condition sitting drops were set up in 96 well Intelli-
Plate (Art Robbins) using an Art Robbins Phoenix crystallisation robot (Alpha Biotech
UK). The PACT (pH, anion and cation crystal trial testing pH within PEG/ion), JCSG
(PEG and salt conditions devised for Joint Centre for Structural Genomics), and CSS
(clear strategy screen) I and II screens (all Molecular Dimensions) were used. Plates
were observed on a  regular  basis  for  the formation of aggregates and any potential
crystals.  
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Figure 5.3.1 Selection of trialled screen conditions from CaMBD crystallisation
trial.
A few conditions in both screens tested had silt like residues develop in the plate wells. 
The presence of silt like residues may be a result of protein and/or salt aggregation. As
the screens tested are sparse matrix screens so a wide range of possible conditions are
tested within one screen. As such wells with silt like residues are considered for further
trials using finer screening conditions based around the original condition. No obvious
crystal formation was observed in the screens trialled.  
5.4 Discussion
As discussed in the introduction to this chapter the aim of this section of the project was
generate the protein tools required to examine the binding between the CaMLD and
CaMBD regions of RyR2, and also the involvement of CaM within this interaction.
Previous  constructs  of  the  regions  of  the  RyR domains  have  been described in  the
literature. This project designed constructs in the equivalent areas of RyR2 based around
the reported regions in RyR1. 
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In the case of the CaMLD region the identification of a CaM like domain (Xiong, 2006)
was used to locate an equivalent region in RyR2. This strategy has subsequently been
reported  in  the  literature  where  an  equivalent  region  in  RyR2  (4020-4166)  was
described (Gangopadhyay, 2011). The equivalent construct designed in this project had
amino acid coordinates 3961-4163. While having a similar C terminal, more residues
are included at the N terminal as exon boundaries were considered beyond a straight
match to the RyR1 reported region. The selected CaMLD construct of this project also
included  the  RIH associated  domain  which  has  been  suggested  may play a  role  in
domain interaction in RyR (Ponting 2000).  
pET15bmod  was  selected  as  an  initial  expression  vector  for  the  CaMLD  based
constructs as only an N terminal 6His tag with a short linker was expressed with the
recombinant protein. This strategy was adopted with a view towards crystallography
work so that as little as possible extra amino acids were included with the protein of
interest  while  still  allowing  for  an  affinity  purification  step.  In  addition  short  (<5
residue) linker regions between co-expressed tags have been identified as increasing the
likelihood of crystal formation as the potential movement of the tag is assumed to be
limited relative to the protein of interest so reducing disorder within the forming crystal
structure (Smyth et al. 2003). Unfortunately there were major solubility issues with the
expressed protein using this  vector. The addition of detergent to the lysis  buffer did
increase  the amount  of  soluble  protein  this  approach was not  followed for  2  major
reasons. Firstly,  as detergent would need to be present in all  downstream buffers to
maintain  solubility  this  would  almost  certainly hinder  downstream experiments  and
would  also  severely limit  the  number  of  crystallisation  screens  that  could  be  used.
Secondly, while the loss of protein is expected with every additional handling step when
working with the sample, the yield obtained by the time the protein was sufficiently
pure was so low that it would have been impractical to continue with this approach. 
Based on the solubility issues observed with the CaMLD constructs it was decided that
co-expressing a solubility tag may offer  a better  solution than additives to  the lysis
buffer. The pETMM series of vectors offered a dual tag system consisting of a range of
proven solubility tags with a 6His tag for affinity purification which could be removed
using the included protease site located between the dual tag and the insert. This series
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of vectors also shared the same MCS allowing a range of solubility tags to be trialled
using the same cloning strategy (Dümmler et al. 2005). As it was unknown if any of
the solubility tags would be beneficial; only 2 constructs were used to increase the speed
of the trials. As discussed in the chapter introduction these constructs were CIR and
CaMLD as it was felt that these offered most further experimental options. The CaMLD
construct when joined with the NusA tag proved to be the most successful combination
tested. With optimisation to the purification protocol it proved possible to produced high
purity  CaMLD protein  though  obviously  serious  stability  issues  remained  once  the
NusA tag had been removed. From the observations in this chapter it appears this region
of RyR2 is unstable. This instability may well be increased further when trying to make
larger pieces of the I domain beyond the strictly identified CaM like domain of RyR1.
Even production of this piece resulted in expression predominantly in inclusion bodies
and had to utilise a refolding step (Liangwen Xiong et al. 2006). Through conversations
with colleagues working on the I domain section 3722-4353 (George et al. 2004a) this
region was found to be  particularly unstable  and difficult  to  produce  even in  small
quantities. As such this CaMLD construct may be one of the first soluble expressed
proteins in this region produced above small scale quantities.  
Although the CaM binding domain of RyR2 has been identified (Naohiro Yamaguchi et
al. 2003) it was decided to attempt incorporate sections of the N and C terminal flanking
regions associated with CaM concentration response in the different isoforms of RyR.
These regions were described in relation to CaMBD in RyR1 (Yamaguchi et al. 2004),
and it was from these coordinates that an equivalent region was identified in RyR2. The
inclusion of the N and C terminal flanking regions would allow potential testing of CaM
and Ca2+ concentration responses. However the primary aim of the CaM binding domain
constructs was to produce stable protein that contained the α helical tube structure as
identified in PDB entries such as 2bcx that would allow for CaM and, presumably,
CaMLD binding to this region. 
Based on assessment of the SDS-PAGE (figure 5.2.2.2) and accompanying western blot
(figure 5.2.2.3) the short (CaMBD) and N1 constructs both appeared to be expressed at
similar levels. However the CaMBD construct had a much weaker signal at the band
size  linked  to  GST indicating  a  much  lower  concentration  of  GST in  this  sample
compared to the N1 construct. As observed in both images the C1 construct is present at
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low levels so was rejected for further use. Owing to the large amount of GST material
seen for the N1 and C1 constructs it is considered that these constructs may be less
stable than the CaMBD construct. If these constructs were less stable and degrading
during expression then large amounts of GST compared to the construct protein would
be  observed.  The  CaMBD  construct  was  selected  owing  to  this  apparent  greater
stability. It would appear that trying to express the CaM binding site with either flanking
region attached reduces the stability of the produced protein. It is difficult to compare
against  the literature as whole RyR was expressed in  HEK cells  in the papers used
during construct design (Naohiro Yamaguchi et al. 2003), (Yamaguchi et al. 2004). Most
other  experiments  involving  the  CaM  binding  domain  reported  in  the  literature
commonly use a synthesised peptide of shorter length than the CaMBD construct. 
CaM is a well characterised protein and can be easily commercially obtained. For the
potential  scale  of  protein  required  by  this  project  it  was  decided  to  recombinantly
produce  the  protein.  Following the  accompanying protocol  supplied  with  the  donor
plasmid  as  described  by  Tan  (Tan  et  al.  1996) could  not  be  repeated  to  generate
sufficient CaM. As optimisation conditions for use of the pETMM60 vector had already
been  established  so  this  allowed  for  larger  scale  production  of  CaM.  The  tag  was
successfully removed from the fusion protein and high purity samples generated. This
approach allowed production of relatively pure CaM protein above the levels required
for the project. 
Crystallography  trials  were  conducted  for  GST-CaMBD  however  they  provided
inconclusive results. The presence of silt like residues in some of the wells indicated
that  some  conditions  may  be  worth  pursuing  in  further  trials.  As  expected  with
crystallography based work a much greater number of trials involving a larger range of
crystallisation  screens  is  required  for  progression  in  this  area.  A significantly  large
amount of protein would have been required to enable these trials to be conducted. This
would represent a major investment in time and resources with the possibility of little
advancement  of  the  project.  These  concerns  would  be  amplified  when  considering
CaMLD owing to the greater instability of the cleaved purified protein that would be
required. While there are examples citing successful crystallography projects in which
crystals have been grown with a solubility tag still attached to the protein, these are rare
and usually involve a short linker between the tag and expressed protein (Smyth et al.
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2003).  Also  these  examples  cite  use  of  MBP,   Trx  and GST tags,  use  of  NusA is
commonly limited to that of purely a solubility tag which is removed as part of the
purification process. This approach was adopted in the trial with CaMBD, it was hoped
that  the presence  of  the  GST tag  would  not  prove detrimental  to  the  crystallisation
process while being beneficial in aiding protein stability and allowing a purer sample to
be used. Although a sufficiently pure sample of CaMLD with the NusA tag removed can
be produced there  were  serious  concerns  about  the  stability of  the  cleaved protein.
While not trialled the initial expectation was that the CaMLD protein would rapidly
aggregate out of solution prior to sufficient time for crystal formation.
Further time could have been spent within this project with the aim to produce more
stable and higher quality protein. However, as discussed, for a number of reasons this
would be very difficult and may not be practically achievable. A compromise between
optimised protein quality and sample suitability for further work had to be reached to
allow the project to continue. As the aim of this section of the project was to generate
protein to investigate domain interaction it was felt that this point had been reached with
the work described in this chapter.      
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Chapter 6:
Functional Studies of the Calmodulin
Like Domain of Human RyR2
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6.1 Introduction 
The primary aim of  this  chapter  was to  examine the interaction  between the  RyR2
domains of CaMBD and CaMLD. As previously discussed there are examples of this
interaction in the literature and the PDB contains structures of CaM bound to CaMBD.
This project aims to further understand the interaction between CaMLD, CaMBD and
CaM, and gain insight into any potential mechanism leading between the transition of
binding of CaM and CaMLD to CaMBD. The role of calcium within this interaction
mechanism is believed to play a key role and, as such, is a studied factor. In addition,
selected known CPVT mutations within CaMLD have been studied to see if further
knowledge can be gained at  a molecular level towards why these mutations lead to
arrhythmia.  
Two main types of analytical technique were employed to conduct this investigation.
Firstly the interaction between the domains was examined using pull down assays. This
technique has been successfully used by colleagues investigating other potential binding
and interaction  sites  within  RyR  (Zissimopoulos  et  al.  2006),  (Zissimopoulos  et  al.
2012b). This established technique offered a means of testing the interaction between
the recombinant protein constructs of RyR2 used in this project.  
The second technique employed was circular dichroism (CD). Initially this technique
was  approached  to  see  if  folded  recombinant  protein  had  been  produced.  Further
examination  in  the  far  UV  region  (170-260nm)  would  allow  assessment  of  the
secondary structure of the produced protein. If sufficient data was collected then the
specific percentage components of secondary structure could be assigned (Kelly et al.
2005),  (Greenfield  2006).  A repeat  of  the  change  observed  in  secondary  structure
composition by the addition of Ca2+ to wt CaMLD (Liangwen Xiong et al. 2006) could
be conducted and extended to examination of the CPVT mutant forms of CaMLD.
The rearrangement of secondary structure elements within CaMLD would expected to
be  accompanied  by  a  conformational  change  within  the  protein  which  may  not
necessarily  observed  in  the  far  UV  region.  The  near  UV  region  (250-350nm)  is
commonly  used  to  look  at  changes  in  3ry structure  through  comparison of  spectra
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recorded under different conditions. This allows analysis of the impact of variations in
reagent  concentration  and  the  presence  of  binding  partners  by  examination  of
divergence in the obtained spectra. The spectra are generated from a combination of the
signals given by the aromatic amino acid content of the studied protein. Tryptophan is
the main contributor to the signal with a peak close to 290nm. Tyrosine residues provide
a smaller addition peaking between 275-282nm. Phenylalanine has a weak contribution
between 250-270nm. Disulfide bonds may give very weak contributions throughout the
entire wavelength range. The differences observed in spectra under varying conditions
result from the changing of conditions in the local environment of the aromatic residues
altering  the  strength  of  signal  given  by  the  affected  amino  acid.  This  means  that
alterations  in 3ry structure which do not affect  aromatic  residues  are  unlikely to be
observed in the near UV. The signal strength in the near UV region is weaker than the
far  UV requiring  more  concentrated  protein  samples  to  compensate  for  the  drop in
signal. However the near UV can be more sensitive for detecting subtle differences in
conformation that would not always be seen by far UV (Kelly et al. 2005). 
As stated the aromatic acid composition of the studied protein plays a key role in the
spectra  obtained  in  the  near  UV  region.  Trytophan  and  tyrosine  are  the  main
contributors to the signal though the absence of tryptophan residues usually indicates
that  a  very  weak  signal  will  be  obtained  from a  protein.  As  such  the  amino  acid
composition  of  the  studied  proteins  by  number  of  residues  and  overall  percentage
component has to be considered. 
CaMLD:
Trp (W)  3 0.9%
Tyr (Y) 11 3.3% 
CaMBD:
Trp (W) 2 2.0%
Tyr (Y) 4 3.9%
CaM:
Trp (W) 0 0%
Tyr (Y) 2 1.3%
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Based on the analysis of amino acid content, both CaMLD and CaMBD are potential
good candidates for examination using near UV however CaM may provide a weak
signal.   
6.2 Results
6.2.1 Chemical denaturation
Chemical denaturation studies were conducted on wt and mutant CaMLD protein that
had been affinity purified, and the NusA tag cleaved and removed. The unfolding state
of protein was monitored by fluorescence spectroscopy while the sample was denatured
by addition of guanidine hydrochloride (GndHCl). 
Figure 6.2.1.1 Weighted average emission wavelength versus the concentration of
guanidine hydrochloride (GndHCl), plots for wt and mutant CaMLD proteins.
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ΔGN-I
(cal/mol)
[GndHCl]
50%
ΔGI-D
(cal/mol)
[GndHCl]
50%
ΔGN-D
(cal/mol)
WT -2214 1.21 -7207 3.46 3 state
HQ -2416 2.07 -13511 3.63 3 state
NK -2597 1.38 -12200 3.05 3 state
GS -3695 1.80 -11960 2.99 3 state
EK -2874 2 state
Table 6.2.1.1 Free  energy  (ΔG)  of  unfolding  states  of  wt  and  mutant  CaMLD
proteins.
The information from the denaturation was analysed and a 2 or 3 state denaturation
process  accordingly  fitted  to  the  data.  The  shape  of  the  plots  (figure  6.2.1.1)  is
indicative  of  this  2  or  3  state  denaturation  process.  The  ΔG (calories/mole)  values
required for the transfer from native (N) to intermediate (I) and denatured (D) states are
shown  in  the  above  table.  The  three  mutations,  G3946S,  N4104K  and  H4108Q,
increased the wt stability with respect to an intermediate state. On the other hand the
E4076K mutation severely affected the stability profile of the CaMLD construct and
decreased its stability with respect to the fully unfolded state. 
6.2.2 Pull Down Assays
The majority of protein used in  the pull  down assays  was affinity purified samples
which had the tags attached. Limited trials with cleaved tag material using SDS-PAGE
for detection were conducted. It was found that smaller amounts of protein could be
used with better detection rates when using the more sensitive western blot technique
for detection of potential interaction. For the western blots to work, with the exception
of CaM, it was only possible to probe against the co-expressed tags of the CaMLD and
CaMBD constructs. Using the tagged protein reduced some of the issues surrounding
the stability of the protein samples though the western blot technique was sensitive
enough to detect degradation in some of the samples. Pull down assays were performed
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following the protocol described in chapter 2.  
6.2.2.1 CaM agarose bead pull down assay
The first  set of pull  down assays performed examined in there as was any potential
interaction between CaM and CaMLD, and, if so, did the CPVT mutations affect this
interaction. For the purposes of this experiment CaM agarose beads were used.  
 
Figure 6.2.2.1 Western blots of CaM agarose bead pull  down assay with wt and
mutant CaMLD.
Western blot probed with anti-NusA antibody.  
Control sample present in left lane to show detection of sample. Without (middle) and
with (right) Ca2+ pull down assay samples. 
wt RyR2 CaMLD construct and its mutants except E4076K displayed CaM binding in
Ca2+ dependent manner. NusA fusion tag, which served as a negative control for this
experiment, did not display CaM binding.
The binding of the CaMBD construct with CaM agarose beads was also tested, weak
Ca2+ independent interaction was observed. Within this experiment the binding of wt
CaMLD was also re-tested, CaMLD displayed the same interaction profile as seen in the
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above figure showing stronger interaction than CaMBD.
6.2.2.2 Pull down assays using CaMLD, CaMBD & CaM constructs
As recombinant protein could be produced for the potential interactions to be tested so
the CaM agarose beads were no further used. This decision was also because bovine
CaM  was  used  for  the  beads  whereas  all  human  versions  of  RyR2  had  been
recombinantly made  allowing  for  the  examination  of  human-human versions  of  the
proteins. 
Initially the recombinant purified CaM protein was tested for any potential unwanted
interactions with either set of the affinity beads that could be used to immobilise the bait
protein. 
Figure 6.2.2.2 Western blot of check of CaM interaction with affinity beads.
Membrane probed with anti-CaM antibody. Left hand contains detection control sample
of CaM protein. CaM protein incubated with listed affinity bead in assay conditions
containing shown concentration (μM) of calcium.   
 
As the CaM protein did not display any interaction with either set of potential affinity
beads the decision to use tagged protein material in the assays initially appeared to offer
a range options regarding towards bait and capture protein variations. However control
condition  testing  revealed  a  number  of  unwanted  interactions  between  the  affinity
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media, used to immobilise the bait protein, and potential capture sample. 
Figure 6.2.2.3 Western  blot  of  GST tag  incubated  with  Ni  affinity  beads  under
increasing Ca2+ concentrations. 
Membrane probed with anti-GST. Left hand lanes contains detection control sample of
GST tag. Signal detected for presence of GST across Ca2+ range.
The apparent binding of the GST tag to Ni affinity beads meant that Ni beads could not
be  used  to  immobilise  CaMLD  protein  to  test  binding  with  CaMBD.  Glutathione
sepharose beads were then tested with CaMLD, this was with the aim of immobilising
CaMBD protein. 
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Figure 6.2.2.4 Western  blot  of  CaMLD  incubated  with  glutathione  sepharose
affinity beads under increasing Ca2+ concentrations. 
Identity of bands based on comparison with size markers on companion gel stained with
Coomassie R250. 
As CaMLD appeared to bind with glutathione sepharose affinity beads this  severely
limited the range of experiments that could be conducted using the pull down assay
technique. To bypass the issues related the affinity beads cross linking experiments were
run.  The  interaction  reaction  was  run  in  the  presence  of  a  cross  linking  agent,
glutaraldehyde.  The cross  linking  reaction  was  stopped prior  to  introducing  affinity
beads  to  pull  down one of  the  reaction  components.  The  detection  of  cross  linked
products was conducted by western blot analysis as previously.  
As the interaction of the CaM binding site with CaM has been reported in the literature
so the binding of CaMBD with CaM was selected to test the cross linking technique.
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Figure 6.2.2.5 Western blot of cross linking trial of CaMBD with CaM.
Membrane probed with anti-CaM antibody. GST-CaMBD incubated with CaM reaction
sample in right hand lane. GST and BD included as negative control samples in their
respective lanes. GST tag incubated with CaM as further negative control. 
Expected sizes of proteins:
GST 26kDa
BD 40kDa
CaM 17kDa
BD + CaM 57kDa 
Bands were expected for CaM (17kDa) in the GST tag with CaM lane, and BD + CaM
(57kDa)  and  possibly  also  CaM  in  the  CaMBD  with  CaM  lane.  As  the  expected
unbound CaM signal from the GST tag incubated with CaM reaction was not detected
so the reaction mixtures were repeated and timed samples collected. 
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Figure 6.2.2.6 Western blot of repeat cross linking of CaMBD with CaM.
Membrane  probed  with  anti-CaM  antibody.  GST  tag  with  CaM  incubation  run  as
negative control to GST-CaMBD with CaM test condition. Timed samples were taken
from both incubation reaction mixtures.
An increasing strength CaM signal is detected for the GST tag with CaM reaction. A
similar signal is observed for the CaMBD with CaM incubation but only for the first 2
samples taken.  
Repeats  of  the  cross  linking  experiments  were  conducted  with  further  inconclusive
results. 
6.2.3 Circular Dichroism
Some early CD data was collected using cleaved tagged material that had been further
purified  by  gel  filtration  however  the  majority  of  data  was  collected  using  tagged
protein. All samples collected in the far UV range underwent dialysis into CD suitable
buffer prior to data collection. Most samples required concentration so that sufficient
detectable  signal  was  generated  from  the  sample.  As  a  precautionary  measure  all
samples were briefly centrifuged prior to data collection to remove any aggregates from
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solution. While samples were monitored during data collection owing to the time taken
to  collect  the  spectra  there  was  degradation  of  samples  during  this  process  which
adversely affected the quality of the recorded spectra. Baseline data was recorded for
the  buffer  used  for  each  data  set  which  was  subsequently  subtracted  from protein
spectra during analysis. It should be noted that data was collected on 2 CD instruments.
Data sets collected on the monochromator system on beamline 23 could be processed in
the  accompanying  Globalworks  software  (OLIS)  which  allowed  for  more  complex
manipulation  of  the  raw  data  during  analysis.  Data  collected  on  the  Chirascan
spectrometer (Applied Photophysics) had to processed in spreadsheet software owing to
the data output format. 
 
Figure 6.2.3.1 Comparison of UV absorbance of purification buffer against buffer
system designed for CD data collection.
Black trace for H2O. Blue trace for buffer system used for latter stage of purification.
Red  trace  for  CD  buffer  system.  CD  buffer  has  much  lower  absorbance  than
purification buffer below 210nm, this difference is greatly amplified as the wavelength
shortens.  However  CD  buffer  still  has  noticeably  higher  absorbance  than  H2O
reference. 
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6.2.3.1 Far UV region (170-260nm)
Some data in this region was obtained for early batches of CaMLD construct protein.
The data were of poor quality and it was not possible to collect lower wavelength data
however  the  protein  signal  appeared  to  be  influenced  by more  than  one  secondary
structure element. The further work conducted on CD buffer and protein sample quality
optimisation  allowed  use  of  this  technique  for  further  investigation  of  the  RyR2
domains.  Despite  these  optimisation  steps,  although  the  spectrometer  systems  were
capable of collecting data within the specified range, it was not possible to record viable
data in the shorter wavelengths owing to protein sample and buffer constraints.
The spectra  of  cleaved  protein  samples,  so  there  was  no  tag  influence  on  the  data
collected, were recorded for CaMBD, and wt and EK CaMLD.  
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Figure 6.2.3.2 Far UV range data collected for CaMLD (top), E4076K (middle) and
CaMBD (lower).
secondary structure fit analysis fitted with CDSSTR algorithm using the SP43 reference
set.
Red spectrum are averaged experimental data with buffer baseline subtracted.
Turquoise spectrum are fitted data for secondary structure prediction showing deviation
required for fit against experimental data. 
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CaMLD E4076K CaMBD
Predicted Experimental Predicted Experimental Predicted Experimental
α helix 42.9% 52% 42.3% 46% 56.9% 45%
β sheet 19.5% 22% 19.5% 18% 12.8% 18%
other 37.6% 26% 38.2% 36% 30.3% 37%
Table 6.2.3.1 Predicted  and  experimentally  derived  secondary  structure  for
CaMLD, E4076K and CaMBD
Experimentally  derived  secondary  structure  obtained  from fit  analysis  generated  in
above figure.
Other  category  in  table  includes  turns  and  random  coils,  category  outputs  differ
between predictive software and CD spectral analysis software. 
Although there is a difference between the experimental spectra and the fitted data this
is  mainly in  the  signal  strength  (given in  millidegrees).  The key component  of  the
spectra, the shape of the curve which is defined by the secondary structure elements of
the sample,  is  closely mirrored in  the fitted structure.  The E4076K CaMLD mutant
protein  has  a  close  match  between  the  predicted  secondary  structure  and  the
experimentally derived values. CaMBD and wt CaMLD show variance between these
two sets of values.    
As  the  chamber  holding  the  sample  in  the  monochromator  could  be  temperature
regulated  so  it  was  possible  to  conduct  thermal  denaturation  studies  of  the  protein
samples. The temperature at which the protein lost its secondary structure characteristics
was considered to be the point at which the sample had denatured. Samples were heated
to 90°C in 5°C increments from 10°C and returned to 20°C to observe if they was a
return to a folded state with cooling. Tag cleaved CaMBD was initially tested.
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Figure 6.2.3.3 Thermal denaturation spectra series for CaMBD.
Spectra from 10°C to 55°C shown. Change in spectra observed for 45°C (light pink),
50°C (dark pink) and 55°C (light green). These spectra are 3 weakest (highest points)
at 210nm and noticeably dip down much earlier at 200nm.
The change in the shape of the spectra for CaMBD between 45°C and 55°C indicates a
decrease in secondary structure content as the spectra becomes flatter when compared to
lower temperature spectra.  For the purposes of comparison the thermal  denaturation
series for CaMBD that had been incubated with E4076K CaMLD was recorded.   
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Figure 6.2.3.4 Thermal denaturation  spectra for CaMBD incubated with E4076K
CaMLD. 
Spectra from 10°C to 55°C shown. Change in spectra observed for 45°C (light pink),
50°C (dark pink) and 55°C (light green). These spectra are 3 weakest (highest points)
at 210nm and noticeably dip down much earlier at 200nm. 
Observed  spectra  are  very  similar  to  just  CaMBD  thermal  denaturation  spectra,
temperature at which spectra change shape are matching.
Ca2+ induced spectral change, predominantly a change in α helix content, was reported
for wt CaMLD in the literature. This experiment was repeated with the recombinant
proteins produced for this project including CaMBD and two of the mutant forms of
CaMLD. 1mM Ca2+ was added in the relevant samples as per the original  trial  and
dilution factors were taken into account for the spectra recorded without added Ca2+. For
all figures shown below red spectrum is averaged data for protein sample and turquoise
spectrum is averaged data for Ca2+ added sample. Variance in spectra below 200nm is
likely to be attributed to protein sample quality. 
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  Figure 6.2.3.5 Spectra of wt CaMLD and wt CaMLD with calcium.
Figure 6.2.3.6  Spectra of E4076K and E4076K with calcium.
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Figure 6.2.3.7 Spectra of N4104K and N4104K with Ca2+.
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Figure 6.2.3.8 Spectra of CaMBD and CaMBD with calcium.
For the above spectra the wavelength region 208-220 associated with α helix is being
examined. For most of the samples there are appears to be very little variation in the
shape of the spectra in this region with or without added calcium. 
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6.2.3.2 Near UV region (250-350nm)
Initially spectra of individual proteins recorded in the near UV region to allow for later
comparison.
Figure 6.2.3.9 Near UV region spectra of CaMBD. 
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Figure  6.2.3.10  Near  UV region  spectra  of  wt  CaMLD  and  wt  CaMLD  with
calcium.
Red spectrum is averaged data for wt CaMLD.
Turquoise spectrum is averaged data for wt CaMLD Ca2+ (1mM) added sample.
 
Change in spectral shape observed in 260-270nm range between wt CaMLD with or
without 1mM Ca2+ samples.  The sample with Ca2+ present shows dip in this  region
compared  to  sample  without  Ca2+ added.  Less  clear  spectra  were  recorded  for  the
CaMLD mutants N4104K and E4076K, any potential dip is lost in signal noise.  
 
Owing to the clear difference between the spectra for CaMBD and the CaMLD proteins
it was decided to monitor the interaction between the 2 domains in the near UV region.
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Figure 6.2.3.11 Near UV range spectra of wt CaMLD incubated with CaMBD with
and without presence of calcium.
Red spectrum is averaged data for wt CaMLD and CaMBD incubated without Ca2+.
Turquoise  spectrum  is  averaged  data  for  wt  CaMLD  and  CaMBD  incubated  with
200μM Ca2+.
Mixture of wt CaMLD with CaMBD has spectrum resembling that of just CaMLD.
Presence of Ca2+ in this incubation triggers change to spectrum observed for CaMBD.
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Figure 6.2.3.12 Near UV range spectra of E4076K CaMLD incubated with CaMBD
with and without presence of calcium.
Red spectrum is averaged data for E4076K CaMLD and CaMBD incubated without
Ca2+.
Turquoise spectrum is averaged data for E4076K CaMLD and CaMBD incubated with
200μM Ca2+.
Difference between spectra is not as pronounced as for wt CaMLD however change to
more CaMBD like spectra, with addition of Ca2+, is observed.
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Figure  6.2.3.13 Near  UV  range  spectra  of  N4108K  CaMLD  incubated  with
CaMBD with and without presence of calcium.
Non-averaged data is  shown for  NK mutant.  A few of the spectra recorded for the
incubation  containing  Ca2+ show the  spectral  shape more  associated  with  CaMBD
however when the data is averaged the influence of these spectra is minimal.  
 The role of Ca2+ concentration was further explored with relation to the interaction of
CaMLD and CaMBD. It should be noted that at this point that the system used to collect
the CD data was changed, this system allowed data to be collected over a wider range of
wavelengths  however  had reduced signal  sensitivity  as  a  result.  A repeat  of  the  wt
CaMLD with CaMBD incubation was conducted with new protein material as a check
of recordable data.
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Figure 6.2.3.14 Repeat of near UV range spectra of wt CaMLD incubated with
CaMBD with and without presence of calcium. 
Blue trace is wt CaMLD with CaMBD. 
Red trace is a repeat of the same incubation but with 200μM Ca2+ added.
Although the spectra are slightly different in appearance to the previously recorded data,
similar  characteristics of  spectral  shape change can be observed.  The distinctive 2nd
peak, though shifted in wavelength, associated with the CaMBD spectrum is observed
when Ca2+ is added to the incubation.   
A range of Ca2+ concentrations were tested to investigate the required concentration to
trigger the swap between spectral shapes observed in the above figure.
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Figure 6.2.3.15 Spectra of CaMLD with CaMBD incubated with range of calcium
concentrations.  
Ca2+ concentrations (μM) shown in key in lower right corner. 
Ca2+ concentration increase was achieved by serial addition of stock Ca2+  solution to
same sample.
There is no clear shift in spectra shape as observed with the incubation with a single
Ca2+ concentration. There is a slight shift down in the spectra in the 250-270nm range. A
dilution effect would be expected to shift the spectra up towards the x axis, with the
suggestion of a 2nd peak for the 200μM Ca2+ trace. A smaller partial shift may have
occurred for the 100μM Ca2+ trace but this is not clear. 
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Repeats  of  this  experiment  were  conducted  using  individual  samples  for  each  Ca2+
concentration tested so that no dilution effects were involved. As previously the swap
between spectral types was observed for 200μM, and higher, Ca2+ concentrations. The
presence of 100μM Ca2+ did not produce a conclusive result, in different experiments a
range of  spectral  shapes  between  those  associated  with  CaMLD and  CaMBD were
observed. Ca2+ concentrations below 100μM did not result in a spectral shape change,
the trace remained the same as a CaMLD sample. 
These experiments were conducted using the CaMLD mutants E4076K and N4108K
and as previously it was difficult to obtain consistent results. As seen in earlier data
200μM Ca2+ seemed to start a trigger towards a change in spectra shape. However use of
higher Ca2+ concentrations did not consistently result in the level of difference seen for
wt CaMLD.  
As these experiments were conducted using tagged protein, the tags were separately
tested against the presence and absence of Ca2+, and in control trials in which one of the
RyR2 proteins was replaced with just its associated tag. In all these cases the tags were
not observed to influence the recorded spectrum in any significant manner.  
The interaction of CaM with CaMBD was also tested.
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Figure  6.2.3.16 Near  UV  region  spectra  of  CaM  incubated  with  CaMBD  in
presence and absence of calcium. 
Blue trace is CaM with CaMBD. 
Red trace is a repeat of the same incubation but with 200μM Ca2+ added.
No change in spectral shape observed between the two conditions. 
For this experiment spectrum without Ca2+ was recorded. Ca2+ was then added to this
sample and allowed to incubate before recording with Ca2+ spectrum. Addition of Ca2+
solution  to  sample  will  have  diluted  protein  concentration  which  is  reflected  in
reduction in protein signal seen as shift of spectrum closer to x axis. 
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6.3 Discussion
The aim of  this  chapter  was to  examine the binding of  the studied RyR2 domains,
further the understanding of the involvement of CaM within this interaction and also
how Ca2+ concentrations affected the binding in these instances. In addition, this chapter
also shows how the selected CPVT mutations in CaMLD would disrupt these processes.
Initially chemical denaturation was used to examine the structural stability differences
between wt and mutant CaMLD. As the proteins were denatured the ΔG values are
negative  though with differences  between the  wt  and mutant  forms.  This  technique
revealed that, apart from the E4076K mutation, the mutant forms of CaMLD had similar
structural integrity to the wt with all of them having an intermediate, partially unfolded,
state between folded and fully denatured states. The three mutations, G3946S, N4104K
and H4108Q, increased the wt stability with respect to an intermediate state, though this
may not increase the overall stability of the protein. The lower ΔG values seen for the
mutants for the transfer from the intermediate to unfolded state, compared to the wt,
means that less energy would be released from this transfer so implying greater stability
in  the  intermediate  state  than  the  wt.  The  E4076K  mutant  does  not  share  the
intermediate  state  rather  going directly to  an unfolded state.  This  mutation severely
affects  the  stability  profile  of  the  CaMLD region.  Interestingly,  the  absence  of  the
intermediate state indicates that the E4076K mutant is less likely to destabilise than the
wt and other mutants, though under conditions favouring denaturation the EK mutant is
expected to be much less stable.   
The pull down assays initially offered an established method of analysing the interaction
between the RyR domains and CaM. The use of western blots for detection over just
SDS-PAGE provided greater sensitivity within the technique though this caused some
issues  with  clarity  of  data  as  protein  degradation  products  were  also  seen.  The
unspecific interactions with the affinity beads limited the potential range of experiments
that could be conducted. Attempts to saturate the beads binding sites were unsuccessful
and doubts remained about the validity of the results produced. Despite these issues,
data of interest was generated using this technique.
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The  use  of  CaM  agarose  beads  with  the  CaMLD  constructs  appeared  to  show
predominantly Ca2+ dependent interaction between CaMLD and CaM. This interaction
is not reported in the literature with only CaMBD binding to either CaM or CaMLD. To
initially explain this potential interaction it was proposed that there may be some partial
interaction between CaM and CaMLD during the transfer on binding with CaMBD.
Based on CaM binding mechanisms described in the literature and the absence of a
probable CaM binding site  in the structure of CaMLD this is  unlikely.  Experiments
conducted under  the same conditions  showed weaker  binding between CaMBD and
CaM than were observed for CaMLD with CaM. It is more probable that there was a
flaw with this pull down assay than a genuine interaction between CaM and CaMLD.
Subsequent repeats using the recombinantly produced human CaM that did not display
any interaction between CaM and CaMLD reinforce this idea.    
The use of cross linking reagents addressed some of the above problems described for
the pull down assays. Based on cross linking operating on that any genuine interacting
proteins would be close enough for long enough to cross link whereas random contact
between non-interacting protein in solution would not produce significant detectable
amounts of x-linked product. The resultant cross linked product would also be of greater
mass so removing it  from the regions  of the blot  affected by degradation products.
Glutaraldehyde, a bi-functional cross linking reagent that reacts with lysine residues on
the exterior of proteins, was used for these experiments. The use of glutaraldehyde can
results in the formation of large aggregates. This may explain the large size band seen
for  the  CaM  with  CaMBD  incubation  (figure  6.2.2.5)  but  not  the  absence  of  the
expected CaM signal for GST with CaM incubation. There were also unexplained CaM
signals produced from the timed sample incubations (figure 6.2.2.6). A constant strength
signal  was  expected  for  the  unbound  CaM in  the  incubation  with  the  GST tag  as
opposed to an increasing signal with time. For the CaM with CaMBD incubation an
increase  in  CaM-CaMBD product  signal  was  expected  with  a  decrease  in  unbound
CaM. It is possible that some of the issues with cross linking could have been resolved.
The use of other cross linking reagents was being trialled as the initial data from CD
experiments  was  obtained.  As  CD  appeared  to  have  greater  potential  for
experimentation, the pull-down assays were not pursued.   
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For work in the far UV region the buffer composition used played a major factor. Owing
to the stability issues found with the RyR2 domain proteins so limitations were placed
on buffer components that could be used. The CD buffer  system used in this project
served as a direct replacement for purification buffer in an attempt to maintain protein
stability while  removing as  many of the far  UV absorbing components  as possible.
Chloride  has  a  strong  absorbance  below  200nm  so  was  replaced  with  fluoride.
Imidazole has a strong absorbance around 210nm which made thorough dialysis and/or
the  use  of  gel  filtration  extremely  important  in  sample  preparation.  Obviously  this
approach did not produce an ideal CD buffer, data collection was limited to >190nm
(figure 6.2.3.1) even when there was a high protein concentration giving good signal
strength. However as the main data wanted from the CD experiments was for the α helix
regions (>190nm, mainly 200-220nm) then this was viable solution.   
Initially  CD  in  the  far  UV  region  was  used  as  a  tool  to  assess  folding  of  the
recombinantly produced proteins. As can be seen in figure 6.2.3.2, spectra for folded
protein  was  obtained  for  all  the  tested  samples.  The  accompanying  table  reveals
potential differences in the structure between wt and E4076K CaMLD. The secondary
structure predictions show wt CaMLD and EK as very similar in expected structure
however  this  not  observed in the experimentally derived values.  The EK values  are
close to the predicted but wt has higher α helical content with a matching reduction in
other components, β sheet content is similar to predicted. It is possible that wt CaMLD
has more defined secondary structure than under predicted conditions. The presence of
the EK mutation may disrupt this structure so resulting in more random coil (included in
other) in the structure.  The experimental values for CaMBD show less α helix than
predicted, and increased β sheet and other content. It is not clear why this occurs. It is
possible, that as with wt LD, experimental conditions differ from those of predicted
resulting in variance between the two sets of values. Also the algorithm used to fit the
secondary structure values to the experimental spectra may cause differences in values.
As data could not collected below 190nm this limited the choice of algorithms that
could  be  selected  and increased  the  deviation  between the  fitted  and recorded  data
(figure 6.2.3.2). The CDSSTR program (Sreerama & Woody 2000) combined with SP43
(reference set containing 43 soluble protein examples) was considered to be the most
accurate option available with the data obtained.       
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The thermal denaturation experiments were trialled as companion data to the chemical
denaturation  work.  Owing  to  the  equilibration  time  delay  required  at  each  new
temperature point the programme to run thermal denaturation was several hours long.
This limited the amount of data that could be collected within allocated B23 beamtime
sessions. As no denaturation data was held for CaMBD so this protein was tested first.
The flattening of BD spectra (figure 6.2.3.3) indicates loss of secondary structure, this
indicates that the protein is denaturing, probably structure is lost somewhere between
50-55°C. There is no real observable difference between the just CaMBD and complex
with E4076K CaMLD spectra. Admittedly further data, in particular with wt CaMLD,
would need to be recorded to allow full comparison. Owing to the time taken to collect
data  and  the  initial  unclear  data  it  was  decided  not  to  further  pursue  the  thermal
denaturation experiments. 
One  of  the  experiments  conducted  in  the  far  UV region  was  to  repeat  the  spectra
recorded for CaMLD with and without Ca2+ reported in the literature (Liangwen Xiong
et al. 2006). This data is shown using ellipticity rather than millidegrees, ellipticity is
the millidegree values corrected for protein concentration, however this difference in
units does not change the shape of the spectra which is the examined component when
assessing  condition  variables.  The  experimental  data  from this  project  reveals  little
difference between the presence or absence of 1mM Ca2+ for wt and mutant CaMLD.
Possibly a slight difference can be seen for wt and NK protein though the EK sample
appears unchanged (figures 6.2.3.5-8).  Based on the expectation of the affect of the
mutations, EK is thought to be less Ca2+ sensitive though 1mM Ca2+ should be well
above any triggering  threshold.  The literature example represents  somewhere in  the
region  of  a  5%  change  in  α  helix  content,  while  this  represents  an  important
rearrangement of the structure of the protein it is not a huge difference in terms of CD
signal and maybe easily lost due to signal noise in a non perfect sample. An illustration
of the impact of signal variation is shown by the CaMBD sample appearing to show a
difference  between conditions.  This  is  not  expected  as  CaMBD does  not  contain  a
known Ca2+ binding site. 
The  quality  of  data  collected  could  have  possibly  been  improved  by  using  more
concentrated protein samples. The increase in signal strength would have also allowed
for a shorter path length cell to be used potentially enabling data collection at shorter
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wavelengths despite the buffer imposed limitations. These experiments were conducted
using cleaved tag protein samples, the problems associated with handling this material
and achieving higher concentrations are discussed in chapter 5. 
As the expected conformational change with CaMLD was difficult to observe within the
far UV region is was decided to collect readings in the near UV region as this offered a
great chance of detection. As discussed in the chapter introduction the RyR2 domain
proteins  appeared  to  be  good candidates  for  work  in  this  region.  Commonly when
working in this region the relative contributions to the spectra based on their percentage
aromatic  acid  composition  is  determined  and  the  concentrations  in  the  CD  sample
altered to provide matching signal strength of the proteins involved. It was calculated
that CaMLD gives a stronger signal than CaMBD. Experiments were conducted using
these corrected concentrations alongside samples using 1:1 concentrations as would be
expected if there was direct binding between the two proteins. No obvious difference
was observed so all further experiments were conducted using 1:1 concentrations. The
only issue from this approach was that the signal contribution from CaMBD might be
diminished compared to CaMLD but the observed changes in spectrum shape indicated
that this was not a problem. 
The repeat of the addition of Ca2+ to wt CaMLD (figure 6.2.3.10) revealed a difference
in spectra  indicating  a  conformational  change in  the CaMLD structure  triggered  by
addition of Ca2+. This result was less clear for the N4104K and E4076K mutants. The
wavelength of the spectra where variation was observed is attributed to phenylalanine
residues  within  the  protein.  There  are  several  Phe  residues  located  in  CaMLD;  2
upstream of 1st EF hand motif,  2 per EF hand motif and 1 downstream of 2nd EF hand
motif. It is plausible that there could be a Ca2+ induced conformational change which
alters the environment around the Phe residues, this is almost certainly the case for the
amino acids in the EF hand motifs, which resulted in the observed spectral change. 
It should be noted that 200μM Ca2+ was used instead of 1mM for this experiment and all
subsequent work involving the triggering of a conformational change in CaMLD. The
CaMLD region in RyR1 was reported to have an apparent Ca2+ binding affinity of 60
(±12) μM. It is assumed that the conformational triggering threshold concentration is
somewhere in this region. The switch to 200μM Ca2+ in experimental conditions was an
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attempt to use a value closer to this threshold and set a lower top concentration for
experiments attempting to discover this threshold concentration.
Based  on  the  successful  observation  of  a  Ca2+ induced  conformational  change  in
CaMLD, the interaction between CaMLD and CaMBD was investigated using near UV
region CD. For the wt CaMLD a clear change in the shape of the spectra is observed
(figure 6.2.3.11). This indicates that a clear conformational change is occurring which
suggests binding with CaMBD. As previously found 200μM Ca2+ is sufficient trigger
conformational change, as this structural rearrangement in CaMLD is considered to be
required  prior  to  CaMBD  binding  so  it  is  not  surprising  that  this  concentration  is
sufficient. As the change in spectra is different to that observed for just the addition of
Ca2+ so it is likely that the difference is a result of the presence of CaMBD.  As the
change in spectrum shape transfers between that associated for CaMLD to CaMBD it is
even more suggestive that CaMBD binding is the cause. What is not so clear is why the
spectra should so clearly differentiate between these two component associated spectra.
This difference suggests that in the absence of Ca2+ CaMLD is the dominant protein
signal. The addition of Ca2+ triggers the conformational change in CaMLD which is
assumed to adopt the “wrap round” binding of CaMBD, as observed for CaM in the
PDB structures, so making CaMBD, or a CaMBD like, signal the dominant observed
component of the spectrum. This potential CaMBD binding result is not so clear for the
NK and EK mutants but appears to occur to some extent suggesting possibly weaker or
a lower percentage of the CaMLD population binding with CaMBD, as thought to be
seen in the NK spectra (figure 6.2.3.13), than compared to wt.
With the change of CD equipment so the CaMLD binding to CaMBD experiment was
repeated. As expected a very similar result is observed with the shift to the CaMBD
associated  spectra  with the  addition  of  Ca2+.  Although the  2nd peak  of  the  CaMBD
spectrum appears  to  be  shifted  closer  to  250nm (figure  6.2.3.14),  appears  closer  to
260nm for previous data sets, this is an artefact produced by the change in x axis scaling
resulting from the change in frequency of data points collected.   
To determine the CaMLD conformational trigger Ca2+ concentration threshold a series
of Ca2+ concentrations were tested (figure 6.2.3.15). The data from this experiment is
unclear, it appears that 200μM Ca2+  is required, though 100μM may be sufficient. The
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use of serial additions of Ca2+ may well skew the results in this experiment. Repeats
using individual Ca2+ concentrations seem to confirm these observations, 100μM Ca2+
may be close to the threshold for this recombinant wt CaMLD under these experimental
conditions.  A 200μM  Ca2+ concentration  is  required  to  start  to  observe  a  similar
triggering  of  conformational  change  for  the  EK  and  NK  mutants.  As  no  Ca2+
concentrations were tested between 100 and 200μM a closer threshold value cannot be
assigned  to  these  mutations  beyond stating  that  the  assumed  required  concentration
>100μM. This difference in required Ca2+ concentrations suggests towards lesser Ca2+
sensitivity for E4076K and N4104K mutants.       
The experiment including the incubation of CaMBD with CaM in the presence and
absence of Ca2+ was conducted as a check against previously observed results using the
CaMBD construct protein. The only difference seen in the spectra (figure 6.2.3.16) is as
a result of a dilution factor of the addition of Ca2+ to the sample to record the with Ca2+
spectrum. Based on the mechanism of CaM binding so any observable conformational
change would be expected in CaM rather than CaMBD. Previously tested CaM samples,
although  generating  spectra,  had  shown no discernible  difference  in  the  absence  or
presence of Ca2+, as discussed in the chapter introduction this was expected. Owing to
this lack of signal change CaM was not further used within CD experiments.     
The data obtained in this chapter indicates that the recombinant CaMLD and CaMBD
proteins bind. This process may first require a Ca2+ induced conformational change in
CaMLD. The interaction between domains occurs for the mutant forms E4076K and
N4104K  though  may  be  affected  by  the  possible  lesser  Ca2+ sensitivity  of  these
mutations. In addition the E4076K mutation severely weakens the stability profile of the
CaMLD protein, this may be reflected in the decrease of α helix and β sheet content
seen in the experimentally derived secondary structure.     
 
232
Chapter 7:
General Discussion
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7.1 General Discussion
The aim of this thesis was to examine the interaction between the CaMBD and CaMLD
of RyR2 and the impact that certain CPVT point mutations within CaMLD have upon
this interaction.  A number of computational,  structural  and functional  techniques,  as
discussed in previous chapters, were applied to this study. The data collected from these
methods is now discussed with regards to the studied domain interaction within RyR2
and how certain CPVT mutations may disrupt this mechanism of interaction. 
The amino acids 3545-4163 of the human RyR2 contains the CaMBD and the CaMLD.
Work carried out previously in this lab using FRET technology have shown that the
cytoplasmic domain of the ryanodine receptor communicated with the inner pore region
(membrane –embedded channel pore segment) via  an interacting domain (I-domain)
consisting of amino acids 3722-4610 (George et al. 2004a). The majority of residues of
this region are expected to traverse through the inner regions of the channel, thus apart
from the CaMLD and CaMBD regions, they are not expected to be solvent exposed.
Recently,  discussion  and  the  presence  of  this  region  in  modulating  the  interaction
between  the  cytoplasmic  domain  and  that  of  the  inner  pore  region  has  also  been
suggested by the Van Petegem group as shown in the figure below.
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Figure 7.1 Hypothetical  schematic  model  of  cross-domain  interaction  in  the
RyR.
Model showing the possible interaction between the N-terminal region of RyR and the
transmembrane pore region. Regions labelled A, B and C are the interacting domains
within the N-terminal segment of the RyR. The segment shaded in green represents the
region in RyR encoded by exon 3, seen in severe CPVT phenotypes where the entire
exon is deleted. Figure adapted from (Lobo et al. 2011).
The current accepted model of allosteric interaction between the cytoplasmic domain
and the pore region is that multiple modulatory interactions exist between these two
important domains. It is thought that the normal gating of the RyR as a channel occurs
via allosteric regulation between the mutation hotspot region in the N-terminal domain
and the pore region, where the N-terminal region plays an important role in slowing
down the opening of the pore. Domain A (as shown in figure 7.1) interacts with the pore
via a helical segment within it (Lobo et al. 2011).
The region encoded by this area of interest which incorporates the CaMLD and CaMBD
region contains a high proportion of amino acids that are highly hydrophobic in nature,
as examined in the computational modelling work in chapter 3. This is to be expected of
a set of amino acid residues that lie buried within a structure, largely hydrophilic amino
acids are usually found at the solvent exposed surfaces of a protein molecule. As such, it
is  extremely  difficult  to  generate  recombinant  versions  of  such  highly  hydrophobic
proteins  since  the  purification  methods  rely  on  the  use  of  water  based  buffers  and
separation media reliant on aqueous conditions.
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Experiments with CaMBD and CaMLD required the production of recombinant protein.
The design of both constructs relied heavily on the identification of secondary structure
elements believed to play important roles in the interaction of the RyR2 domains. The
constructs designed for CaMBD were based around a section of protein that had well-
established  structures.  CaMLD  posed  more  problems.  Traditionally  when  trying  to
produce  stable  protein  then  whole  proteins  or  clearly identified  domains  within  the
protein of interest are targeted. There are published reports of a CaMLD area within
RyR1 and RyR2 that interact (Liangwen Xiong et al. 2006) (Gangopadhyay & Ikemoto
2008) (Gangopadhyay & Ikemoto 2011) which are all  based on the initial  report  in
RyR1 by Xiong and colleagues (Liangwen Xiong et al. 2006). While CaMLD appears to
offer an identifiable domain, it is not entirely clear from a structural viewpoint where
the  domain  begins  and  ends.  When  compared  to  a  lobe  of  CaM  then  portions  of
predicted  α  helix  that  are  proposed  to  play  a  role  in  binding  to  CaMBD  can  be
identified. It is probably around these residues, close to the published coordinates, that
CaMLD starts and finishes. 
Various recombinant constructs of CaMBD and CaMLD were tested as explained in
chapter  5,  however,  only  few  were  marginally  soluble.  The  expression  of  such
hydrophobic constructs is also not conducive to the growth and propagation of  E.coli,
thus protein recovery from E.coli is also a major factor to be considered. Furthermore,
to protect itself from the recombinant protein, E.coli frequently sequester the protein as
soon as it  is  translated into inclusion bodies,  enveloping it  with various  heat  shock
proteins so that it does not interfere with the cytoplasmic milieu of the bacteria. Thus,
when bacteria are first lysed and the broken cell membrane portions are centrifuged as a
pellet for removal, the inclusion body sequestered protein also aggregates with the pellet
fraction. Isolating the inclusion body sequestered proteins is possible but the method
involves  denaturing  the  tight  interaction  between  the  recombinant  protein  from the
inclusion  body  and  heat  shock  proteins  using  strong  denaturants  such  as  urea  or
detergents as detailed in chapter 5. The downside of this  method is  that the tertiary
folding of a protein is often lost upon these treatments. While refolding protocols can be
applied there is no guarantee that the functional folded protein will be obtained and, as
such, the recovery of the protein of interest at the end is very poor at best. 
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To combat these issues various affinity tags were also used to encourage the solubility
of the recombinant protein. The NusA protein is one of a complex of proteins that is
used  by  bacteriophage  lambda  to  prevent  the  early  termination  of  an  RNA
transcriptional  step.  Thus,  with  the  use  of  these  “anti-termination”  proteins,  RNA
transcription can be coaxed to continue for longer than intended. The NusA protein is
also a highly soluble protein molecule,  which is  also used as a recombinant protein
expression modifier. Proteins that poorly expressed were highly hydrophobic and not
amenable  to  standard  purification  methods  usually  were  “workable”  again.  These
proteins  showing  better  expression  profiles,  enhanced  purification  and  yield  from
recovery steps when expressed as a fusion partner with the 495 amino acid NusA tag at
the  N-terminus.  However,  upon cleavage  of  the  solubility  tag  such as  NusA,  these
proteins frequently started to form insoluble aggregates and dropped out of solution.
Examples of this phenomena are related in chapter 5.  
Other solubility tags tried and used for improving expression of recombinant proteins
were the Trx tag (thioredoxin tags), MBP tags (maltose binding protein tags) and the
GST tag (glutathione S-transferase tag). However, as shown in chapter 5, none of these
tags  were as  effective at  attempting to  gain the large milligram scale  production of
recombinant proteins that is necessary for the production of crystals for determination of
structure by x-ray crystallography.
There is some evidence in the literature that disulphide bonds are possible and present
within the RyR molecule  (Favero et al. 1995), however it is not certain if the region
encoded by aa  3545-4163 contains  any disulphide  bridges  in  the  intact  whole  RyR
molecule  in vivo. The cytoplasm of  E.coli is a very strong reducing environment and
recombinant proteins that are normally stabilised by disulphide bridges would not be
correctly folded as these disulphide bonds would be broken within E.coli using enzymes
such as thioredoxin and glutaredoxin. Such proteins would then be randomly folded,
form  aggregates  within  the  cytoplasm  of  E.coli and  be  sequestered  into  inclusion
bodies. If disulphide bonds are crucial for the maintenance of protein structure, then
there are  E.coli strains, such as the commercially available Origami strains, that have
oxidising  properties  in  the  cytoplasm  which  allow  the  maintenance  of  disulphide
linkages.  Since it  is  unknown if  disulphide bonds are crucial  for the folding of this
region of the RyR, so no steps were taken to preserve those S-S bonds.
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Certain additives can be used to increase the expression of highly hydrophobic proteins
and to encourage their presence within the aqueous milieu of the cell extract following
lysis. These additives, namely the osmolytes such as betaine have been used but to little
effect  in  this  thesis.   Various  growth  conditions,  low temperatures  for  induction  of
protein from the plasmid, different formulations of media and other techniques have
been tried but to little effect as described in chapter 5. Due to this, the production of
large quantities of recombinant protein were not feasibly possible, and thus the initial
aims of producing adequate amounts of protein for the purpose of obtaining protein
crystals to try to solve the 3D structure of the regions of interest, was not met.
Since it was not possible within the time frame of this research study to persevere with
the ultimate goal of crystallisation, it was decided to obtain some preliminary answers
by  theoretical  and  homology  modelling.  The  computational  based  work  produced
models of the studied region. These models contained both domains of interest and the
predicted secondary structure elements in the proposed loop region between the two
domains.  The  theoretical  modelling  was  carried  out  using  the  homology modelling
software,  MODELLER  (A Sali  & Blundell  1993).  Within MODELLER, it  was also
possible  to  force  the secondary folding  of  regions  of  the protein based on the data
obtained from secondary structure prediction software. Thus, after the CaMBD-CaMLD
regions were folded using a homologous template, MODELLER was used to force the
folding of stretches of protein with unknown structure by  ab-initio folding methods.
Following this, the model was refined to incorporate bond lengths and angles that were
within the prescribed values that have been empirically established.
Having finished the theoretical modelling using first principles (ab initio modelling),
the  model  was  coaxed to  fold  further  by the  interaction  of  proximal  molecules.  In
molecular  simulations,  usually  the  non-bond  values  of  molecules  are  specified  to
approximately 12-15 Å. In reality, two atoms that are not bonded to each other would
still exert at attractive force on each other that tails off to infinity, the force of attraction
may be minuscule  at  infinite  distance  but  is  still  present.  In  a  computer  simulation
however, due to the enormous amounts of computation required should the non-bond
values be specified to infinity, it is common to specify them to approximately 12-15 Å.
In the conducted simulations, to coax the molecule to fold in 3D-space, the non-bond
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value was set to the largest dimension between two atoms placed furthest from each
other. In the time taken for the simulation to run, the structure was observed to become
more  compact,  however,  for  a  simulated  folding  to  occur  in-silico,  this  would  be
expected to take a much longer time and require much greater computational processing
power. It is interesting that protein folding  in-vivo takes place in an extremely short
period of time, as described in chapter 4.  The structure presented in chapter 4 therefore
is best taken as a structure that is still in the process of folding.
Although  various  energy  parameters,  bond-distances  and  angles  were  analysed
exhaustively in chapter 4, one of the most remarkable observations is that despite the
high mobility of the molecule during the simulations, the CaMBD and CaMLD domains
did not migrate very far away from each other. This shows that the non-bond interacting
forces (such as Van der Waals forces, ionic-interaction, etc) are sufficient to keep the
two domains proximal to each other. Thus, there is a natural propensity for these two
domains to interact with each other.
The  functional  assays  that  were  conducted  displayed  interaction  between  the
recombinant protein of CaMBD and CaMLD constructs. As the interaction was also
observed when the solubility tags had not been removed this addressed some of the
issues  raised  above.  This  suggested  that  functional  structure  of  RyR2  domain
recombinant proteins is not affected by the presence of the tags either at the level of
steric  hindrance  or  through  unwanted  interaction.  The  tags  were  shown  not  to  be
responsible for potential false positive binding in control experiments. 
A calcium induced conformational change was observed in CaMLD which seemed to be
required before interaction with CaMBD. While a specific threshold concentration to
trigger the conformational change, for these construct proteins, was not not found, data
suggested in the range 100-200 μM calcium. This value is higher than the 60 ±12μM
calcium binding with CaMLD concentration reported from fluorescence binding assays
by Xiong (Liangwen Xiong et al. 2006). While this concentration is above the sub μM
calcium concentrations observed for RyR2 activation it  is  below the mM inhibitory
levels (Lamb, 2000). As CaM is expected to unbind from CaMBD with the increasing
calcium levels during RyR2 channel activation, it is plausible that the conformational
change required for CaMLD binding to  CaMBD could be triggered in the range of
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100μM calcium. The same set of experiments indicated that the CPVT point mutations
E4076K and N4104K may decrease calcium sensitivity as CaMLD construct protein
containing these mutations appeared to require higher calcium concentrations than the
wt for binding with CaMBD. 
The requirement for a calcium induced conformational change prior to binding further
strengthens the comparison between CaMLD and CaM. CaMLD is seen to share very
similar structure and functional response to a lobe of CaM. However, beyond showing
CaM interaction with the recombinant CaMBD protein this project did not address the
potential competition between CaM and CaMLD for binding to CaMBD. Competition
assays between CaM and CaMLD under varying calcium concentrations were attempted
but with no clear data produced. Part of this was due to the low CaM signal given in
near UV CD experiments as discussed in chapter 6. As such, it is not possible to discuss
the conditions required for CaM to dissociate from CaMBD so that CaMLD will bind
using results from this project. It is known that this transition in binding occurs as part
of  the  channel  function,  the  impact  of  calcium concentrations  are  discussed  in  the
literature (Balshaw et al. 2001) (Naohiro Yamaguchi et al. 2003).
The mutation, E4076K was found to significantly weaken the structural integrity of the
CaMLD domain. The other mutations studied, G3946S, N4104K and H4108Q had a
similar  denaturation  profile  to  that  of  the  wt  sharing  an  intermediate  stage  before
becoming unfolded. However, these three mutations were less likely to transfer to this
intermediate  state  than  the  wt.  This  would  appear  to  link  to  work  conducted  by
colleagues which showed that mutations in the I domain caused variation in calcium
release that were not observed for central domain mutations. N4104K was one of these
studied  mutations  and  was  implicated  in  causing  conformational  instability  in  the
functional channel (George et al. 2006). If the ability of the protein to undergo a calcium
induced conformational  change is  reflected in  the ease of  a  transfer  from native  to
intermediate  state,  i.e.  internal  rearrangement,  then the data  obtained in  this  project
would  start  to  explain  the  structural  and  functional  impact  of  the  CPVT mutation
N4104K. The wt version would respond to a lower calcium concentration and then have
a lower energy requirement to undergo a conformational change as part of the channel
opening in response to increasing calcium levels. 
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E4076K was identified at the start of the project as a CPVT point mutation of particular
interest  in RyR2. Its  position within the EF hand loop, although not in a conserved
position, lead to speculation that this mutation would disrupt the function of CaMLD
though it was not clear to what extent this mutation would disrupt function. The data
from this  thesis,  as  discussed above,  indicated  a  structural  weakness  and a  reduced
calcium sensitivity compared to the wt recombinant protein when this mutation was
present. However it would appear, that from the studies conducted in this thesis, that
even with this mutation present CaMLD is still able to function in its expected CaMBD
interaction role. This is consistent with the understanding of CPVT in that the condition
does not present until the heart is in a “stressed” state as described in relation to the
phosphorylation state of RyR in chapter 1.  As such, this  thesis  has provided further
understanding  of  the  possible  mechanism  by  which  certain  CPVT point  mutations
within CaMLD disrupt the interaction with CaMBD and so lead to the manifestation of
CPVT symptoms. 
7.2 Future directions
One of the main concerns with the functional experiments conducted in this project was
the quality of protein. High throughput studies for crystallisation work are increasingly
generating a large number of potential constructs which test a large range of domain
boundaries  encompassing  the  region  of  interest.  A range  of  vectors  and  expression
systems are also trialled. This approach, because of its required scale, may not be fully
applicable  within  the  scale  of  a  project  such  as  this  but  smaller  versions  can  be
attempted  and external  laboratories  offer  this  as  a  service.  However,  for  reasons  as
discussed above, even this approach may not find a noticeably improved solution to the
issue  of  CaMLD  based  construct  protein  stability.  As  discussed  in  chapter  5,  a
compromise for the production of usable protein has to be reached at some point. 
The use of other techniques in functional assays would allow further investigation into
the interaction between the two RyR2 domains and CaM. A number of techniques were
considered  though  it  was  considered  that  isothermal  titration  calorimetry  (ITC)  or
surface plasmon resonance (SPR) would offer the most possibilities. The use of SPR
had been considered for the purposes of competition assays. This technique would allow
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CaM or CaMLD to be flowed over CaMBD, bound to a chip,  under changing Ca2+
concentrations  to  monitor  binding  affinities.  Once  these  had  been  established  then
competition between CaM and CaMLD under varying conditions could be examined.
There were some concerns over the methods to attach the protein to the chip. Most of
the  chemical  binding  options  as  the  acidic  conditions  required  would  denature  the
proteins.  One of the tagged based systems would probably provide the solution,  the
presence of tags did not appear to affect the interaction between CaMLD and CaMBD
though this could be test more fully be examination of binding affinities under control
condition  experiments  using  SPR.  It  may  also  be  possible  to  examine  if  the  RIH
associated domain plays any role in binding for CaMLD with this technique by the use
of the range of CaMLD constructs generated for this project.  
Structural biology was planned as a significant content of the original thesis. Prior to
commencement cryo-EM structures of RyR with predictions of the locations of domains
had been published. During the course of the project a number of papers containing
crystal x-ray derived structures were published. Notable amongst these were the work of
the Van Petegem group examining the N terminal of RyR and the structural implications
of mutations within this region (Lobo & Van Petegem 2009), (Tung et al. 2010). These
papers  illustrate  the  additional  level  of  understanding  that  can  be  gained  when  the
physical impact of a mutation can be seen upon the structure. It was hoped that further
progress to equivalent result in the domains studied in this project could be made but as
discussed in chapter 5 this did not prove possible. This is clearly an area for further
exploration  beyond  this  project.  Gaining  a  structure  of  CaMLD bound  to  CaMBD
would further help to see any similarities with CaM binding and help to clearly identify
key residues involved in CaMLD binding. Comparison of structures involving mutant
forms of CaMLD would greatly aid in the understanding of CPVT mutations in this
region. While likely to be resource and time heavy this approach would offer potentially
great benefits. 
One of the techniques that can be used to identify more likely crystallisation buffer
conditions is the thermal shift assay. The strength of a fluorescent signal is monitored as
the protein sample is heated in a variety of buffer conditions. As the protein unfolds so
the signal is quenched, the more stable the protein is in a certain condition then the
higher the temperature as which it denatures. This technique was trialled, using sypro
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orange (Sigma) in a qPCR system, for the cleaved tag proteins of CaMLD and CaMBD
in attempt to identify better storage buffers. Unfortunately owing to the existing stability
issues  of  CaMLD it  did  not  prove  possible  to  identify an  improved  buffer  system.
With regards to crystallography work, if a protein sample is more stable under a certain
condition then there is more probability that it may crystallise in that condition than one
in which it degrades though this is not guaranteed. However it should be noted that
minor degradation, particularly the loss of N and/or C terminal residues, may result in a
more  stable  form of  protein.  This  is  same  theory  behind  limited  tryptic  digests  of
potential crystallisation target proteins as the aim is to remove away “flappy” amino
acids on ends of protein. This refers back to the ideas regarding domain boundaries and
may offer an additional layer of identification. 
Part  of  the  process  to  identify  further  mutations  to  study  could  be  addressed  by
development of the model system shown in chapter 4. This approach could potentially
offer a quicker way of identifying the potential impact of mutations on the structure so
identifying more likely targets prior to the commencement of laboratory based studies.
Single or multiple mutation models could be produced as required and the impact on
model structure and energy levels examined. The limitations of this approach are the
capabilities of the software,  which are steadily increasing as additional experimental
data is accrued, the users interpretation and choice of route to direct the software, and
the processing power and time required. The latter concern is becoming less of an issue
though  as  increased  computing  power  becomes  available  then  more  complex,  and
potentially realistic, simulations may be performed. 
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